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BURKITT LYMPHOMA: THE EARLY YEARS.
DennisWright, Emeritus Professor of Pathology
University of Southampton, UK
7KH¿UVWFOLQLFDOUHFRUGVRI%XUNLWWO\PSKRPD%/DUHIRXQGLQWKH0HQJR
Hospital case-notes of Sir Albert Cook at the beginning of the 20th century. 
Sporadic reports of tumours resembling BL, but often reported as atypical 
QHXUREODVWRPDVDSSHDUHGLQSXEOLFDWLRQVIURP$IULFDLQWKH¿UVWKDOIRI
the century. Denis Burkitt’s seminal publication in 1957 not only described 
the clinical features of this tumour but showed that the jaw tumours and 
the visceral tumours were part of the same disease entity. Discussions with 
George Oettle of the South African Institute for Medical Research, in which 
it became apparent that the disease had not been recognised in South Africa, 
VWLPXODWHG'HQLVWRLQYHVWLJDWHLWVGLVWULEXWLRQLQ$IULFD8VLQJOHDÀHWVLO-
lustrating the distinctive clinical features of the tumour he contacted medical 
FHQWUHVDFURVV$IULFD7KHUHVXOWVRIWKLVVXUYH\WRJHWKHUZLWKWKH¿QGLQJV
of his famous safari through East and Central Africa showed that the tumour 
was restricted to the “wet topics”. This gave rise to the hypothesis that the 
tumour might be caused by a mosquito borne virus. The observation of space 
time clustering and epidemic drift in the West Nile District appeared to lend 
further support to this hypothesis. Following an intensive search for this vi-
rus Tony Epstein and his colleagues later discovered the Epstein Barr virus 
in biopsy samples of BL sent from Uganda. Since this virus has a worldwide 
distribution it is now thought that the “wet tropics” distribution of BL is 
related to holoendemic malaria acting as a co-factor in the aetiology of the 
tumour. 
In the 1950’s and early 1960’s there was no effective treatment for BL in 
Uganda. Surgery was sometimes attempted but with such a rapidly growing, 
widely disseminated disease such treatment was futile and radiotherapy was 
not available locally. Burkitt, with no previous experience of chemotherapy, 
developed a simple single drug regime using cyclophosphamide. Responses 
to this therapy were usually dramatic and in some cases led to long term 
remission.
The term Burkitt tumour’s (subsequently changed to Burkitt’s lymphoma) 
was adopted at an international meeting on African Lymphoma in recogni-
tion of Burkitt’s pioneering contributions to the clinical studies, epidemiol-
ogy and treatment of this tumour. At a later international meeting held in 
:DVKLQJWRQWKHPDMRULW\RIGHOHJDWHVDJUHHGWKDW%/VKRXOGEHGH¿QHGE\LWV
morphology (cytology and histology). Two members of the group, however, 
were of the opinion that clinico-anatomical features were an essential part of 
WKHGH¿QLWLRQ7LPHKDVVKRZQWKDWERWKJURXSVZHUHFRUUHFWLQVRIDUDV%/
FDQEHGH¿QHGRQPRUSKRORJ\EXWFOLQLFRDQDWRPLFDOIHDWXUHVDUHUHTXLUHGWR
differentiate between endemic, sporadic and AIDS-related BL.
HOW DENIS DISCOVERED THE LYMPHOMA
David Allbrook, Emeritus Professor 
University of Western Australia
I was Senior Lecturer in Anatomy, 1952-58 at Makerere College when Denis 
Burkitt used to bring interesting patients for discussion to the weekly Mulago 
Hospital clinical meetings. At these Mulago and Makerere medical staff dis-
cussed Burkitt‘s clinical demonstrations of these children he brought in from 
his surgical safaris. But it was Denis who perceived a pattern of disease and 
realised that these various tumours might be a single clinical entity. I remem-
ber one evening in 1958, just before we were leaving for the USA, he asked 
me to the Burkitt house on Mulago hill to show me a series of homunculi 
drawings he had made of the various tumour sites in these children. They 
ZHUHO\LQJRQWKHÀRRU+HDVNHGP\RSLQLRQÄDVDPHGLFDOVFLHQWLVWEHFDXVH
I am only a surgeon“!! (I can‘t remember my reply- though I probably agreed 
with him..) In 1961 I returned to Makerere from Washington University, St 
Louis, Missouri (I had been learning electronmicroscopy to set up a unit 
at Makerere.) I met a very excited Denis in Mulago Hospital car park,“We 
KDYHDFXUHDQGLWµVLQDOLWWOHZD\VLGHÀRZHUWKH0DGDJDVFDQSHULZLQNOH
thank God!“ I recall the loaded car as he and colleagues left our Makerere 
home  for his amazing pan-African safari,which was another of his amazing 
¿HOGUHVHDUFKHVLQJHRJUDSKLFPHGLFLQH,WKLQNLWZDVIXQGHGE\DVPDOO
MRC grant. Then I vividly remember  being at a seminal meeting in the bone 
store of the Anatomy Department at Makerere when Denis demonstrated his 
JHRJUDSKLF¿QGLQJVWR6LU+DUROG+LPVZRUWK8.µV05&6HFUHWDU\$OH[
Haddow (Virus Research Institute, Entebbe) and several others on a huge 
map of Africa spread on a lab bench. I remember the intense discussion and 
that Himsworth backed the concept of an insect born vector initiating a virus 
born cancer.  For the historical record and your interest, my talk describes 
these and other memories of my friend Denis Burkitt and about the impor-
tant steps he contributed to our present understanding of lymphoproliferative 
disorders diseases. As they are from my memory (which may be at fault in 
its detailed time sequences after 50 years,) I must disclaim absolute accuracy 
of the record.
THE WHO CLASSIFICATION OF BURKITT LYMPHOMA
Elaine S. Jaffe, M.D.
Hematopathology Section, Laboratory of Pathology,  
National Cancer Institute, USA
7KHGH¿QLWLRQRI%XUNLWWO\PSKRPD%/LQWKH:+2FODVVL¿FDWLRQGH¿QHV
a homogeneous morphological and molecular entity, although there is some 
variation in the clinical presentation and epidemiological features among the 
clinical variants of BL. Three clinical variants are recognized: Endemic BL, 
6SRUDGLF%/DQGLPPXQRGH¿FLHQF\DVVRFLDWHG%/PDLQO\DVVRFLDWHGZLWK
HIV-infection. The association with EBV varies among the variants, being 
highest in endemic BL, and lowest in sporadic BL. Additionally, the pro-
portion of EBV-positive cases corresponds to other epidemiological factors, 
including the average age of seroconversion in the population and socio-eco-
nomic status in the population.
The histological variants of BL include: classical BL, atypical BL, and BL 
with plasmacytoid differentiation. The latter category is closely linked to 
EBV-positivity and is often HIV-associated. Atypical BL and classical BL 
KDYHQRWEHHQGLVWLQJXLVKDEOHXVLQJJHQHH[SUHVVLRQSUR¿OLQJVWXGLHVDQG
the presence of slightly atypical cytology does not appear to have any bio-
ORJLFDORUFOLQLFDOLPSDFW7KHFXUUHQW:+2FODVVL¿FDWLRQRI%/KDVDKR-
mogeneous immunophenotype, with expression of CD20, CD10, BCL-6, 
absence of Bcl-2, and a proliferation rate of close to 100% of the neoplastic 
FHOOV8VLQJJHQHH[SUHVVLRQSUR¿OLQJFDVHVFDUU\LQJERWK%&/-+DQG&
0<&WUDQVORFDWLRQVKDYHSUR¿OHGDV%/EXWFOLQLFDOO\GRXEOHKLWFDVHVKDYH
a very different prognosis, and should be distinguished in clinical trials from 
classical BL. 
EPIDEMIOLOGY OF BURKITT LYMPHOMA
EPIDEMIOLOGY OF ENDEMIC BURKITT‘S LYMPHOMA IN 
KENYA
R. Rochford1, O. Sumba2, E. Piriou1, A. Asito2, J. Rainey3,  
P. Rosenbaum1, R. Ploutz-Snyder1
1SUNY Upstate Medical University, Syracuse NY, USA; 2Kenya Medical 
Research Institute, Kisumu, Kenya; 3CDC, Atlanta, GA, USA
The question of why Burkitt’s lymphoma (BL) is endemic in equatorial 
$IULFDKDVLQWULJXHGVFLHQWLVWVVLQFHWKH¿UVWFOLQLFDOGHVFULSWLRQRIWKLVFDQFHU
by Denis Burkitt. Investigation of the geographic restriction demonstrated 
that BL occurred primarily in regions where there was sustained and intense 
exposure to holoendemic malaria. We began our studies in Kenya by revisit-
ing the question of whether malaria transmission intensity and BL incident 
rates were linked. Using a large sample size, stable BL incident rate estimates 
IURPD\HDUFDVHVWXG\DQGPRUHVSHFL¿FPDODULDHQGHPLFLW\GH¿QLWLRQV
at a district level of analysis, we found that BL rates were 3.5 times greater 
in regions with chronic and intense malaria transmission intensity than in re-
gions with no or sporadic malaria transmission. To further localize BL cases 
within Nyanza Province Kenya where the overall risk for BL is high, medi-
cal records for all BL cases diagnosed between 1999 and 2004 at Nyanza 
Provincial Hospital were abstracted to determine the place of residence. 
Spatial analysis of BL cases within Nyanza Province revealed that BL cases 
Journal of Hematopathology (2008) 1:47  74   49 – ZHUHQRWHYHQO\GLVWULEXWHG,QWHUHVWLQJO\ZHIRXQGRQHVLJQL¿FDQWORZULVN
%/FOXVWHUS DQGWZRVLJQL¿FDQWKLJKULVNFOXVWHUVS 
Spatial clustering of BL cases in a high-malaria transmission region suggests 
that there are additional environmental factors in the etiology of BL. Current 
studies are examining differences in plasma selenium – an essential micro-
nutrient – between the high and low-BL risk regions in Nyanza Province. 
Other ongoing studies are examining how infection with Epstein-Barr virus 
(EBV) early in life alters viral children is being followed from birth through 
3 years of age and EBV viral load, antibody levels, B-cell phenotype and 
(%9VSHFL¿F7FHOOUHVSRQVHVDUHEHLQJPHDVXUHG$QDO\VLVDWPRQWKVRI
age revealed that children living in a region with holoendemic malaria were 
LQIHFWHGZLWK(%9HDUOLHULQOLIH%FHOOSKHQRW\SHVZHUHVLJQL¿FDQWO\GLIIHU-
HQWGHSHQGLQJRQPDODULDH[SRVXUHDQG(%9VSHFL¿F7FHOOUHVSRQVHVWRO\WLF
peptides corresponded with EBV infection. A model for the etiology of BL 
based on our studies and the studies of others will be presented.
MALARIA-INDUCED DYSREGULATION OF EBV-SPECIFIC T 
CELL IMMUNITY IN THE ETIOLOGY OF ENDEMIC BURKITT 
LYMPHOMA
Ann M. Moormann1, Kiprotich Chelimo2, Kevin N. Heller3,  
Peter Odada Sumba2, Paula Embury1, Robert Ploutz-Snyder4,  
Juliana Otieno5, Margaret O’Dour5, Christian Munz3 and Rosemary 
Rochford4
1Case Western Reserve University, Cleveland, OH, USA; 2Kenya Medical 
Research Institute, Kisumu, Kenya; 3The Rockefeller University, New York 
NY, USA; 4SUNY Upstate Medical University, Syracuse, NY, USA; 5Kenya 
Ministry of Health, Kisumu, Kenya.
Why children in Equatorial Africa are at high risk for endemic Burkitt lym-
phoma (BL) has been linked to both early-age Epstein Barr Virus (EBV) 
infection and holoendemic Plasmodium falciparum malaria exposure. The 
importance of cytotoxic T cells in controlling EBV infections has been well 
established and it has long been hypothesized that EBV immunity is sup-
pressed as a consequence of repeated malaria infections. However, the means 
E\ZKLFKPDODULDRUFKHVWUDWHVGH¿FLHQFLHVLQDQWL(%9LPPXQLW\WKDWUHVXOWLQ
tumorigenesis have not been so well explained. Our investigations of healthy 
children with divergent malaria exposure have demonstrated that malaria-in-
GXFHG7FHOOG\VIXQFWLRQLVDJHGHSHQGHQWWUDQVLHQW(%9VSHFL¿FDQGGLIIHU-
HQWLDOO\DIIHFWV(%9VSHFL¿F7FHOOPHPRU\VXEVHWV7KHSDUDGR[KRZHYHULV
WKDW(%9VSHFL¿F&',)1ȖUHVSRQVHVDUHSULPDULO\WDUJHWHGWR(%9ODWHQW
antigens other than Epstein-Barr nuclear antigen 1 (EBNA1) while BL tumors 
expresses only EBNA1. Our investigations of children diagnosed with BL at 
Nyanza Provincial General Hospital in Kenya show that there is a select loss 
RIWKH(%1$VSHFL¿F&',)1ȖUHVSRQVHLQ%/SDWLHQWV(%1$VSHFL¿F
&'7FHOOVVXSSUHVVWXPRUJURZWKLQD%/PRXVHPRGHOVXJJHVWLQJWKDWWKH
DEVHQFHRI,)1ȖUHVSRQVHWR(%1$LQ%/SDWLHQWVDOORZVWKHHPHUJHQFHRI
the malignant clone. Furthermore, children with BL maintain IgG1 dominated 
(%1$VSHFL¿FDQWLERG\UHVSRQVHVVLPLODUWRKHDOWK\FKLOGUHQVXJJHVWLQJD
ORVVRI,)1ȖVHFUHWLQJ(%1$VSHFL¿F7FHOOVDVRSSRVHGWRDGHIHFWLQSULP-
LQJRU7KSRODUL]DWLRQ&'PHGLDWHG7FHOOGH¿FLHQFLHVZHUHQRWREVHUYHG
in BL children for other EBV lytic and latent antigens or for a recombinant 
blood stage malaria protein, merozoite surface protein 1 (MSP1) which is pri-
PDULO\PHGLDWHGE\&'7FHOOV7KHFDXVDOPHFKDQLVPVE\ZKLFKPDODULD
could alter the maintenance of immunity to EBV have led us to postulate a 
more comprehensive model for eBL pathogenesis.
A ROLE FOR ARBOVIRUSES IN ENDEMIC BURKITT‘S 
LYMPHOMA.
C. A. van den Bosch, MB, BS.,MSc., MD, DCH
Institution: Health Protection Agency, UK
Recent advances in virology, parasitology and immunology have helped to 
elucidate the important contributions of the Epstein-Barr virus and heavy 
malarial infection to lymphomagenesis in African endemic Burkitt‘s lym-
phoma. However, these infections cannot explain the shifting foci and space-
time case clusters of the lymphoma that have been recorded.
Theoretical considerations and epidemiological data raise the possibility that 
these phenomena may be associated with arboviral epidemics and that they 
can better explain certain aspects of the epidemiology of the tumour than can 
the Epstein-Barr virus and malaria. Data from Malawi also suggest that in-
fection with one or more arboviruses is implicated in the crucial later stages 
of lymphomagenesis.
An increased incidence, and space-time case clusters of endemic Burkitt‘s 
lymphoma were observed during the course of an epidemic of the arbovi-
rus, Chikungunya Fever, in Malawi. Cases of Burkitt‘s lymphoma showed 
evidence of recent infection with Chikungunya virus and other arboviruses 
DWWLPHRI¿UVWDGPLVVLRQ/\PSKRPDFDVHVZHUHVLJQL¿FDQWO\PRUHOLNHO\
to be seropositive for Chikungunya viral antibodies than controls and many 
Burkitt‘s Lymphoma cases seroconverted for antibodies to this virus dur-
LQJWKHLU¿UVWDGPLVVLRQ7KHVHREVHUYDWLRQVVXSSRUWDQDVVRFLDWLRQEHWZHHQ
arboviral infection and the late stages of development of endemic Burkitt‘ s 
lymphoma. Plant extracts with tumour-promoting factors could also partici-
pate in lymphomagenesis.
ANTIBODIES AGAINST MALARIA AND EPSTEIN BARR VIRUS 
IN CHILDHOOD BURKITT LYMPHOMA:  
CASE-CONTROL STUDIES IN UGANDA AND MALAWI.
Lucy M Carpenter1, Robert Newton2, Delphine Casabonne3,  
Nora Mutalima1, Elizabeth Molyneux4, John Ziegler5, Sam Mbulaiteye5, 
Edward Mbidde5, Henry Wabinga5, Harold Jaffe1, Valerie Beral3
1Department of Public Health, University of Oxford, UK; 2Epidemiology 
and Genetics Unit, Department of Health Sciences, University of York, UK; 
3Cancer Epidemiology Unit, University of Oxford, UK; 4Department of 
Paediatrics, College of Medcine, Blantyr, Malawi; 5Uganda Cancer Institute 
and Makerere University Medical School, Kampala, Uganda.
Burkitt lymphoma, a childhood tumour common in parts of sub-Saharan 
Africa has been associated directly with Epstein Barr Virus (EBV), based 
on studies involving individual children, and indirectly with malaria, based 
on patterns of population prevalence. We have examined antibodies to both 
EBV and malaria in individual children diagnosed with this cancer in Uganda 
and Malawi. In both studies, we performed case-control analyses of HIV-
seronegative children (&#8804; 15 years) admitted to hospital. Cases were 
diagnosed with Burkitt lymphoma and controls with non-malignant condi-
tions or non-lymphatic cancers. Interviews were conducted and serological 
samples collected which, when possible, were tested for both EBV and ma-
laria. Adjusted odds ratios (OR) for Burkitt lymphoma were estimated using 
unconditional logistic regression adjusting for sex, age, residential district, 
household income and tribe. In the Uganda study, mean age of cases was 7 
years and 61% were male. Compared to controls, cases were more likely to 
be reported having received more frequent treatment for malaria in the past 
year (OR=2.0; P=0.001) and less likely to be living in a home where insecti-
cides were used (OR=0.2; P<0.0001). Odds of Burkitt lymphoma in children 
increased with increasing antibody levels against EBV (P<0.0001) and ma-
laria (P=0.05). Findings were similar for children residing in districts close 
to the capital city and in remote areas. Compared with children with low 
antibody levels against both EBV and malaria, children with raised levels 
DJDLQVWERWKZHUH¿YHWLPHVPRUHOLNHO\WRKDYH%XUNLWWO\PSKRPD25 
P=0.003). Results obtained from the study conducted in Malawi are similar. 
2XU¿QGLQJVVXJJHVWWKDW(%9DQGPDODULDPD\DFWV\QHUJLVWLFDOO\LQWKH
pathogenesis of childhood Burkitt lymphoma. Malaria prevention measures 
have the potential to also prevent this childhood cancer.
EFFECTS OF DIVERGENT P.FALCIPARUM MALARIA 
TRANSMISSION DYNAMICS ON B CELL HOMEOSTASIS IN 
CHILDREN FROM WESTERN KENYA.
A.Amolo1,2, E.Piriou3, P.0. Sumba1, Z.W, Ng ang a2, A.M.Moormann4, and 
R.Rochford3
1Kenyan Medical Research Institute, Center for Global Health Research, 
Kisumu, Kenya; 2Jomo Kenyatta University of Agriculture and Technology; 
3Department of Microbiology and Immunology, SUNY Upstate Medical 
University, Syracuse, NY; 4Center for Global Health and Diseases, Case 
Western Reserve University, Cleveland, OH, USA
Chronic or acute P.falciparum malaria has been associated with perturba-
tion of peripheral B cell subsets, B cell activation, and an increased risk for 
endemic Burkitt lymphoma. It has been postulated that these aberrancies re-
ÀHFWFKURQLFDQWLJHQLFVWLPXODWLRQZLWKLQWKHFRQWH[WRIFKURQLF3IDOFLSDUXP
infection. To test this hypothesis we measured the expression of differentia-
tion markers on peripheral blood B cells from one year old children from 
two geographically proximate districts; Kisumu district which is a malaria 
endemic area and Nandi that experiences unstable malaria transmission. 
&KLOGUHQIURP.LVXPXGLVWULFWVKRZHGVWDWLVWLFDOO\VLJQL¿FDQWLQFUHDVHG%
cell frequencies (mean, 21%) compared to those from Nandi district (mean, 
50 Journal of Hematopathology (2008) 1:47  74   – 16%). Children from Kisumu and Nandi districts had higher frequencies of 
QDćYH%FHOOV&',J'PHDQYHUVXVUHVSHFWLYHO\%FHOOVDQG
ORZIUHTXHQFLHVRIPHPRU\%FHOOV&'&'PHDQRIYHUVXV
UHVSHFWLYHO\+RZHYHUWKHIUHTXHQFLHVRI,J'&'PHPRU\ZHUHVLJ-
QL¿FDQWO\LQFUHDVHGLQFKLOGUHQIURP1DQGLGLVWULFWPHDQFRPSDUHGWR
Kisumu district (mean, 4%).
2IQRWHWKHSRSXODWLRQRILPPDWXUHWUDQVLWLRQDO%FHOOV&',J'&'
ZDVVLJQL¿FDQWO\LQFUHDVHGLQFKLOGUHQIURP.LVXPXGLVWULFWFRPSDUHGWR
Nandi district (mean, 31.9 % versus mean 25.8%, respectively). The preva-
lence of immature transitional B cells in peripheral circulation raises the pos-
sibility that B cell dysfunction due to P.falciparum infection may either result 
in elevation of a population of B cell susceptible to chromosomal transloca-
tion or Epstein-Barr virus infection, which may explain the emergence of 
B cell malignancies like endemic Burkitt s lymphoma in endemic malaria 
settings.
SELENIUM LEVELS AND RISK FOR ENDEMIC BURKITT’S 
LYMPHOMA IN WESTERN KENYA.
Peter Odada Sumba1, Ephantus Kabiru2, Michael Opiyo1, Chelimo 
Kiprotich1, Alloys S.S. Orago2, Paula Rosenbaum3, Ann M.Moormann4, 
Rosemary Rochford3
1Kenya Medical Research Institute, Kisumu, Kenya; 2Kenyatta University, 
Nairobi, Kenya; 3SUNY Upstate Medical School, Syracuse, New York, 
USA; 4Case Western Reserve University, Cleveland, Ohio, USA.
Endemic Burkitt’s lymphoma (eBL) is the most prevalent pediatric can-
cer in Equatorial Africa. The etiology of this lymphoma is multi-factorial 
involving early-age infection with Epstein Barr virus (EBV) and frequent 
exposure to Plasmodium falciparum malaria. Since these co-infections are 
common in African children living in malaria endemic areas, other eBL risk 
factors are being investigated. One potential co-factor could be selenium de-
¿FLHQF\6HOHQLXPLVDQHVVHQWLDOPLFURQXWULHQWDQGLVDQLQWHJUDOFRPSRQHQW
of the antioxidant enzyme glutathione peroxidase (GPx). Many populations 
ZRUOGZLGHH[KLELWVHOHQLXPGH¿FLHQFLHVEXWOLWWOHLVNQRZQDERXWVHOHQLXP
GH¿FLHQF\ZLWKLQ$IULFDQSRSXODWLRQV0RUHRYHUWKHUHLVHPHUJLQJGDWDWR
VXJJHVWWKHVHOHQLXPGH¿FLHQF\SRWHQWLDWHVYLUDOLQIHFWLRQV:HK\SRWKHVL]HG
WKDWGH¿FLHQFLHVLQVHOHQLXPFRXOGFRQWULEXWHWRLQFUHDVHGULVNIRUH%/E\GH-
creasing host ability to control EBV infection. To test this hypothesis, a cross 
sectional survey was conducted in children living in a region of Western 
Kenya that have higher than expected and in a region where lower than 
expected incident rate of eBL (Rainey et al., 2007, Int J.Cancer, 120:121). 
Blood was collected from 145 children ages 1 to 11 years, to determine se-
lenium levels using Plasma GPx enzyme immunoassay for selenium GPX. 
We found that children living in a low-risk area for BL had a mean selenium 
OHYHORIȝJGOQ ZKLOHFKLOGUHQOLYLQJLQDKLJKULVNDUHDIRU%/KDG
DPHDQVHOHQLXPOHYHORIȝJGOQ 7KHVHYDOXHVZHUHFRPSDUHG
XVLQJDWWHVWIRUHTXDOLW\RIPHDQVDQGWKHGLIIHUHQFHVZHUHKLJKO\VLJQL¿-
cant (p<0.0001). Our data demonstrates that there is evidence that children 
OLYLQJLQDKLJKULVNUHJLRQIRUH%/KDYHVLJQL¿FDQWO\OHVVVHOHQLXP*3[
than children living a low-risk region for eBL but more studies are needed to 
GHWHUPLQHZKDWLPSDFWVHOHQLXPGH¿FLHQF\KDVRQLPPXQHIXQFWLRQ
COMMON SINGLE NUCLEOTIDE POLYMORPHISMS IN TOLL 
LIKE RECEPTOR.
Mulama D1,2, Ptaschinski C3, Greene J4, Chelimo K2, Sumba PO2, Miller K4, 
Ng ang a Z1, Vulule J2, Rochford R3 and Moormann AM4 
1Jomo Kenyatta University of Agriculture and Technology, Kenya; 2Kenya 
Medical Research Institute, Kisumu, Kenya; 3Sunny Upstate Medical 
University, Syracuse, NY, USA; 4Case Western Reserve University, 
Cleveland, OH, USA
Endemic Burkitt s lymphoma (eBL) is the most prevalent paediatric can-
cer in equatorial Africa. Although an epidemiological link exists between 
eBL, early childhood Epstein-Barr virus (EBV) infection and holoendemic 
Plasmodium falciparum malaria transmission, the mechanisms by which 
these pathogens interact to increase the risk of eBL remain largely unknown. 
0DODULDLQGXFHGLPPXQRVXSSUHVVLRQRI(%9VSHFL¿F7FHOOLPPXQRVXUYHLO-
lance has been suggested as a mechanism that increases a child s risk of 
developing eBL.
A novel line of investigation into eBL etiology lies in understanding innate 
LPPXQHUHVSRQVHVWRWKHVHFRLQIHFWLRQVDQGWKHLULQÀXHQFHRQWKHGHYHO-
opment of adaptive immunity. Recent studies implicate single nucleotide 
polymorphisms (SNPs) in toll-like receptors (TLR) 4 and 9 in susceptibil-
ity to severe clinical malaria. However the role of innate immunity in eBL 
pathogenesis has yet to be determined. Kenyan children (n=264) from re-
gions with divergent malaria endemicity and children diagnosed with eBL 
(n=204) were screened for the frequencies of TLR9 SNPs (T/C-1486, T/C-
1174, G/A1174 and G/A2848) determined by multiplex ligation detection 
reaction; and TLR4 SNP (Asp299Gly) determined by real timequantitative 
3&55743&5(%9YLUDOORDGPHDVXUHGE\5743&5DPSOL¿FDWLRQRI
DNA extracted from whole blood, was also compared in these three groups 
RIFKLOGUHQVWUDWL¿HGE\7/5SRO\PRUSKLVP7KHUHZDVQRVLJQL¿FDQWDVVR-
ciation between TLR9 or TLR4 SNP allele frequency and eBL. However, a 
borderline association of EBV viral load with the TLR9 T/C-1486 SNP was 
REVHUYHGDWDVLJQL¿FDQFHOHYHORI7KLVVXJJHVWVWKDWLQQDWHLPPXQLW\
may play a role in determining viral set points and therefore may belong in 
the mechanistic pathway leading to eBL. Future studies are warranted to in-
vestigate the functional role of TLR in controlling persistent viral infections 
and if TLR ligands contributed by malaria co-infections modulate antiviral 
immunity.
COMPARISON OF EBV STRAINS IN PERIPHERAL BLOOD 
AND SALIVA OF MOTHER-CHILD PAIRS IN A BURKITT’S 
LYMPHOMA ENDEMIC REGION OF WESTERN KENYA.
Namuyenga E.T1, Piriou E2,Odada P.K2, Moorman A3, Ofulla A1,Vulule J2, 
Rochford R4
1Maseno University, Maseno, Kenya, 2Kenya Medical Research Institute, 
Kisumu Kenya, 3Case Western Reserve University, Cleveland OH USA, 
4SUNY Upstate Medical University, Syracuse New York USA,
There are 2 strains of EBV, EBV Type 1 and Type 2 that exhibit both phe-
notypic and genotypic differences. Type 1 is the dominant strain in US and 
Europe while a relatively equal distribution of Type 1 and 2 has been re-
ported in a select number of African countries. There is little information on 
the prevalence of these two strains in children living in a region at risk for 
endemic Burkitt s lymphoma. The goal of this study was to determine the 
prevalence of EBV Type 1 and Type 2 in children and their mothers. Since 
EBV can be detected in both saliva and blood, we also wanted to compare 
the differences in virus type between these compartments. In a pilot study, 
nineteen mother/child pairs were recruited from a region in Western Kenya. 
For 12 groups, samples were collected from more than one child in the fam-
ily. PCR primers were used to amplify a region of the EBNA3C gene that 
can distinguish between the two strains based on the size of the PCR product. 
'1$ZDVH[WUDFWHGIURPSHULSKHUDOEORRGDQGVDOLYDDQG3&5DPSOL¿FDWLRQ
ZDVGRQHRQDOOVDPSOHV(%9W\SHDQGDUHLGHQWL¿HGEDVHGRQOHQJWK
differences within the EBNA3C gene. EBV DNA was detected in the saliva 
of 46.7% of the mothers and 57.1% of the children. In the blood, EBV DNA 
was detected in 63.2% of the mothers and 57.9% of children. When we ex-
amined the type of EBV strain in saliva in the children, we found in 40.7% 
were Type 1, 11.1% were Type 2 and 7.4% were Type 1 and 2. In contrast, 
we observed more mixed infections in the blood where 20.6% were Type 1, 
38.2% Type 1 and 2, and in 41.2% no EBV was detected. Comparison of the 
type of EBV found in mothers and children showed only 37.5% match in 
strain in saliva but 83.3% match in the EBV strain detected in the blood. In 
summary, we observed a high percentage of children co-infected with both 
EBV Type 1 and 2 and the numbers found were much higher than reported 
for healthy adults in the US. In addition, the information on strain prevalence 
and transmission patterns will help us better understand the epidemiology of 
EBV and the potential role of EBV strains in the etiology of eBL.
THE BURKITT TUMOR PROJECT IN ACCRA, GHANA
Robert J. Biggar, MD, Francis Nkrumah and Janet Neequaye U.
State Serum Institute, Copenhagen, Denmark; Ghana Medical School, 
Accra, Ghana .
In 1969, the US National Cancer Institute established a parallel Burkitt 
Tumor Project (BTP) at Korle Bu Hospital, the University of Ghana’s teach-
LQJKRVSLWDOLQ$FFUD*KDQD,WVLQLWLDOPLVVLRQZDVWRFRQ¿UPHOVHZKHUH
what was being reported in Uganda. However, it soon became critical to 
Burkitt lymphoma (BL) studies as Uganda became increasingly affected 
by political turmoil. Active NCI participation lasted until 1979, and local 
leadership was soon overtaken by the emerging AIDS epidemic. Coverage 
included mainly the south half of Ghana, from which about 30-40 patients 
per year were referred for a total evaluation of more than 1,000 patients. 
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BL. Important observations contrasting with Uganda were the increasing 
proportion of abdominal rather than facial BL, failure to see a clear-cut re-
lationship to malaria, an HLA Dr7 association, and lack of geographic or 
familial clustering. A major research focus to understand the natural history 
RI(%9DFFHSWHGDVEHLQJFDXVDOO\LPSRUWDQWLQ%/7KHVHVWXGLHV¿UVWHV-
WDEOLVKHGWKHODWHLQIDQF\¿UVW\HDU(%9LQIHFWLRQSDWWHUQLQ$IULFDDQGD
lack of clinical symptoms or haematological changes associated with early 
childhood infection. The observations, now text book standards, are basic to 
our knowledge of EBV infection. There was no relationship between EBV 
and malaria antibody titers, a still controversial issue.
MALARIA, HIV AND MALIGNANT LYMPHOMAS IN EAST AND 
CENTRAL AFRICA AND IN GERMANY. 
Schmauz R
Institut für Pathologie, Papenburg and Universität zu Lübeck, Germany
%XUNLWW¶VO\PSKRPD%/LQWKHXSGDWHG.LHOFODVVL¿FDWLRQLVDPDOLJQDQW
lymphoma (ML) of high-grade malignancy, and associated with both falci-
parum malaria (FMA) and HIV. A synopsis of own collaborative studies is 
given assessing such relationships in the remainder of ML. Four different 
areas are compared, namely two in Uganda during the years 1966-1973 with 
marked and little FMA. The third area was Rwanda 1979-1987 during the 
rise of the AIDS-epidemic and without FMA, and the fourth Oberbergisches 
Land near Cologne during 1991-1993 without FMA and with AIDS in negli-
gible frequency. The cases came from the Kampala Cancer Registry, and the 
Pathology Departments in Butare and in Gummersbach. Histological review 
ZDVDFFRUGLQJWRWKHXSGDWHG.LHOFODVVL¿FDWLRQDQGDOZD\VZLWKDVVLVWDQFH
of a senior hematopathologist. Proportional frequencies of BL were 52, 28, 9 
and 1%, respectively, and for all types of high-grade malignant lymphomas 
86, 62, 53 and 40%. For aggressive Hodgkin’s lymphomas the values were 
75, 60, 64 and 38%, and for high-grade Non-Burkitt, Non-Hodgkin’s lym-
phomas (NBNHL) 70, 44, 45 and 30%. Conclusions: In areas endemic for 
FMA aggressive/high-grade lymphoid malignancies other than BL are also 
relatively more common although the difference is not as marked as in BL, 
DQGLQ$,'6DIÀLFWHG5ZDQGDDPLOGLQFUHDVHRIWKHVHO\PSKRPDVDSSHDUV
possible. Among single types of NBNHL immunoblastic and immunocytic 
lymphomas were seen most frequently in Rwanda. By contrast, in the other 
three areas centroblastic and centroblastic/-cytic types were leading. – Other 
\HWXQH[SODLQHG¿QGLQJVRILQWHUHVWZHUHWKHORZUHODWLYHIUHTXHQFLHVRI7
cell lymphomas observed in Africa in comparison to Germany with values of 
3, 3, 5 and 20%, and the absence of cases of immunocytoma in the very large 
material from Uganda. – Efforts are under way to include for comparison 
recent data from an area where both FMA and AIDS are prevalent.
DEVELOPMENT OF EBV-SPECIFIC IMMUNITY DURING 
THE FIRST YEAR OF LIFE IN CHILDREN WITH DIVERGENT 
EXPOSURE TO PLASMODIUM FALCIPARUM.
Erwan Piriou1,2, Amolo Asito1, Michael Opiyo1, Chelimo Kiprotich1,  
Peter Odada Sumba1, Ann Moormann3, Nancy Fiore2,  
Robert Ploutz-Snyder2, Rosemary Rochford2
1Kenya Medical Research Institute, Kisumu, Kenya; 2SUNY Upstate 
Medical University, Syracuse NY, USA; 3Case Western Reserve University, 
Cleveland OH, USA
It is hypothesized that P. falciparum induced activation of EBV-infected B 
FHOOVDQGVXSSUHVVLRQRIDQWLJHQVSHFL¿FLPPXQHUHVSRQVHVSOD\DQHVVHQWLDO
role in the pathogenesis of endemic Burkitt‘s lymphoma. To determine how 
WKHGHYHORSPHQWRI(%9VSHFL¿FLPPXQLW\LVDIIHFWHGLQFKLOGUHQUHSHDWHGO\
infected with P. falciparum, 2 groups of children are being followed longi-
WXGLQDOO\IURPELUWKWKURXJK\HDUVRIDJH7KH¿UVWJURXSLVIURPDQDUHD
where P. falciparum is holoendemic (Kisumu District, Kenya), whereas the 
second group is from an area with sporadic P. falciparum transmission (Nandi 
District, Kenya). EBV DNA load in whole blood, as well as EBV (VCA, 
EBNA1, EAd, Zta) and P falciparum (AMA1, MSP1p19, CSP1, LSA1)-spe-
FL¿FDQWLERG\OHYHOVZHUHGHWHUPLQHGDWPRQWKO\LQWHUYDOVGXULQJWKH¿UVW
\HDU(%9VSHFL¿F7FHOOVZHUHHQXPHUDWHGE\,)1Ȗ(/,6327DWPRQWKV
of age. By 12 months of age, 33.8% of children from Kisumu and 20.4% of 
children from district were infected with EBV as determined by detection of 
EBV DNA. The mean age of infection was 9.5 months versus 10 months in 
Kisumu vs. Nandi, respectively. Correspondingly, at 12 months of age, 34% 
and 21% of children had T-cell responses to a pool of lytic EBV epitopes in 
Kisumu and Nandi, respectively (p<0.05). In contrast, the frequency of T cell 
UHVSRQVHVWRDSRRORIODWHQWHSLWRSHVZDVQRWVLJQL¿FDQWO\GLIIHUHQWEHWZHHQ
the Kisumu (30%) and Nandi groups (25%). EBV- and P falciparum –spe-
FL¿FDQWLERGLHVDUHFXUUHQWO\EHLQJPHDVXUHGXVLQJDPXOWLSOH[HGVXVSHQVLRQ
EHDGDUUD\7KHVH¿UVWUHVXOWVVXJJHVWWKDWPRUHFKLOGUHQOLYLQJLQD
region with holoendemic malaria are infected with EBV earlier in life and 
WKDW(%9VSHFL¿F7FHOOUHVSRQVHVWRO\WLFSHSWLGHVFRUUHVSRQGZLWK(%9
viral load. Analysis of later time points will help us better understand how the 
GHJUHHRIH[SRVXUHWR3IDOFLSDUXPDIIHFWVWKHGHYHORSPHQWRI(%9VSHFL¿F
immunity and the ability to control EBV-infected cells.
SINGLE NUCLEOTIDE POLYMORPHISMS IN TOLL LIKE 
RECEPTOR 4 & 9 ARE NOT ASSOCIATED WITH ENDEMIC 
BURKITT LYMPHOMA LYMPHOMAGENESIS.
Mulama D1,2, Ptaschinski C4, Greene J3, Chelimo K2, Amolo A2,  
P. O. Sumba2, Ng ang a Z1, Vulule J2, Rochford R4 and Moormann AM3
1Kenyatta University, Kenya; 2Kenya Medical Research Institute, Kisumu, 
Kenya; 3Case Western Reserve University, Cleveland OH, USA, 4SUNY 
Upstate Medical University, Syracuse NY, USA
Endemic Burkitt s lymphoma (eBL) is the most prevalent pediatric tumor in 
equatorial Africa where malaria is holoendemic. Although strong epidemio-
logical link exists between early childhood EBV and chronic P. falciparum 
infection with eBL, the mechanisms by which these ubiquitous microbes 
interact to increase the risk of tumorigenesis are unknown. Plasmodium fal-
ciparum stimulates host immune cells via toll-like receptors especially TLR4 
and 9. Polymorphisms in these receptors have been associated with increased 
susceptibility to human diseases due to altered innate immune responses. In 
RUGHUWRGHWHUPLQHLIWKHVHSRO\PRUSKLVPVLQÀXHQFHH%/ULVNWKHIUHTXHQFLHV
of four common TLR9 SNPs (T/C-1486, T/C-1174, G/A1174 and G/A2848) 
and the one TLR4 SNPs (Asp299Gly) were examined in 494 children re-
siding in two regions of western Kenya differing in malaria transmission 
dynamics and an eBL population. TLR4 SNP was determined by R-T PCR 
while TLR9 genotypes were determined by multiplex LDR. Results demon-
strated that there was no association between TLR9 or TLR4 SNP genotype 
or allele frequency and history of malaria exposure or risk of eBL (p> 0.05). 
What was however interesting in these populations was the high percentages 
of heterozygous individuals for any genotype for all of the SNPs. This study 
highlights the fact that apart from malaria-induced immunosuppression of T 
cell immunity to EBV there may
be a role for the innate immune response in the etiology of eBL. Future stud-
LHVDUHZDUUDQWHGWRLQYHVWLJDWHKRZPDODULDLQIHFWLRQVLQÀXHQFHLQQDWHLP-
mune responses to EBV as a putative mechanism in eBL lymphomagenesis.
IMPACT OF EBV ON BURKITT LYMPHOMA
EPSTEIN-BARR VIRUS IN BURKITT’S LYMPHOMA: 
HISTORICAL ASPECTS AND INTERACTION OF PERSISTING 
EBV DNA WITH ENDOGENOUS HUMAN RETROVIRUSES/ 
HERV
Harald zur Hausen 
Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280,  
69120 Heidelberg, Germany. 
Fifty years ago, in 1958 and subsequently in 1962, Dennis Burkitt de-
scribed an African lymphoma as a malignancy frequently affecting primarily 
the jaw region of children aged 5-12 years. The occurrence of this tumor 
ZLWKLQVSHFL¿FFOLPDWLF]RQHVFKDUDFWHUL]HGE\KRORHQGHPLFWUDQVPLVVLRQ
of Plasmodium falciparum-caused malaria resulted in his speculation that it 
may have an infectious origin, possibly transmitted by an arthropod vector. 
The subsequent development of suspension tissue cultures of cells derived 
from this lymphoma, independently by Puvertaft and Epstein, permitted a 
more careful characterization of the tumor tissue. Epstein and his co-workers 
described in 1964 the presence of herpes virus-like particles in occasional 
WLVVXHFXOWXUHFHOOVGHULYHGIURPWKLVWXPRU$QLPPXQRÀXRUHVFHQWWHVWGH-
veloped by Werner and Gertrude Henle in Philadelphia permitted a further 
characterization of these particles, now labelled Epstein-Barr virus (EBV), 
and some of their biological properties. They showed that EBV was unre-
lated to other human pathogenic herpesviruses, that Burkitt’s lymphoma pa-
tients revealed elevated antibody levels against this virus, that EBV is able to 
immortalize normal human lymphocytes and that it represents the causative 
agent of infectious mononucleosis.
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titers to EBV also in nasopharyngeal carcinoma (NPC) patients. My own 
group demonstrated between 1970 and 1973 the presence of EBV DNA in 
non-virus producing Burkitt’s lymphoma cells, as well as in primary biopsies 
of African Burkitt’s lymphoma and nasopharyngeal cancer biopsies. In addi-
tion, we showed that the viral DNA persisted in NPC carcinoma cells and not 
LQWKHFRPPRQO\SUHVHQWO\PSKDWLFLQ¿OWUDWHV7KHVXEVHTXHQWGHPRQVWUD-
tion of a lymphoma-like disease after inoculation of EBV into squirrel or owl 
PRQNH\VXQGHUOLQHGWKHUROHRI(%9DVDWXPRUYLUXVLQIDFWWKH¿UVWKXPDQ
YLUXVFRQVLVWHQWO\IRXQGLQVSHFL¿FKXPDQPDOLJQDQFLHV
Within the following years the molecular structure of the EBV genome was 
unravelled, as well as varying expression patterns of the viral genome in dif-
ferent forms of genome latency. Viral DNA was also demonstrated in human 
immunoblastomas, arising under conditions of prolonged immunosuppres-
VLRQLQDVLJQL¿FDQWSHUFHQWDJHRI+RGJNLQ¶VO\PSKRPDVLQDVXEVHWRI
T-cell lymphomas, and in approximately 10% gastric cancers. This will be 
EULHÀ\VXPPDUL]HG,QVSLWHRIDGHWDLOHGNQRZOHGJHRIYLUDOJHQRPHVWUXF-
ture and viral gene expression patterns, up to today a number of questions still 
remain open. They concern in part the preferential geographic distribution of 
the endemic form of Burkitt’s lymphoma in equatorial Africa and of NPC 
in South East Asia, but also the requirement of EBV genome persistence in 
maintaining the malignant phenotype of the tumor cells. Indeed, evidence is 
accumulating that EBV may not be required for continuous growth of the re-
spective tumor cells under cell culture conditions or after xenografting NPC 
cells into nude mice. In addition, outside the endemic regions a high percent-
age of histologically identical tumors is devoid of detectable EBV DNA, 
although EBV-positive and –negative Burkitt’s lymphomas share similar 
chromosomal translocations.
Obviously, there exists a need to explain the different patterns of EBV per-
sistence and to identify common mechanisms in the positive and negative 
tumors driving the growth pattern into a histological more or less identical 
direction. Recent reports on the induction of a human endogenous retrovi-
rus (HERV) HERV-K18 supernantigen (Sutkowski et al., Immunity 15: 579, 
2001, Hsiao et al., J. Immunol. 177: 2056, 2006) may point to an interesting 
interaction between EBV infection and HERV sequences that comprise ap-
proximately 8% of the human genome.
For these reasons we initiated studies to analyze HERV expression and the 
expression of HERV-related microRNAs in EBV-infected lymphoblasts and 
latently EBV-carrying Burkitt’s lymphoma cells, as well as in EBV-negative 
Burkitt’s lymphoma cells and in cells of additional leukemic and lymphoma 
FHOOOLQHV,QSUHOLPLQDU\GDWDZHFRXOGLGHQWLI\WKHVSHFL¿FH[SUHVVLRQRID
microRNA in all EBV-infected cells tested thus far. Interestingly, the same 
microRNA was also highly expressed in EBV-negative Burkitt’s lymphoma 
FHOOVEXWQRWLQOHXNHPLFDQGRWKHUO\PSKRPDFHOOOLQHV7KHVLJQL¿FDQFHRI
these observations is presently being studied.
THE EVOLVING AND INTERTWINING STORY OF PERSISTENT 
INFECTION WITH EBV AND THE ORIGINS OF BURKITT’S 
LYMPHOMA
David A. Thorley-Lawson
Tufts University School of Medicine, Jaharis Building, 150 Harrison Ave. 
Boston MA, USA 
(SVWHLQ%DUUYLUXVZDV¿UVWGLVFRYHUHGLQWKHWXPRUFHOOVRIHQGHPLF%XUNLWW¶V
lymphoma. The subsequent discovery that EBV encodes several oncogenes, 
was able to transform human B lymphocytes in culture and was found in 
VHYHUDORWKHUWXPRUVOHQWVXSSRUWWRWKHLGHDWKDW(%9ZDVWKH¿UVWKXPDQ
oncogenic virus to be discovered. However it was subsequently found that 
EBV expressed different patterns of latent proteins in different tumor types 
and most surprisingly that none of EBVs oncogenic proteins were expressed 
in BL. The role of EBV as an oncogenic virus became even more mystifying 
when it was discovered that:
1.   There was an EBV negative form of BL and that the unifying defect in 
BL was a translocated, deregulated c-myc oncogene not the presence of 
EBV. 
2.   >95% of the human population harbor EBV for life without pathogenic 
consequences.
3.   The virus persists in resting memory B cells which, as far as we can tell, are 
completely normal. They are not transformed and the virus is essentially 
transcriptionally quiescent for latent proteins – a state reminiscent of BL. 
This raised the previously unlikely possibility that EBV played no role in 
BL pathogenesis and was just along for the ride in a memory B cell that hap-
pened to become a tumor. Given that 98% of endemic BL are EBV positive 
this coincidence is hard to explain but how to resolve these contradictions? 
Answers are now beginning to emerge through the description of a detailed 
model of EBV persistence that explains the origins of BL and other EBV 
DVVRFLDWHGWXPRUV,QWKLVWDON,ZLOOEULHÀ\UHYLHZWKHKLVWRU\RI(%9DVDQ
oncogneic virus in the context of BL, summarize the model of how EBV nor-
mally establishes and maintains persistent infection in memory B cells and 
¿QDOO\KRZDPROHFXODUXQGHUVWDQGLQJRIWKHPHFKDQLVPRIWKLVSHUVLVWHQFH
may explain the role of EBV in BL.
IMMUNE T CELL CONTROL OF EPSTEIN-BARR VIRUS 
INFECTION AND T CELL TARGETING OF VIRUS-ASSOCIATED 
TUMOURS
Alan Rickinson 
Cancer Research Institute for Cancer Studies University of Birmingham, 
UK
Epstein-Barr virus (EBV) replicates in permissive cells within the orophar-
ynx and colonises the B cell system through a latent, growth-transforming 
LQIHFWLRQ3ULPDU\LQIHFWLRQHOLFLWVVWURQJ&'7FHOOUHVSRQVHVWRO\WLFDQG
latent cycle antigens that then persist for life in the immunocompetent host. 
Both sets of antigens show marked hierarchies of immunodominance, with 
focusing of responses against epitopes drawn mainly from the immediate 
early and some early antigens of lytic cycle and against the EBNA3 nuclear 
DQWLJHQVRIODWHQWF\FOH7KRXJKOHVVDEXQGDQW(%9LQGXFHG&'7FHOO
responses are also becoming well characterised. Interestingly, these show 
different immunodominance hierarchies, with late lytic cycle antigens and 
the latent cycle EBNA1 antigen often eliciting the strongest reactivities.
With this a background, it is important to know (i) whether EBV-associated 
WXPRXUVDULVHLQWKHSUHVHQFHRUDEVHQFHRIYLUXVVSHFL¿FLPPXQLW\LLZKDW
are the most effective responses to harness against the tumour (ii) how best 
to boost such responses and direct them to the tumour site? The example of 
Burkitt Lymphoma (BL) is particularly interesting because the tumour cells 
show restricted viral antigen expression (usually EBNA1 only) and have a 
GHIHFWLQ0+&FODVV,SURFHVVLQJWKDWSUHYHQWV&'7FHOOUHFRJQLWLRQ
However BL cells do retain MHC class II processing function and a capac-
LW\WRSUHVHQWVRPHHQGRJHQRXVO\H[SUHVVHGDQWLJHQVWR&'7FHOOV7ZR
immunotherapeutic approaches are being explored in this context. One seeks 
WRWDUJHW%/XVLQJ&'7FHOOVVSHFL¿FIRU(%1$GHULYHGHSLWRSHV$VHF-
RQGH[SORLWVDQRYHOSRSXODWLRQRIF\WRWR[LF&'7FHOOVWKDWUHFRJQLVHDX-
WRORJRXV(%9WUDQVIRUPHG%FHOOVEXWDUHQRW(%9VSHFL¿F7KHVHHIIHFWRUV
appear to be directed against cellular target antigens that are up-regulated in 
EBV-infected (but not mitogen-activated) B cells and are also expressed in 
BL cell lines of endemic and sporadic origin irrespective of EBV status. 
THREE RESTRICTED FORMS OF EPSTEIN-BARR LATENCY 
COUNTERACTING APOPTOSIS IN C-MYC EXPRESSING 
BURKITT LYMPHOMA CELLS
Gemma Kelly, Julianna Stylianou, Andrew Bell, Wenbin Wei, Martin Rowe 
and Alan Rickinson.
CRUK Institute for Cancer Studies, The University of Birmingham, UK
Epstein-Barr virus (EBV) is aetiologically linked with Burkitt Lymphoma 
(BL) but its contribution to lymphomagenesis, versus that of the chromo-
somal translocation activating c-myc expression, remains unclear. This is in 
part because the full virus growth transforming programme that is expressed 
when EBV infects normal resting B cells, is not expressed in BL. Instead 
EBV in BL normally exhibits a restricted Latency I form of infection charac-
terised by expression of only one latent antigen EBNA1 from the BamHI Q 
promoter. Here we describe an endemic BL, Awia, which
uniquely is heterogeneous at the single cell level for EBV gene expression. 
Analysis of single cell clones of Awia-BL revealed cells displaying three 
forms of restricted EBV latency: (i) classical Latency I, (ii) Wp-restricted 
ODWHQF\H[SUHVVLQJ(%1$V$%&DQG/3DQGLLLDQRYHO(%1$
LMP1 latency in which all EBNAs including EBNA2 are expressed without 
the latent membrane proteins LMPs 1 and 2. Comparison with rare EBV-
negative clones from the same tumour showed that each form of infection 
SURYLGHVWKHFP\FH[SUHVVLQJ%/FHOOVZLWKDVSHFL¿FGHJUHHRISURWHFWLRQ
from apoptosis. Microarray analysis was carried out on the isogenic Awia-BL 
FORQHVWRGHWHUPLQHWKHLQÀXHQFHRI(%9JHQHH[SUHVVLRQRQFHOOXODUWUDQ-
scription. Interestingly it was found that expression of the pro-apoptotic Bcl2 
family protein BIM, which has previously been implicated in c-myc induced 
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suggests that EBV acts as an anti-apoptotic rather than a growth-promoting 
agent in BL by down regulating expression of the cellular BIM protein. In 
addition microarray analysis on these isogenic Awia-BL clones showed that 
WKH(%1$SUR¿OHLQÀXHQFHVWKHGLIIHUHQWLDWLRQVWDWXVRIWKH%/FHOORQWKH
JHUPLQDOFHQWUHWRSODVPDF\WRLGGLIIHUHQWLDWLRQSDWKZD\7KHVH¿QGLQJVPD\
UHÀHFWYLUDOIXQFWLRQVWKDWDUHLPSRUWDQWIRU%/SDWKRJHQHVLVDQGIRU(%9
persistence.
EBV GENOME LOSS FROM ENDEMIC BURKITT LYMPHOMA 
AND ITS EFFECTS ON CELL PHENOTYPE.
A. Boyce, R. Feederle, H.J. Delecluse, A. Bell, A. Rickinson, G. Kelly.
Cancer Research Institute for cancer studies., University of Birmingham, 
UK
EBV’s growth transforming function appears central to the pathogenesis of 
post-transplant lymphoproliferative disease. However the virus contribution 
to Burkitt Lymphoma (BL) remains uncertain since usually only one viral 
protein (the virus genome maintenance protein EBNA1) is expressed in BL 
cells. Studies on Akata-BL, an unusual sporadic BL line which spontane-
RXVO\JHQHUDWHV(%9ORVVFORQHVLQODWHSDVVDJH¿UVWVXJJHVWHG(%9VUROH
LQ%/ZDVDQWLDSRSWRWLF7RWHVWWKHJHQHUDOLW\RIWKLV¿QGLQJZHVLQJOH
cell cloned 11 early passage endemic BL cell lines and obtained EBV ge-
nome-negative clones from four lines, two in very early passage (Mutu-BL 
and Awia-BL), two at passage 40 (Eli-BL and Kem-BL). The propensity for 
genome loss did not correlate with steady state levels of EBNA1 but was 
associated with a more unequal segregation of the multiple EBV episomes 
DWPLWRVLVDVYLVXDOLVHGE\ÀXRUHVFHQFHLQVLWXK\EULGL]DWLRQ),6+:H
LQIHUWKDWWKHLQDELOLW\WRUHVFXH(%9QHJDWLYHFORQHVIURPRWKHUOLQHVUHÀHFWV
the rarity of complete genome loss among their daughter cells rather than 
any inherent non-viability of such EBV-loss cells. On all four of the above 
BL backgrounds (as in Akata-BL), EBV-loss clones were consistently more 
sensitive to a range of apoptosis inducers including anti-IgM cross linking, 
LRQRP\FLQDQGWKHQHXURWUDQVPLWWHUÀXR[HWLQH7KLVDVVRFLDWLRQEHWZHHQ
EBV status and a BL cell s sensitivity to apoptosis could not be explained by 
any observed difference in expression of the Bcl-2 family member proteins. 
By microarray analysis, while EBV-positive and EBV-loss clones show very 
VLPLODUFHOOWUDQVFULSWLRQSUR¿OHVVRPHJHQHVDUHGLIIHUHQWLDOO\H[SUHVVHG
their relevance to the above differences is being investigated.
EBNA1-SPECIFIC IFN-GAMMA PRODUCING T CELL MEMORY 
SUBSETS DIFFER WITH AGE.
Kiprotich Chelimo1, Paula Embury2, Peter O. Sumba1, Christian Münz3, 
Rosemary Rochford4 and  
Ann M. Moormann2
1Kenya Medical Research Institute, Kisumu, Kenya; 2Case Western Reserve 
University, Cleveland, Ohio, USA; 3Sunny Upstate Medical University, 
Syracuse, NY, USA; 4The Rockefeller University, New York, NY, USA.
The importance of cytotoxic T cells in controlling EBV infections has been 
HVWDEOLVKHGKRZHYHUIXUWKHULQYHVWLJDWLRQLQWRWKHSKHQRW\SHRI(%9VSHFL¿F
T cell may shed light into the etiology of endemic Burkitt lymphoma (eBL). 
IFN-gamma; mediates antiviral immunity though the source of this effector 
function may differ between children and adults, and in those exposed to 
malaria. T cells can be categorized into subsets based on surface marker ex-
SUHVVLRQDQGDELOLW\WRVHFUHWF\WRNLQHVLQUHVSRQVHWRVSHFL¿FDQWLJHQV7KH
development of immunity to EBV in children co-infected with Plasmodium 
falciparum malaria may therefore result in altered memory T cell differentia-
tion. We focused our initial investigations on IFN-gamma; T cell responses 
to EBNA1, the sole viral antigen expressed in eBL tumors. Peripheral blood 
mononuclear cells were isolated from Kenyan children and adults from a ma-
laria holoendemic area. IFN-gamma; responses were measured by ELISPOT 
DQGLPPXQRSKHQRW\SHGE\LQWUDFHOOXODUVWDLQLQJDQGÀRZF\WRPHWU\$VH[-
pected, the frequency of IFN-gamma; responses to EBNA1 increased with 
age coincident with overall T cell maturation. The majority of EBNA1-spe-
FL¿F,)1JDPPD7FHOOUHVSRQVHVZDVJHQHUDWHGE\&'DQG&'HIIHF-
tor memory T cells (TEM: CD62L-/CD45RA-) however there was a slight 
EXWQRWLFHDEOHWUHQGIRU&'7(0WRLQFUHDVHZLWKDJHZKLOH&'7(0
decreased. When examining IFN-gamma; T cell responses from RA re-ex-
SUHVVLQJHIIHFWRUPHPRU\7FHOOV7(05$&'/&'5$WKHLQYHUVH
ZDVREVHUYHG(%1$VSHFL¿F,)1JDPPDUHVSRQVHVIURP&'7(05$
GHFUHDVHGZLWKDJHZKLOH&'7(05$LQFUHDVHG7KHVHUHVXOWVUHYHDODQ
DJHDVVRFLDWHGGLIIHUHQFHLQ(%1$VSHFL¿F7FHOOPHPRU\VXEVHWVSURGXF-
ing IFN-gamma. Since EBNA1 is processed differently for presentation to 
&'YHUVXV&'7FHOOVWKHVH¿QGLQJVVXJJHVWDPHFKDQLVPE\ZKLFK
malaria could interfere with the development of immunity to EBV and there-
by predispose a child to eBL.
RAF2 BY EPSTEIN BARR VIRUS LATENT MEMBRANE PROTEIN
Ilaria Guasparri, Ethel Cesarman
Weill Cornell Medical College, USA.
A mechanism used by Epstein-Barr virus (EBV) for in vitro transformation 
of B cells into lymphoblastoid cell lines (LCLs) is activation of the nuclear 
factor kappa B (NF-954;B)pathway, which is largely mediated by the EBV 
latent membrane protein 1 (LMP1). LMP1 is co-expressed with a few other 
EBV latent proteins, including LMP2A, in some AIDS-related diffuse large 
B cell lymphomas, post-transplantation Lymphoproliferative disorders and 
Hodgkin‘s lymphomas. Since inhibition of NF-954;B leads to apoptosis of 
EBV-infected lymphoblastoid and lymphoma cell lines, we sought to deter-
mine whether LMP1 alone, or in combination with other viral proteins, is 
responsible for initiating NF-954;B activation in these cells, thereby playing 
a role in cell survival. Using RNA interference, we found that suppression of 
HLWKHU/03RU/03$UHVXOWVLQLQKLELWLRQRIEDVDO1)ț%DQGLQGXFWLRQ
of apoptosis in LCL and lymphoma cell lines. Simultaneous elimination of 
ERWK/03DQG/03$VKRZHGQRVLJQL¿FDQWDGGLWLYHRUV\QHUJLVWLFHIIHFW
Studies to elucidate the mechanistic basis for this observation revealed that 
suppression of LMP2A results in decreased transcription of TRAF2, which 
in turn is essential for LMP1-mediated activation of NF-954;B in LCL and 
EBV-infected lymphoma cell lines, while other TRAFs are not. Our data 
contrasts with previous studies showing that transfected LMP1 can signal in 
the absence of LMP2A or TRAF2, and demonstrate the requirement for both 
LMP2A and TRAF2 in naturally infected lymphoma cells and LCLs. These 
results also support LMP1, LMP2A and TRAF2 as potential therapeutic tar-
gets in a subset of EBV-associated lymphoid malignancies.
DNA METHYLATION PATTERN OF THE LMP1 GENE IN THE 
EPSTEIN-BARR VIRUS (EBV) AND ITS ASSOCIATION WITH 
LYMPHOPROLIFERATIVE DISORDERS.
Filipe Jacinto, Sónia Guedes-Melo, Augustin Fernandez-Fernandez,  
Pilar López, Irene Pino, Cecília Rosales, Biola Javierre, Miguel Angel Pires 
and Manel Esteller 
Institution: Cancer Epigenetics Laboratory, Molecular Pathology 
Programme, Spanish National Cancer Centre (CNIO), Melchor Fernandez 
Almagro 3, 28029 Madrid, Spain
It has been estimated that 15% of cancer cases are etiologically linked to 
viral infection; accounting for nearly 1.5 million new cases annually world-
wide. One of the viruses most related with carcinogenesis is Epstein-Barr 
virus (EBV) which is a ubiquitous herpes virus associated with a variety of 
lymphoid and epithelial tumours, as the nasopharyngeal carcinoma or even 
gastric cancer (Young, 2004). 90% of the world s adult population is infected 
by the virus, and it persists in the vast majority of individuals as a lifelong, 
asymptomatic infection of the B-lymphocyte cells (Gatza, 2005).
Previous studies have shown that EBV expression can be modulated by pro-
moter methylation. Since most parasitic elements that are methylated in the 
Human Genome never reactivate again, EBV has evolved using CpG pro-
moter hypermethylation to maximize persistence in host cells silencing gene 
expression. This epigenetic alteration of the viral genome appears to play a 
crucial role in the regulation of viral gene expression in normal and neoplas-
tic tissue, in the escape of infected cells from immune surveillance, and in 
the resistance of infected tumour cells to antiviral drugs. Further studies are 
needed to better understand the biology of this tightly regulated process of 
EBV gene expression and thus to maximize the therapeutic strategy for the 
treatment of EBV-associated tumours.
The main aim of this study was to characterize the DNA methylation pattern 
of the EBV gene LMP1 to better understand the role played by DNA meth-
ylation in the biology of the EBV infection in patients with lymphoprolifera-
tive disorders associated with the virus and how this epigenetic signature can 
be used for future therapeutic treatments.
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1Department of Human Pathology and Oncology, Division of Pathological 
Anatomy, University of Siena, Siena, Tuscany, 53100, Italy. 2Institute for 
Research in Biomedicine, Bellinzona, CH-6500, Switzerland. 3Ospedale 
San Giovanni, Bellinzona, CH-6500, Switzerland.
Recent studies suggest that Epstein-Barr virus (EBV) infects naïve B cells, 
driving them to differentiate into resting memory B cells via the germinal 
center reaction. This has been inferred from parallels with the biology of 
QRUPDO%FHOOVEXWKDVQHYHUEHHQSURYHGH[SHULPHQWDOO\5DJȖFPLFH
WUDQVSODQWHGDVQHZERUQVZLWKKXPDQ&'FRUGERRGFHOOVZHUHUHFHQWO\
shown to develop human B, T, and dendritic cells, constituting lymphoid 
RUJDQVLQVLWX+HUHZHXVHGWKLVPRGHOWREHWWHUGH¿QHWKHVWUDWHJ\RI(%9
infection of human B cells in vivo and to compare this with different condi-
tions of EBV infection in humans. Our results support the model of EBV 
persistence in vivo in cases characterized by follicular hyperplasia and a 
UHODWLYHO\QRUPDO&'DQG&'7FHOOGLVWULEXWLRQ,QWULJXLQJO\LQFDVHV
characterized by nodular and diffuse proliferation with a preponderance of 
&'7FHOOVVLPLODUWRLQIHFWLRXVPRQRQXFOHRVLV(%9VWLOOLQIHFWVQDwYH
B cells, but also induces clonal expansion and somatic ongoing mutations, 
without germinal center reactions. Our results reveal different strategies of 
EBV infection in B cells, possibly resulting from variations in the host im-
mune response.
EBV ONCOPROTEINS EBNA3A AND EBNA3C FUNCTIONALLY 
INTERACT TO REPRESS EXPRESSION OF THE TUMOUR-
SUPPRESSOR BIM: CLUES TO THE PATHOGENESIS OF 
BURKITT’S LYMPHOMA (BL)
Emma Anderton, Jade Yee, Kostas Paschos, Paul Smith, Tim Crook,  
Rob White and Martin J Allday
Department of Virology, Imperial College London, Faculty of Medicine, 
Norfolk Place, London W2 1PG, UK.
Bim is a pro-apoptotic member of the Bcl-2-family of proteins. The level of 
Bim is a critical regulator of lymphocyte survival and reduced expression is a 
major contributor to lymphoproliferative disease in both>mice and humans; 
%LPLVDKDSORLQVXI¿FLHQWWXPRXUVXSSUHVVRULQ%FHOOV0RUHRYHUEHFDXVH
LWLVDVSHFL¿FWDUJHWLQ0\FLQGXFHGDSRSWRVLV%LPLVXQLTXHO\LPSRUWDQW
in the pathogenesis of BL, since here Myc is always deregulated by gene 
translocation. EBV induces the continuous proliferation of primary B cells as 
lymphoblastoid cell lines (LCLs) and if EBV-negative BL-derived cells are 
infected with EBV, latency-associated viral factors confer resistance to vari-
ous inducers of apoptosis and dramatically reduce Bim expression. Nuclear 
proteins EBNA3A and EBNA3C are essential to establish LCLs and they 
are involved in the resistance of BL cells to cytotoxic treatments. We there-
fore created using an EBV-BAC system recombinant EBVs from which each 
(or all) of the EBNA3 genes has been independently deleted and revertant 
viruses in which the genes have been re-introduced into the viral genome. 
Infection of EBV-negative BL cells with this panel of EBVs and challenge 
with various cytotoxic agents revealed that EBNA3A and EBNA3C cooper-
ate as the main determinants of drug-resistance and the down-regulation of 
Bim transcription. There was no evidence of altered Bim RNA or protein sta-
bility and relief of EBV-mediated repression by histone deacetylase (HDAC) 
LQKLELWRUVVXJJHVWVWKDWHSLJHQHWLFPRGL¿FDWLRQVWRFKURPDWLQDUHLQYROYHG
By epigenetically suppressing the expression of Bim, through the combined 
DFWLRQRI(%1$$DQG(%1$&(%9VLJQL¿FDQWO\LQFUHDVHVWKHOLNHOLKRRG
of B-lymphomagenesis in general and endemic (e)BL in particular. These re-
sults may partly explain the selection pressure giving rise to a subset of eBL 
WKDWUHWDLQH[SUHVVLRQRIWKH(%1$SURWHLQVDQGZK\ZH¿QGWKDW0\FS
and 14ARF can remain non-mutated in these tumours.
IMMUNE ESCAPE IN EBV-POSITIVE BURKITT´S LYMPHOMA
Judith Reschke1, Martin Schlee1, Sebastian Grömminger1,Gerhard Laux1, 
Hanna Scheller1, Madhusudhanan Sukumar2, Andrea Wilke2,  
Armin Gerbitz2,3, and Georg W. Bornkamm1
1Institute of Clinical Molecular Biology and Tumor Genetics, GSF-
Research Center for Environment and Health, Marchioninistr. 25, D81377 
Munich, 2Med. Klinik III, LMU University Hospital and GSF-Clinical 
Cooperation Group, D3177 Munich, Germany, 3present address: Med. 
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Germany
%XUNLWWVO\PSKRPDLVQRWUHFRJQL]HGE\F\WRWR[LF7FHOOVVSHFL¿FIRU(%9
antigens. We have shown in a conditional in vitro system mimicking essential 
steps of the pathogenesis of BL that c-MYC contributes actively to immune 
HVFDSHE\QHJDWLYHO\UHJXODWLQJWKH1)ț%DQGWKH,)1UHVSRQVH6WXG\LQJ
the IFN response in BL cell lines in more detail, we have found that EBV-
SRVLWLYHEXWQRW(%9QHJDWLYH%/FHOOVDUHUHVLVWDQWWR,)1Ȗ\HWWKH\DUH
VXVFHSWLEOHWR,)1Įȕ,Q(%9ORVVYDULDQWVRI%/FHOOVWKH,)1ȖUHVSRQVHLV
QRWUHVWRUHGUXOLQJRXWDYLUDOJHQHSURGXFWDVPHGLDWRURI,)1ȖUHVLVWDQFH
*HQHWLFGHIHFWVLQWKH,)1ȖSDWKZD\FRXOGDOVREHH[FOXGHGE\GHPRQVWUDW-
ing that group III BL cells (as well as EBV-immortalized cells) are invariably 
VHQVLWLYHWR,)1ȖZKHUHDVJURXS,FHOOVDUHUHVLVWDQW7KHVHGDWDSRLQWWRDQ
HSLJHQHWLFPHFKDQLVPOHDGLQJWRVLOHQFLQJRIWKH,)1ȖVLJQDOOLQJSDWKZD\
in EBV-positive BL group I cells. No difference was observed in the ex-
SUHVVLRQRIWKH,)1ȖUHFHSWRUE\)$&6DQGTXDQWLWDWLYH573&5DQDO\VLV$
VLJQL¿FDQWGLIIHUHQFHZDVKRZHYHUIRXQGZKHQ-$.H[SUHVVLRQZDVVWXG-
ied. EBV-negative BL cells consistently expressed JAK2, albeit at low level, 
ZKHUHDVWKHPDMRULW\RI,)1ȖUHVLVWDQW(%9SRVLWLYHJURXS,%/OLQHVODFNHG
-$.H[SUHVVLRQYLUWXDOO\FRPSOHWHO\5HLQWURGXFWLRQRI-$.UHVWRUHG,)1Ȗ
responsiveness at least partially. Our data suggest that immune escape in BL 
cells to viral antigens is mediated by two mechanisms: the immunesuppres-
VLYHDFWLRQRIF0<&DQGWKHXQUHVSRQVLYHQHVVRI%/FHOOVWR,)1Ȗ:HSUR-
pose a model in which cross priming of phagocytosed BL cells may stimulate 
,)1ȖSURGXFWLRQE\DFWLYDWHG7FHOOV,)1ȖVHFUHWHGE\DFWLYDWHG7FHOOVPD\
thus overcome the immune suppressive action of c-MYC. According to this 
PRGHO,)1ȖUHVLVWDQFHPD\EHDQHFHVVDU\VWHSLQWKHGHYHORSPHQWRI(%9
SRVLWLYH%/LQYLYR:H¿QDOO\SUHVHQWD,JȜP\FWUDQVJHQLFPRXVHPRGHO
that allows to address this question experimentally.
EPSTEIN-BARR VIRUS AND OTHER MALIGNANCIES: OUR 
EXPERIENCE
Buda Francesco1,Argona Pietro2,Lagostina Fernando3, Martellotti Miranda
1Internal Medicine-Medical Oncology-City of Udine Hospital, Udine,Italy; 
2Clinacal Research Laboratory and Pathology, S,Vito Hospital,Pordenone,It
aly; 3Dpt of Pathology,University of Messina;
In addition to Burkitt‘s lymphoma ad undifferentiated nasopharyngeal car-
cinoma the association of the EBV and other malignancies is emerging. We 
KDYHLGHQWL¿HG(%9'1$E\6RXWKHUEORWK\EULGL]DWLRQDQDO\VLVLQPDOLJ-
nant limphoproliferations in nodes obtained from patients with Wiskott-
Aldrich syndrome, Cheidiak-Higashi syndrome and in a well differentiated 
secondary B-cell lymphoma arising in a patient with hairy cell leukaemia. 
We have determined the clonality  of these lymphoproliferations by identify-
ing rearranged heavy chain immunoglobulin sequences. Hybridization with 
a recombinant DNA  probe containing the immunoglobulin heavy chain join-
LQJUHJLRQLGHQWL¿HGPXOWLSOH'1$IUDJPHQWVLQ'1$IURP:LVNRWW$OGULFK
and Chediak-Higashi syndrome indicating the expansion of several clonal 
B-cell populations. The secondary malignancy in hairy cell leukemia was 
monoclonal. These results are similar to the malignant progression in EBV 
SUROLIHUDWLRQVLQRUJDQWUDQVSODQWUHFLSLHQWVRUVHYHUHO\LPPXQRGH¿FLHQWLQ-
dividuals in wich there is proliferation of several EBV-infected clones and 
eventual emergence of a monoclonal population. The emergence of EBV-
infected lymphoproliferation in Chediak-Higashi or hairy cell leukemia, 
suggest a role for natural killer cells(NKC)in controlling EBV-transformed 
lymphocytes.
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The Epstein Barr virus is a ubiquitous human herpes virus and can be as-
sociated with silent or symptomatic primary infection such a infectious 
mononucleosis, a self limiting lymphoproliferative disease characterized by 
polyclonal proliferation of EBV infected B cells. EBV is associated with 
malignant lymphoproliferation such as African Burkitt‘s lymphoma, B-cell 
O\PSKRPDVDULVLQJLQLPPXQHGH¿FLHQWSDWLHQWVLQFOXGLQJ+,9SRVLWLYHLQ-
dividuals, and various types of peripheral T cell lymphomas in apparently 
immunocompetent individuals of  Asian and Western population. Moreover, 
(%9LV¿UPO\DVVRFLDWHGZLWKFHUWDLQHSLWKHOLDOQHRSODVLDVVXFKDVORZGLI-
ferentiated nasopharyngeal carcinoma and undifferentiated carcinoma of 
the salivary gland in Greebìnladic Eskimos. These tumours are usually of 
the lymphoepithelioma-type, i.e. the neoplastic cells are associated with a 
prominent lymphoid stroma. The possible association between EBV and 
certain other epithelial tumours are presently less clear. Importantly, in the 
EBV-associated human tumours mentioned, EBV genomes and EBV gene 
products have been demonstrated by in situ methods (nucleic acid hybridiza-
tion, immunohistology)to be localized to the tumour cells and are not easily 
found in adjacent non neoplastic lymphoid or epithelia cells.
INFLUENCE OF HIV ON BURKITT LYMPHOMA
CLINICAL AND PATHOLOGICAL DATA ON HIV-RELATED 
BURKITT LYMPHOMA.
Martine Raphaël, Caroline Besson, Alex Duval, Chrystèle Bilhou-Nabera, 
Fanny Ménard, Hélène Antoine-Poirel, Christian Gisselbrecht, Jean Gabarre
Univ Paris-Sud, Inserm U802, AP-HP Hôpital Bicêtre,  
Le Kremlin-Bicêtre F94270, France
Three clinical variants of Burkitt lymphoma (BL) are recognised by the 
:+2FODVVL¿FDWLRQHQGHPLF%/VSRUDGLF%/DQGLPPXQRGH¿FLHQF\DV-
sociated BL. The latter is one of the main histologic subtype of HIV-related 
O\PSKRPD7KHUHLVDVLJQL¿FDQWUHODWLRQVKLSEHWZHHQWKHVXEW\SHRIO\P-
SKRPDDQGWKH+,9VWDWXV%/RFFXULQJLQOHVVVHYHUHO\LPPXQRGH¿FLHQW
patients. Most BL patients present with advanced clinical stage. Bulky dis-
HDVHZLWKDKLJKWXPRXUEXUGHQLQ¿OWUDWLRQRIWKHERQHPDUURZEXWXQIUH-
quent peripheral blood involvement, extracerebral nervous system and liver 
are clinical features, LDH is markedly elevated. At histologic level, classi-
cal BL and the plasmacytoid differentiation morphological variant showing 
abundant basophilic cytoplasm and eccentric nucleus are described. There is 
VLJQL¿FDQWGLIIHUHQFHRI&'FHOOFRXQWEHWZHHQWKHWZRYDULDQWVFODVVLFDO
%/KDYLQJDVLJQL¿FDQWKLJKHU&'FHOOFRXQWWKDQWKHSODVPDF\WRLGYDUL-
ant. Epstein-Barr virus (EBV) is present in 30% of classic BL and in 50-70% 
RISODVPDF\WRLGGLIIHUHQWLDWLRQ%/7KHUHDUHQRVLJQL¿FDQWGLIIHUHQFHVDW
genetic level between the two morphological variants of BL involving C-
myc oncogene and some additional genetic abnormalities.
Thus, the characteristics of HIV-related BL are the most aggressive clinical 
features but associated with a better HIV disease status.
HIGH-GRADE LYMPHOMA IN PATIENTS WITH AIDS-RELATED 
NON-HODGKIN’S LYMPHOMA (AR-NHL) IN EAST AFRICA: 
OBSERVATIONS FROM A PROOF-OF-CONCEPT PHASE II 
TRIAL WITH ORAL CHEMOTHERAPY.
1,4Remick SC, 2Orem J, 3Mwanda W, 2Katongole-Mbidde E, 4Meyerson H, 
and 5Ayers L
1West Virginia University Morgantown, WV, USA; 2Uganda Cancer 
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Introduction: The emergence of Burkitt’s-like lymphoma in homosexual 
men heralded the onset of the AIDS epidemic and the recognition that NHL 
was seen in increased incidence in HIV-infected patients. At the outset of the 
epidemic high-grade tumors clearly predominated. As the epidemic evolved 
intermediate-grade lesions were more commonly encountered. In Africa, 
detailed histopathological and molecular characterization of NHL has not 
been reported. A retrospective series of Burkitt’s lymphoma in Kenya (Int 
J Cancer 92:687, 2001) reported an approximate 3-fold increase incidence 
in adult patients coincident with the AIDS epidemic and median survival of 
15 weeks.
Patients and Methods: From among 257 prospectively screened patients 
ZLWK$51+/ZHWUHDWHGZLWKGRVHPRGL¿HGRUDOFKHPRWKHUDS\7KLV
regimen had a very acceptable 6% mortality rate, 78% objective response 
rate, and median survival of 12 mos. Pathology was reviewed and tumor 
phenotype was analyzed using a tissue microarray (TMA) method.
Results: Thirty-two of 49 (65%) patients had pathological material submit-
WHGIRUUHYLHZ7KLUW\RQHVDPSOHVZHUHVXI¿FLHQWIRUKLVWRSDWKRORJ\UHYLHZ
and 29 samples suitable for attempted TMA phenotyping. Overall histo-
ORJLFUHYLHZWXPRUVZHUHFODVVL¿HGDVKLJKJUDGH1+/QRWRWKHUZLVH
VSHFL¿HGLQFOXGLQJFDVHVWKDWZHUHRULJLQDOO\DVVHVVHGLQ(DVW$IULFDDV
intermediate to high-grade. Another 20 tumors were regarded as intermedi-
ate-grade including one low and one low-intermediate grade originally as-
sessed in East Africa. Immunophenotyping delineated 4 B-cell lymphomas, 
6 diffuse large-cell lymphomas (DLBCL), 1 anaplastic large cell lymphoma, 
1 Hodgkin’s disease, 4 lymphoblastic lymphomas including one T-cell de-
ULYHG%XUNLWW¶VO\PSKRPD(%(5SODVPDEODVWLFO\PSKRPDVERWK
(%(5DQGZLWKRXWVXI¿FLHQWQXPEHUVRILQWDFWFHOOVQHFURVLV&P\F
JHQHUHDUUDQJHPHQWVZHUHFRQ¿UPHGLQ%XUNLWW¶VKDGQRSUREHVLJQDO
and in one DLBCL. Six other samples had normal c-myc arrangements and 
the remainder had no probe signal. Survival was increased in patients with 
intermediate vs. high-grade tumors (p=0.013).
Conclusions: High-grade lymphoma appears to predominate in the back-
drop of AIDS in East Africa. The diversity of lymphoma in this setting is 
greater than anticipated suggesting molecular testing for as a worthwhile 
IXWXUHFDSDFLW\EXLOGLQJHQGHDYRU1+/SKHQRW\SLQJDQGPROHFXODUSUR¿OHV
of lymphoma encountered in HIV infection in Africa may yield important 
clues to improved therapy. [Supported in part by NIH grants nos.: CA83528, 
CA70081, and CA066531.]
EVIDENCE FOR AN ASSOCIATION BETWEEN INFECTION 
WITH HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV) AND 
BURKITT LYMPHOMA FROM CASE-CONTROL STUDIES IN 
UGANDA AND MALAWI.
Robert Newton1, Nora Mutalima2, Elizabeth Molyneux3,  
Delphine Casabonne4, John Ziegler5, Sam Mbulaiteye6, Edward Mbidde7, 
Henry Wabinga8, Harold Jaffe2, Valerie Beral4, Lucy M Carpenter2
1Epidemiology and Genetics Unit, Dept. Health Sciences, University 
of York, UK; 2Department of Public Health, University of Oxford, UK; 
3College of Medicine, Blantyre, Malawi; 4Cancer Epidemiology Unit, 
University of Oxford, UK; 5UCSF, California, USA; 6NCI, USA; 7UVRI, 
Uganda; 8Uganda Cancer Institute & Makerere University Medical School, 
Kampala, Uganda.
Studies from Europe and the USA indicate a substantial excess risk of the 
sporadic form of Burkitt lymphoma among HIV infected children, but this 
KDVEHHQOLWWOHVWXGLHGLQ$IULFDZKHUHWKHFODVVLFDOIRUPRIGLVHDVH¿UVWGH-
scribed by Denis Burkitt, is relatively common. We investigated the impact 
of infection with HIV on the risk of Burkitt lymphoma among children aged 
15 years or less in two case-control studies conducted in Kampala, Uganda 
and in Blantyre, Malawi. In both studies, cases were children diagnosed with 
Burkitt lymphoma and controls were children diagnosed with non-malig-
nant conditions or cancers other than those known to be HIV-associated (i.e. 
excluding Kaposi s sarcoma and other haematological cancers). Interviews 
were conducted and serological samples collected and, when possible, tested 
for antibodies against HIV. Odds ratios (OR) for Burkitt lymphoma were 
estimated using unconditional logistic regression adjusting for sex, age and 
residential district. In Uganda 10/33 cases were HIV seropositive, compared 
WRFRQWUROVDGMXVWHG25 FRQ¿GHQFHLQWHUYDO&,
In Malawi, 9/146 cases were HIV seropositive, compared to 2/93 controls 
(adjusted OR=12.4, 95% CI 1.3-116.2). In conclusion, infection with HIV 
increases the risk of Burkitt lymphoma among children in Africa, although 
the magnitude of the excess risk appears less than for the sporadic form of the 
tumour found among HIV infected children in Europe and the USA.
56 Journal of Hematopathology (2008) 1:47  74   – IMMUNITY IN PERSONS WITH AIDS-RELATED BURKITT 
LYMPHOMA COMPARED TO OTHER LYMPHOID 
MALIGNANCIES.
Robert J. Biggar (State Serum Institute, Copenhagen, Denmark);  
Anil Chaturvedi, Sam Mbulaiteye, James Goedert and Eric Engels 
(National Cancer Institute, Bethesda, Maryland USA)
State Serum Institute, DK and NCI, USA
Background. Burkitt lymphoma (BL) incidence in persons with AIDS is 
declining as therapies improve, although not so much as diffuse large B cell 
types or Kaposi sarcoma (KS). We examined risk of the AIDS-related can-
cers and Hodgkin lymphoma by CD4 count. Methods. PWA registered in 12 
regional US AIDS registries were linked to local cancer registry data. Among 
those entering follow-up cancer-free, cancer incidence was determined for 
4-27 months from AIDS onset in 1990-1995 and 1996-2002. We used pro-
portional hazards models to assess the relationship between CD4 count at 
AIDS onset and cancer incidence.
Results. Among 325,516 adult PWA, the incidence of KS and overall NHL 
was inversely associated with CD4 counts in both time-periods. In 1996-
2002, for each 50 CD4 cells/uL decline, the hazard ratio (HR) for KS was 
1.40 (1.33-1.50). Among NHL subtypes, the relationships with CD4 counts 
varied markedly. For BL, the hazard ratio with each 50 CD4 cells/uL decline 
was 0.93 (0.81-1.06) whereas for central nervous system (CNS) NHL the 
HR was 1.75 (95% CI: 1.64-1.88), and for non-CNS diffuse large B cell lym-
SKRPDLWZDVWR+RGJNLQO\PSKRPDULVNGHFUHDVHGVLJQL¿-
cantly in severely immunosuppressed patients, and shifted phenotype, with 
nodular sclerosing types being hardly seen in persons with <50 CD4 cells. In 
1990-95, the same relationships were seen with even stronger hazard ratios.
Conclusions. BL was not CD4-sensitive, and Hodgkin lymphoma risk ac-
tually decreased with profound immunosuppression, in contrast to patters 
for other NHLs. These variations indicate a complex pathogenesis underly-
ing each malignancy. They are particular surprising for BL, which has been 
considered an immunologically sensitive, virally-related tumour. Events in-
creasing BL in persons with HIV/AIDS appear to start before profound im-
munosuppression occurs and, we speculate, might be related to antigen drive 
UDWKHUWKDQLPPXQRGH¿FLHQF\
ROLE OF CHROMATIN REMODELLING MEDIATED BY THE 
HIV-1 TAT PROTEIN IN THE GENESIS OF HIV-ASSOCIATED 
MALIGNANCIES.
Giulia De Falco, Giovanna Cerino, Eleonora Leucci, Joshua Nyagol,  
Mario Cocco, Anna Onnis, Piero Tosi and Lorenzo Leoncini
Dept. Human Pathology and Oncology, University of Siena, Italy
The incidence of non-Hodkin’s lymphoma (NHL) is greatly increased in 
HIV-infected individuals. Malignant lymphoma is the second most common 
neoplasm (after Kaposi’s sarcoma) that occurs in association with acquired 
LPPXQRGH¿FLHQF\V\QGURPH$,'67KHYDVWPDMRULW\RIQHRSODVPVDUH
clinically aggressive, monoclonal B-cell neoplasms that exhibit Burkitt’s, 
immunoblastic, or large cell lymphoma histopathology. Although the molec-
ular mechanism underlying HIV-mediated transformation is not clearly un-
derstood, the Tat protein of HIV is a likely candidate to contribute to tumour 
pathogenesis in HIV-infected patients. Tat protein is an early non-structural 
protein necessary for virus replication, which is secreted by infected cells 
and taken up by uninfected cells. Extensive evidence indicates that Tat is a 
cofactor in the development of AIDS-related neoplasms and the protein has 
also been found to have an oncogenic role in vitro and in vivo. There is ex-
perimental evidence to suggest a potential role of Tat-mediated chemotaxis 
and invasion in the pathogenesis of AIDS-related malignancies. Deregulation 
of cellular genes and functions by Tat can also cause abnormalities that may 
contribute to AIDS pathogenesis and to the development of AIDS-associ-
ated disorders. The molecular mechanism underlying Tat’s pleotropic activ-
ity may include the generation of functional heterodimers of Tat with cell 
cycle proteins. In particular, Tat protein of HIV has also recently been shown 
to physically interact with the RB2/p130 tumour suppressor gene product 
and E2F4, resulting in uncontrolled cell proliferation. The interaction of Tat 
ZLWKFHOOF\FOHUHJXODWRU\SURWHLQVDORQHPD\QRWEHVXI¿FLHQWIRUQHRSODVWLF
transformation in vivo and other cofactors may be required.
$QRWKHUPHFKDQLVPWKURXJKZKLFK7DWPD\LQÀXHQFH+,9PHGLDWHGWUDQV-
formation, is by hyper-activation of transcription by interacting with chro-
matin remodelling complexes. Though viral transcription is fully dependent 
XSRQKRVWFHOOXODUIDFWRUVDQGWKHVWDWHRIKRVWDFWLYDWLRQUHFHQW¿QGLQJV
indicate a complex interplay between viral proteins and host transcription 
regulatory machineries, including histone deacetylases (HLACs), histone 
acetyltransferases (HATs), cyclin-dependent kinases (CDKs), and histone 
PHW\OWUDQVIHUDVHV+07V7KHFKURPDWLQVWUXFWXUHSUHVHQWVDVLJQL¿FDQW
EDUULHUWRWUDQVFULSWLRQ7KHVHPRGL¿FDWLRQVDQGDOWHUDWLRQVRIFKURPDWLQ
structure increase DNA accessibility to transcription factors and activators, 
WKXVSURPRWLQJWUDQVFULSWLRQLQLWLDWLRQDQGHI¿FLHQWHORQJDWLRQ0DQ\UHSRUWV
in the last several years have linked Tat transactivation to chromatin remod-
elling in vitro and in vivo. 
The aim of our study is to investigate whether Tat-mediated chromatin re-
modelling may have a role in HIV-associated transformation. The results of 
our work will be discussed during the meeting.
T-HELPER 1 VERSUS T-HELPER 2 LYMPHOCYTE 
IMMUNODYSREGULATION IS THE CENTRAL FACTOR IN 
GENESIS OF BURKITT LYMPHOMA: HYPOTHESIS
Joseph Lubega
University Hospital of North Staffordshire, Stoke-on-Trent, UK
Background. The HIV epidemic has challenged our previous understanding 
of endemic Burkitt‘s lymphoma. Despite the strong association of Burkitt‘s 
lymphoma and HIV infection in the Developed world, and against previ-
ous postulations that the cancer is due to immunosupression among African 
children, the HIV epidemic in the Malaria belt has not been associated with a 
corresponding increase in incidence of childhood Burkitt‘s lymphoma. Even 
outside the context of HIV infection, there is substantial evidence for a strong 
but skewed immune response towards a TH2 response in
genesis of Burkitt lymphoma.
Presentation of the hypothesis. Rather than a global and/or profound im-
PXQRVXSUHVVLRQWKH¿QDOFRPPRQSDWKZD\LQJHQHVLVRI%XUNLWWµVO\P-
phoma is the dysregulation of theimmune response towards a TH2 response 
dominated by B-lymphocytes, and the concomitant suppression of the TH1 
cell-mediated immune surveillance, driven by various viral/parasitic/bacte-
rial infections. 
Testing the hypothesis. Case control studies comparing TH2 and TH1 im-
mune responses in Burkitt lymphoma of different etiological types (sporadic, 
+,9UHODWHGHQGHPLFDQGSRVWWUDQVSODQWWRGHPRQVWUDWHVLJQL¿FDQWGRPL-
nance of TH2 immune response in presence of poor CMI response as a com-
PRQIDFWRU,PPXQRORJLFDOSUR¿OLQJWRHYDOXDWHGLIIHUHQFHVEHWZHHQLPPXQH
states that are associated (such as recurrent Malaria infection) and those that 
are not associated (such as severe protein-energy malnutrition) with Burkitt 
O\PSKRPD 3URVSHFWLYH FRKRUWV SUR¿OLQJ FKURQRORJ\ RI LPPXQRORJLFDO
events leading to Burkitt lymphoma in children with EBV infection. 
Implications of the hypothesis. The dysregulation of the immune response 
may be the missing link in our understanding of Burkitt lymphomagenesis. 
This will provide possibilities for determination of risk and for control of 
development of malignancy in individuals/populations exposed to the rel-
evant infections.
HIV-1 TAT INCREASES MICRO VESSELS DENSITY 
INDEPENDENTLY OF VEGF EXPRESSION IN AIDS-RELATED 
DIFFUSE LARGE B-CELL AND BURKITT’S LYMPHOMAS.
Nyagol J1, De Falco G1, Palummo N1, Shaheen S2, Bellan C1, Lazzi S1, 
Spina D1, Giordano A1,3, Leoncini L1
1Department of Human Pathology and Oncology, University of Siena-Italy; 
2Department of Pathology, Aga Khan University Hospital, Nairobi-Kenya; 
3Sbarro Institute of Molecular Medicine, Temple University, Philadelphia, 
USA.
Angiogenic switch marks the beginning of tumour’s strategy to acquire an 
independent blood supply. In some subtypes of non-Hodgkin’s lymphomas, 
higher local vascular endothelial growth factor expression has been correlat-
ed with increased micro vessel density. However, this local VEGF expression 
seems to be higher only in tumours with elevated expression of the receptors 
of the growth factor, suggesting an autocrine growth-promoting feed back 
loop. Several studies have indicated that VEGFRs are also targeted by the Tat 
protein expressed by HIV-1-infected cells. Given the similarity of the basic 
region of Tat to angiogenic factors (bFGF, VEGF), Tat is thought to mimic 
these proteins and binds to their receptors. In this study, we sought to evalu-
ate the role of HIV-1 Tat protein in regulating the level of VEGF expression 
and micro vessel density in AIDS-related diffuse large B-cell and Burkitt’s 
lymphomas. Using luciferase assay, we found out that VEGF promoter was 
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VEGF protein expression in primary HIV-1 positive BL and DLBCL as com-
SDUHGWRWKHQHJDWLYHFDVHVVXSSRUWHGWKH¿QGLQJVRISURPRWHULQDFWLYDWLRQ
from the cell lines. Micro vascular density assessed by CD34 expression was, 
however, higher in HIV-1 positive than in HIV-1 negative tumours. These 
results suggest that Tat binds to a different site on the VEGFRs, and acts 
as angiogenic factor independent of VEGF expression. Thus, targeting Tat 
protein itself and stabilizing transient silencing of VEGF expressions or use 
of monoclonal antibodies against their receptors in AIDS-associated tumours 
will open a window for future explorable pathways in management of angio-
genic phenotypes in AIDS-associated non-Hodgkin’s lymphomas.
PATHOLOGY AND BIOLOGY OF BURKITT LYMPHOMA 
MOLECULAR PATHOGENESIS OF BURKITT LYMPHOMA.
Kishor Bhatia 
National Cancer Institute, NIH, Bethesda, USA
A sine quo non of Burkitt’s lymphoma is the presence of a translocation be-
tween the c-myc gene and the IgH gene which is an early and a pivotal event 
in lymphomagenesis. In addition to this c-myc rearrangement, the features of 
which vary depending upon geography, sustainance of the tumor
phenotype and or progression potentially involves a varaible contribution by 
EBV as well as accumulation of other genetic events. These lesions include 
mutations in p53 and c-myc genes as well epigenetic modulation of silencing 
of other tumor suppressor genes. Additional studies using BL tumor cell lines 
demonstrate mutiple abberrations in the apoptotic pathway. Some of these 
YHU\OHVLRQVSURYLGHWXPRUVSHFL¿FWDUJHWVIRUGHVLJQLQJQRYHOWKHUDSHXWLF
strategies. The question of the biological and clinical relevance of these mo-
lecular lesions has not been fully studied. We hypothesize that variations 
in the genetic and epigenetic lesions in BL could be responsible for some 
differences of the clinical features of BL in Africa, including it’s heightened 
chemosensitivity.
C-MYC REGULATION AND THE CONSEQUENCES OF ITS 
DEREGULATION
Juhong Liu1, Fedor Kouzine1, Lawrence Benjamin, Hye-Jung Chung1, 
Zuqin Nie1, Ashutosh Gupta1,2, and David Levens1
1Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, 
MD 20892-1500, USA. 2Department of Physics, University of Maryland 
College Park, MD
Because c-myc translocation with an Ig-locus in is a sine quo non for Burkitt 
lymphoma, it necessary to understand the function and regulation of MYC 
in order to explain the pathogenesis and describe the pathology of this dis-
ease. MYC is an HLH-bZIP protein that heterodimerizes with MAX and is 
a master regulator of transcriptional and chromatin activity, regulating the 
expression of hundreds, if not thousands of targets. While most MYC-targets 
are up-regulated by the oncogene, some are repressed. Through these targets 
WKHLQÀXHQFHRI0<&LVSURMHFWHGSK\VLRORJLFDOO\RUSDWKRORJLFDOO\XSRQ
proliferation, cell growth, apoptosis, differentiation, metabolism, macromo-
lecular synthesis and cell signaling. Thus far, no discrete set of MYC targets 
KDYHGH¿QHGDOLQHDUSDWKZD\IRUFDUFLQRJHQHVLVLQ%XUNLWWO\PSKRPDRULQ
other tumors associated with deregulated c-myc expression. Whether the pa-
thology associated with MYC results from deregulation of just a few proper 
targets or from the inappropriate activation of pathologic targets has not been 
fully resolved. Moreover, what constitutes pathologic c-myc activation re-
mains unclear; for example in Burkitt lymphoma MYC levels range from 
physiological to massively over-expressed. 
  Recent evidence suggests that physiological c-myc expression is held to 
close tolerances with the potential for untoward consequences from exces-
sive cell-to-cell variation in MYC levels. Many features of the c-myc pro-
moter may be explained (or at least rationalized) as a system to constrain such 
variation, both at steady state and during induced peaks of c-myc transcrip-
tion. Because MYC protein and mRNA are normally both sparse and short 
lived, a hierarchy of systems have evolved to control c-myc transcription 
precisely and accurately in real-time. Though the c-myc promoter is robust to 
inactivation, its physiological operation is sensitive to the conformation and 
WRSRORJ\RILWV'1$DQGWRWKHFRQ¿JXUDWLRQRILWVFKURPDWLQUHQGHULQJWKH
gene susceptible to genetic disturbances.
MYC BREAKPOINTS IN BURKITT LYMPHOMA.
PM Kluin1, JEJ Guikema1,2, S Rosati1, EJ Boerma1, E Schuuring1
1Dept. of Pathology and Laboratory Medicine, University Medical Center 
Groningen, The Netherlands, 2Department of Molecular Genetics and 
Microbiology, Program in Immunology and Virology, University of 
Massachusetts Medical School, Worcester, MA 01655, USA
The t(8;14), or the variants t(8;22) and t(2;8) are hallmark translocations of 
Burkitt lymphoma (BL). These Ig-MYC breakpoints are found in approxi-
mately 75-80%, 10-15% and 5% of all cases and lead to juxtaposition to Ig 
enhancers and to constitutive over expression of MYC. Somatic mutations 
and breakpoints within the MYC gene might result into additional deregula-
tion by inactivation of regulatory regions or use of the P3 promoter, and might 
also interfere with binding of BIM involved in apoptosis. In BL, Ig-MYC 
breakpoints are primary events; similar translocations but also translocations 
involving MYC and other partner genes, can occasionally be found in dif-
fuse large B cell lymphoma and during progression of “indolent” lymphomas 
such as follicular lymphoma. Mapping of MYC breakpoints indicate distinct 
clustering far 5’ or far 3’of MYC in endemic BL and clustering immediately 
5’or within MYC in sporadic cases. Recent studies indicate the presence of 
two smaller breakpoints clusters within MYC itself. Approximately 10% of 
otherwise characteristic molecular BL, including some endemic BL lack a 
detectable breakpoint. This might be due to methodological problems or al-
ternative mechanisms leading to MYC over expression. In endemic BL the Ig 
breakpoint most often involves the VH-JH regions and in sporadic BL mostly 
the heavy chain switch regions. Both breakpoints are thought to be mediated 
by aberrant, AID-mediated recombination events in germinal centre B-cells. 
During normal class switch recombination, DNA double stranded breaks are 
LQWURGXFHGLQ6ȝDQGDGRZQVWUHDPVZLWFKUHJLRQZKLFKDUHVXEVHTXHQWO\
juxtaposed and ligated with deletion of the intervening DNA. In contrast, in 
almost all sporadic BL switch recombination of the translocated allele af-
fects only one switch region, resulting in a perfect reciprocal translocation. 
,QVRPHFDVHVZLWKDEUHDNSRLQWGRZQVWUHDPRI&ȝѽҏ,J0LVWUDQVFULEHGIURP
this allele and not from the non-translocated IgH allele.
C-MYC NEGATIVE CLASSICAL BURKITT LYMPHOMA: 
ALTERNATIVE PATHOGENETIC MECHANISMS 
Eleonora Leucci1, Mario Cocco1, Anna Onnis1, Patricia van Cleef2, 
Cristiana Bellan1, Anke van Rijk2, Giulia De Falco1, Joshua Nyagol1, Bessie 
Byakika3, Stefano Lazz1, Piero Tosi1, Johan van Krieken2,  
Lorenzo Leoncini1
1Department of Human Pathology and Oncology, University of Siena, 
Italy; 2Department of Pathology, Radboud University Nijmegen Medical 
Center, Nijmegen, The Netherlands; 3Department of Pathology, The Nairobi 
Hospital, Nairobi, Kenya
The molecular hallmark of Burkitt lymphoma (BL) is the translocation that 
place MYC under the control of immunoglobulin gene regulatory elements. 
However, from the EUROFISH project, aiming at the standardization of 
FISH procedures in lymphoma diagnosis, emerged that 5 cases out of 35 
classic endemic BLs were negative for MYC translocation. Here we inves-
tigated the expression of miRNAs directed against c-myc in eBL cases; we 
found Let-7c to be down-regulated in BLs compared to the reactive lymph 
node. More interestingly, hsa-mir34b was down-regulated in BL cases nega-
tive for MYC translocation. This event might be responsible for c-myc de-
regulation, since we demonstrated that hsa-mir-34b is able to regulate c-myc. 
0RUHRYHUWKH¿QGLQJWKDWFP\FLVUHJXODWHGE\WKLVPL51$FUHDWHVDQLP-
portant regulatory link between p53 and c-myc pathway.
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A Zettl3, A Rosenwald3, E Campo4 , PM Hoogerbrugge5, JHJM Krieken6, 
WA Kamps7, KH Lam8, IM Appel9, SS Dave10, LM Staudt10, E Schuuring1, 
A van den Berg1, PM Kluin1 – *EGB and VN contributed equally
1Department of Pathology & 2Department of Medical Genetics, University 
Medical Center Groningen, The Netherlands, 3Institute of Pathology, 
University of Würzburg, Germany, 4Department of Pathology and 
Hematology, Oncology Hospital Clinic, University of Barcelona, Spain, 
5Department of Paediatrics & 6Department of Pathology, University 
Medical Center Nijmegen, The Netherlands, 7Department of Pediatric 
Oncology, University Medical Center Groningen, 8Department of 
Pathology, Erasmus Medical Center, Rotterdam, 9Dutch Childhood 
Oncology Group, The Hague, The Netherlands, 10Metabolism Branch, 
Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 
USA.
Two recent studies show that sporadic Burkitt lymphoma (BL) has a rela-
WLYHO\UREXVWJHQHH[SUHVVLRQSUR¿OH,QERWKVWXGLHVWKHSUR¿OHZDVPDLQO\
based on the analysis of paediatric sporadic BL, which therefore may be 
considered as a prototype of BL. Without additional array-type gene expres-
sion analysis, BL is less easily to diagnose. For example in adult patients 
%/PD\EHGLI¿FXOWWRGLVFHUQIURPGLIIXVHODUJH%FHOOO\PSKRPDVZLWKD
VLPLODUYHU\KLJKSUROLIHUDWLRQUDWH$EHWWHU'H¿QLWLRQRIJHQHWLFDOWHUDWLRQV
additional to the hallmark MYC-translocation (with juxtaposition to one of 
the immunoglobulin loci) might therefore help to improve diagnosis. 
Classic and an array based comparative genomic hybridization (CGH) with 
6465 BAC/PAC clones were applied on 18 abdominal BL from homoge-
neously treated paediatric patients. Genomic alterations were compared to 
gene expression analyses obtained with the Affymetrix U133 plus 2.0 plat-
form. 
,QRXWRIWKH%/ZHIRXQGDEHUUDWLRQV$UUD\&*+LGHQWL¿HGPRUH
DEHUUDWLRQVWKDQFODVVLF&*+5HFXUUHQWVHJPHQWDOJDLQVQZHUHRE-
served at 3q29, 7q11, 11q22-q23 and 13q31-q32. Recurrent hemizygous 
ORVVHVQLQYROYHGTTTWHUTTTWHUTDQGS
ACEit analysis pointed out a number of potential target genes including 
TP53. The most common genetic aberration was gain at 13q31-q32 (n=6) 
with a minimal common region of 6.9 Mb. The two differentially expressed 
genes located in this region were c13orf25 and glypican-5
(GPC5). Quantitative RT-PCR of the individual micro-RNAs in the polycis-
tron c13orf25 also showed differential expression levels indicating differ-
ences in processing and/or stability of these microRNAs.
BURKITT LYMPHOMA IN UGANDA IN THE THIRD 
MILLENNIUM: A MORPHOLOGIC AND MOLECULAR 
APPRAISAL ON TISSUE MICRO-ARRAY.
Cristina Campidelli MD1, Lynnette K. Tumwine MD2, Simona Righi BS1, 
Stefano A. Pileri MD1
1Chair of Pathology, Unit of Hematopathology, Institute of Hematology 
DQG&OLQLFDO2QFRORJ\/	$6HUĚJQROL%RORJQD8QLYHUVLW\6FKRRO
of Medicine, 40138 Bologna, Italy 2Department of Pathology, Makerere 
University Medical School, P.O. Box 7072, Kampala, Uganda
129 routine tissue samples, collected over 10 years at Makerere University, 
were used for tissue micro-array (TMA) construction. Sections were cut 
from TMAs and used for Giemsa staining, immunohistochemistry and in 
VLWXK\EULGL]DWLRQFDVHVZHUHFODVVL¿HGDV%XUNLWWVO\PSKRPD7KHVLWHV
of disease were the abdomen (57%), lymph node (33%), and jaw (10%). 
Morphologically, BL showed a cohesive and monotonous medium-sized 
QHRSODVWLF LQ¿OWUDWH ZLWK IUHTXHQW PLWRWLF ¿JXUHV DSRSWRWLF ERGLHV DQG
starry sky pattern. 43 cases exhibited plasmacytoid differentiation. BL al-
ways expressed CD10 and Bcl-6. In all instances but three, Bcl-2 was nega-
tive. Proliferation index was close to 100%. Interestingly, CD30 and CD138 
were found in 35 and 43 cases, respectively. EBV integration was detected 
in all instances. As expected, BL was the commonest diagnostic category 
DFFRUGLQJWRWKH:+2FODVVL¿FDWLRQ7KLVUHVXOWLVPXFKKLJKHUWKDQZKDW
found in a similar study in Kenya but lower than what reported in a case 
control study in Uganda. This difference might be due to the fact that only a 
limited number of immunohistochemical markers were used in such studies. 
BL is a high grade neoplasm that occurs sporadically worldwide, but is en-
demic in Papua New Guinea and in central Africa. Notably, the phenotypic 
SUR¿OHREWDLQHGLQWKLVVWXG\ODUJHO\FRQ¿UPHGSUHYLRXVUHSRUWV$ODUJH
DPRXQWRI&'DQG&'SRVLWLYHFDVHVZDVREVHUYHG7KHIRUPHU¿QG-
ing largely corresponded to the plasmacytoid differentiation observed at mi-
croscopic evaluation. On the contrary, the latter was recorded irrespectively 
RIPRUSKRORJ\DQGPLJKWUHÀHFWWKHWXPRULJHQHVLVSURFHVV2XU¿QGLQJV
partly differ from Burkitt’s prototypic description and resemble what seen in 
Western Countries among sero-positive patients. Studies on the HIV status 
and MYC aberrations are ongoing at present and will be presented at the 
meeting, along with the possible correlation with the low incidence of jaw 
involvement.
Id PROTEINS IN BURKITT LYMPHOMA
Annette H. Schmitt-Graeff1, Michael Müller2, Hendrik Veelken3 and  
Oliver Opitz2
Institute of Pathology and comprehensive Cancer Center, University 
hospital of Freiburg, Germany.
Background: Id proteins (Inhibitor of differentiation/DNA binding) are 
dominant negative regulators of basic helix-loop-helix transcription factors. 
Members of the family include Id-1, Id2, Id3, Id4. Their interaction with E-
transcription factors blocks E-protein activity and results in a disruption of 
the differentiation program of various cell types. Id proteins are expressed in 
normal fetal and adult lymphoid tissues. Until now, the precise function of Id 
proteins in malignant lymphomas is incompletely assessed.
Methods and results: This prompted us to investigate the expression pat-
terns of Id proteins in lymph node and bone marrow biopsies from 25 pa-
tients with sporadic Burkitt lymphoma. We used commercially available Id1, 
Id2, Id3 and Id4 antibodies and the LSAB detection method. The staining 
intensity and the immunolocalization (nuclear vs. cytoplasmic) of tumor 
samples were evaluated and compared to normal lymph nodes and bone mar-
row specimens. All cases showed a strong predominantly nuclear expression 
of Id1. Immunolabeling by Id2 and Id2 antibodies revealed both cytoplasmic 
and nuclear expression patterns. Interestingly, the expression levels were 
higher in tumor cells disseminated to the bone marrow than in nodal mani-
festations. Id4 was clearly down-regulated both in nodal disease and in bone 
marrow trephines.
Conclusions: The high levels of Id1, Id2 and Id2 may be positively associ-
ated with the proliferation of Burkitt lymphoma cells and promote the dis-
semination to extra lymphatic sites, such as the bone marrow. Apparently, 
Id4 is inactivated in tumour cells. Whether the silencing is due to mutation of 
the Id4 gene or rather DNA methylation remains to be further investigated. 
Hypermethylation of the Id4 gene has been reported in EBV transformed B 
cells. Our data suggest that Id4 may play a role as tumor suppressor gene in 
Burkitt lymphoma.
FOXP1 IN BURKITT LYMPHOMA PATIENTS CROATIAN 
EXPIRIENCE.
Petra Kora1, Ivana Peran1, Roland A Ventura2, Slobodanka Ostoji; Koloni3, 
Alison H Banham2, Mara Dominis1
1Department of Pathology and Cytology, Merkur University Hospital, 
Zagreb, Croatia, 21XI¿HOG'HSDUWPHQWRI&OLQLFDO/DERUDWRU\6FLHQFHV
University of Oxford, John Radcliffe Hospital, Oxford, UK, 3Department of 
Internal Medicine, Merkur University Hospital, Zagreb, Croatia
Since 1980, 15 patients with Burkitt or Burkitt-like lymphoma have pre-
sented at the University Hospital Merkur in Zagreb, Croatia. Burkitt lym-
phoma is a very rare tumor in Croatia, not necessarily linked to younger 
patients. Tumor cells of this aggressive lymphoma are believed to originate 
from normal germinal centre or post-germinal center B-cells. Recently it has 
been shown that the FOXP1 transcription factor is an essential transcrip-
tional regulator for early B-cell development. The FOXP1 locus is targeted 
by recurrent chromosome translocations in both diffuse large B-cell lym-
phoma and MALT lymphoma, which are thought to de-regulate its expres-
sion. FOXP1 also represents a prognostic marker in these malignancies, and 
in cutaneous B-cell lymphoma, with high-level expression identifying poor 
prognosis patients. In this study we analyzed 15 Burkitt and Burlitt-like lym-
phoma patients by immunohistochemistry and detected FOXP1 protein in all 
cases and in almost all tumor cells. We performed FISH, detecting various 
FOXP1 gene abnormalities (n=6) and verifying the presence of the IGH/
MYC translocation (n=5). The same strong FOXP1 protein expression was 
observed independently of FOXP1 gene translocation (n=1), additional gene 
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protein expression levels. Furthermore, we searched for EBV infection (2 
cases being positive) and grouped patients according to age, gender or tumor 
localization and found no correlation with FOXP1 aberrations. In conclu-
VLRQZHUHSRUWWKH¿UVWVWXG\GHPRQVWUDWLQJ)2;3H[SUHVVLRQLQ%XUNLWW
lymphoma and suggest that genetic abnormalities do not appear to be the 
primary mechanism regulating its expression.
BURKITT‘S LYMPHOMA: A HISTOPATHOLOGICAL ANALYSIS 
OF 26 CASES.
Samaila Modupela Omotara A
Ahmadu Bello University Teaching Hospital
Background: Endemic African Burkitt‘s lymphoma has a predilection for 
the jaw. However, other sites are increasingly involved in affected children 
and adolescents.
Aim: To analyze the site distribution of Burkitt‘s lymphoma.
Materials &Method: A review of all cases of Burkitt‘s lymphoma diag-
nosed from tissue specimens seen in Pathology department of Ahmadu Bello 
University Teaching Hospital, Zaria over a 7year period (2000-2006).
Histology slides stained routinely with Haematoxylin & Eosin were studied. 
Patients‘ personal data and clinical information were obtained from records.
Results: Twenty-six cases were analyzed. They accounted for 24.5% of all 
lymphomas cases and 28.6% of malignant childhood tumours seen within 
the study period. There were 16 males and 10 females. The age range was 
18months to 16years with a mean age of 6.9years for both sexes. Four pa-
tients were aged above 11years. Eleven (11) patients presented with jaw 
PDVVHVLQYROYLQJWKHPDQGLEOHDQGPD[LOOD2IWKHVH¿YHKDGELODWHUDOMDZ
masses and four had associated intra-abdominal masses while four patients 
had associated dental anarchy and proptosis. Eleven (11) of the children 
presented with abdominal masses while four (4) had orbital swellings and 
impaired vision. Histologically, all showed diffuse sheets of lymphoblasts 
having fairly uniform round blue nuclei with scanty cytoplasm interspersed 
by foamy histiocytes and exhibiting characteristic starry sky appearance. The 
KLVWRORJ\LGHQWL¿HGVSHFL¿FRUJDQVDIIHFWHGLQWKHDEGRPHQDVWKHRYDU\
kidney (2), retroperitoneum (2) and mesentery (2). Cytogenetic analysis to 
determine if all the cases were endemic was not possible in our resource 
constraint setting.
Conclusion: Burkitt‘s lymphoma is still prevalent in our environment and 
abdominal presentation is common. Adolescents are increasingly affected.
BURKITT LYMPHOMA: ROLE OF pRB2/p130 INACTIVATION 
DURING LYMPHOMAGENESIS.
Eleonora Leucci1, Giulia De Falco1,2, Anna Onnis1, Annalisa Roberti1,2, 
Antonella Guzzo1,2, Lorenzo Leoncini1 and Antonio Giordano1,2
1Department of Human Pathology and Oncology, University of Siena, 
2Sbarro Institute for Cancer Research & Molecular Medicine, Biolife 
Science Building Suite 333, Temple University Philadelphia, PA19122, 
USA.
Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma consisting 
LQWKUHHYDULDQWVHQGHPLFVSRUDGLFDQGLPPXQRGH¿FLHQF\DVVRFLDWHG7KH
molecular hallmark of BL is the over-expression of c-Myc, due to the translo-
cation of this gene in proximity of the immunoglobulin promoter. However, 
0<&WUDQVORFDWLRQVDUHQRWVSHFL¿FIRU%/LQIDFW0<&WUDQVORFDWLRQV
have been reported 5-10% of DLBCL (diffuse large B cell lymphoma) and B 
lymphoblastic leukaemia/lymphoma. Moreover additional genetic and epi-
genetic alterations involving particularly p16 and p53 pathways have been 
described. 
We previously demonstrated, that the RBL2/p130 gene, a member of the 
retinoblastoma family, is mutated in BL cell lines and primary tumors. As 
pRb2/p130 controls cell growth, its inactivation may enhance the effect of 
c-myc over-expression and may contribute to transformation. In this study, 
we tried to reproduce c-myc over-expression and RB2/p130 silencing in a 
human non-transformed lymphoblastoid cell line, to analyze the contribution 
of these two genes in malignant transformation.
We found that pRb2/p130 silencing cooperates with c-myc over-expression 
decreasing the percentage of apoptotic cells and speeding up proliferation. 
Moreover, we demonstrated that pRb2/p130 mutation is not essential for ma-
lignant transformation, but is crucial for tumor progression, by conferring to 
the cells the ability to cross the extra cellular matrix.
CYTOGENETIC ANALYSIS IN DIFFERENTIAL DIAGNOSTICS 
OF BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL 
LYMPHOMA.
Obukhova TN, Baryakh EA, Zvonkov EE, Magomedova AU, Kaplanskaya 
IB, Kremenetskaya AM, Kravchenko SK, Domracheva EV, Vorobjev AI 
National Research Center for Hematology, Moscow, Russia
The distinction between Burkitt lymphoma (BL) and diffuse large B-cell lym-
SKRPD'/%&/LVGLI¿FXOWLQDVXEVWDQWLDOQXPEHURIFDVHV1HYHUWKHOHVV
this distinction is of great importance because these two lymphomas require 
different treatment strategies. We analyzed 119 patients with aggressive pre-
dominantly extranodal highly proliferative mature B-cell lymphomas using 
morphological, immunohistochemical and cytogenetic assay to establish 
differential diagnostic criteria. Conventional cytogenetic assay (CCA) was 
SHUIRUPHGLQSWVVWDQGDUG),6+LQSWVLQFDVHVRQO\SDUDI¿QHP-
bedded tissue was available for FISH-detection of c-myc rearrangements 
(c-mycR). By CCA t(8;14)(q24;q32) was revealed in 9 cases and variant 
t(8;22)(q24;q11) was found in 2 cases. 
In 15 pts complex karyotypes were found without c-mycR. By FISH t(8;14) 
was detected in 43 pts, c-mycR - in 2 cases and in 48 cases c-mycR was not 
revealed. Group with c-mycR consists of 56 pts: 44 males, 12 females, mean 
age 22 years. 83% has generalized disease stages, bone marrow Involvement 
was in 30 %, neuroleukemia in 24%. Extranodal sites of involvement were: 
ovarium 64%, intestine 43%, liver 35%, kidneys 24%, stomach 21%, facial 
bones in 2 cases. Atypical morphology was observed in 26% of pts; atypical 
immunophenotype in 21% ; in 5 cases Ki-67 was < 80%. Group without c-
mycR consists of 63 pts: 27 males, 36 females, mean age 47 years. In 89% 
RIFDVHVH[WUDQRGDOWXPRXUORFDOL]DWLRQZDVREVHUYHGKRZHYHUVSHFL¿FIRU
BL organs involvement was rare: intestine 15%, kidneys 5%, ovarium 0%. 
We did not revealed pts with bone marrow involvement or neuroleukemia. 
Typical for BL morphology was found in 10% of pts; 29% of cases were 
&'%FO%FOLQ.LZDVa:HFRQFOXGH7\SLFDOIRU
BL clinical, morphological and immunohistochemical pattern can be ob-
served in DLBCL. Differential diagnostics between BL and DLBCL is pos-
sible only on the basis of cytogenetic analysis.
HSA-MIR-127 IS IMPLICATED IN B CELL DIFFERENTIATION 
AND ITS EXPRESSION IS ALTERED IN BURKITT’S LYMPHOMA.
E Leucci1, A Onnis1, M Cocco1, V Costanzo1, G De Falco1,2, C Bellan1,  
L Leoncini1
1Department of Human Pathology and Oncology, University of Siena, Italy. 
2Sbarro Institute for Cancer Research and Molecular Medicine Center of 
Biotechnology, Biolife Science Building Suite 333, Temple University 
Philadelphia, PA 19122, USA.
Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma that occurs 
LQWKUHHFOLQLFDOYDULDQWVHQGHPLFVSRUDGLFDQGLPPXQRGH¿FLHQF\DVVRFL-
ated-BL.
Recent data suggests that EBV-positive and EBV-negative BLs have differ-
ent cells of origin. In particular, immunoglobulin gene mutation analysis, 
suggests an early centroblast origin for EBV-negative BLs, on the other hand 
EBV-positive BLs appears to originate from post germinal center cells, in 
spite of their germinal center phenotype. The appearance of a germinal cen-
ter phenotype in EBV-positive cells, might result from the activity of de-
UHJXODWHGF0\FDQGWKXVQRWUHÀHFWLQJWKHFHOORIRULJLQRI%/RUPLJKW
derives from a block in B cell terminal differentiation. MiRNAs are a class 
of small RNAs that regulate gene expression post-transcriptionally. We re-
cently reported a down regulation of a c-Myc-regulating miRNA in Burkitt 
lymphoma cases lacking MYC translocation. Here we showed that hsa-mir-
127 is strongly up regulated only in EBV-positive BL samples. Moreover we 
showed that it is implicated in physiological B cell differentiation both in 
vivo and in vitro. According with the down-regulation of this miRNA during 
plasma cell differentiation, we also demonstrated that it is able to inhibit in a 
dose dependent manner BLIMP-1 and XBP-1, resulting in up regulation of 
BCL6 and c-Myc. The deregulation of hsa-mir-127 in EBV-positive BL may 
well explain how a post-germinal center cell acquire an immunophenotype 
of germinal center due to the over expression of hsa-mir-127. 
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CORRELATION WITH EBV STATUS AND IGH MUTATION 
PATTERN
Cristiana Bellan1, Stefano Lazzi1, Mario Cocco1, Teresa Amato1, * 
Giulia De Falco1, Eleonora Leucci1, Giuseppina Antonicelli1,  
Nazzareno Palummo1, Susanna Mannucci1, Piero Tosi1, Miguel Piris2, 
Lorenzo Leoncini1
1Department of Human Pathology and Oncology, University of Siena, Italy; 
2Lymphoma Group, Spanish National Cancer Centre (CNIO), Madrid, Spain
Gcet1(serpin A9), a gene that belongs to the serpin family of proteins, is lo-
cated on chromosome 14q32. It is induced when B cells are stimulated with 
CD40L and it may play an important role in GC-B cell physiology and sur-
vival. Previous studies have shown that the expression of GCET1 is primar-
ily restricted to GC B-cells (centroblasts and large centrocytes but not small 
centrocytes) and also to lymphoid malignancies with GC B-cell maturation. 
7KH%/H[KLELWDKHWHURJHQHRXVVWDLQLQJIRU*&(7WKDWSUREDEO\UHÀHFWV
the eterogeneity of cell of origin of this lymphoma. The normal counterpart 
of the neoplastic B cells in BL is still unclear. Based on immunoglobulin gene 
rearrangement studies, some authors suggest an origin from germinal center 
cells and others from memory B cells. To better clarify the origin of BL we 
analysed the GCET1 expression on 38 endemic BL, and we correlated the 
GCET1 expression with the EBV status and with the immunoglobulin muta-
tion pattern of these cases. For that purpose we have performed immunohis-
tochemical analysis using a newly generated monoclonal antibody reactive in 
SDUDI¿QHPEHGGHGWLVVXHVDQG(%951$LQVLWXK\EULGL]DWLRQ,6+XVLQJ$
seminested polymerase chain reaction (PCR) to amplify the VDJ rearrange-
ments of the immunoglobulin heavy chain (VH) genes was perfomed and the 
UHVXOWDQWDPSOL¿FDWHVZHUHVHTXHQFHGIRUFRPSDULVRQZLWKNQRZQJHUPOLQH
9+VHJPHQWV:HIRXQGWKDW*&(7H[SUHVVLRQZDVVLJQL¿FDQWO\FRUUHODWHG
ZLWK(%9VWDWXVLQIDFWPRVWRIWKH(%9FDVHVZHUH*&(7ZKLOHPRVW
RIWKH(%9FDVHVZHUH*&(7,QWHUHVWLQJO\WKHPXWDWLRQSDWWHUQRI,J
JHQHVGLIIHUHGEHWZHHQ(%9*&(7FDVHVDQG(%9*&(7FDVHVZLWK
an average mutation frequency 1.7 and 5.1 respectively. In addition, we 
IRXQGVLJQVRIDQWLJHQVHOHFWLRQRQO\LQ(%9*&(7±FDVHV$OOWRRJKHWHU
WKHVHUHVXOWVDJDLQVXJJHVWHGWKDW(%9DQG(%9%/PD\RULJLQDWHIURP
distinct subsets of B cells, pointing to a particular role for the germinal center 
reaction in the pathogenesis of these tumors.
GENOMIC GAIN OF AURORA KINASE A IS FREQUENTLY 
FOUND IN BURKITT LYMPHOMA AND MAY HAVE SOME 
EFFECT ON CYCLIN D3 OVEREXPRESSION.
Bibiana I. Ferreira1, SM Rodriguez-Pinilla2 , Miguel A. Piris2,  
Juan C. Cigudosa1
1Molecular Cytogenetics Group and 2Lymphoma Group. Centro Nacional 
de Investigaciones Oncológicas (CNIO). Madrid. Spain
Burkitt lymphoma (BL) is one of the most aggressive types of B cell lympho-
ma. Apart from the pathogenomonic translocation t(8;14)(q24;q32), which 
results in the rearrangement of the CMYC oncogen, additional or secondary 
aberrations are frequent in BL that may play a relevant role in the variable 
clinical outcome of BL patients. Aurora A (AURKA) is a centrosome-associ-
ated serine/threonine kinase, which overexpression (normally due to gene 
DPSOL¿FDWLRQOHDGVWRFHQWURVRPHDPSOL¿FDWLRQDQGFKURPRVRPDOLQVWDELO-
ity. It has been associated with a worse prognosis in breast cancer patients. A 
putative similar role has been proposed for this gene in Non-Hodgkin lym-
phoma but nothing is known in BL.
AIMS: To evaluate the genomic status (number of copies) of AURKA in BL 
DQGWRSODFHLQFRQWH[WWKLVDQRPDO\ZLWKLQWKHSURWHLQH[SUHVVLRQSUR¿OHRI
this type of lymphoma.
M&M: A TMA containing 60 samples of BL (39 cases) and Burkitt-like 
diffuse large B-cell limphomas (21 cases) was subjected to FISH analy-
sis: AURKA probe was designed to cover the gene locus (RP5-1167H4). 
A breakapart CMYC probe from DAKO (Cat # Y5410) was used for 
proper BL diagnosis. FISH assay was carried with standard protocols. 
Immunohistochemistry was done for: cyclins (A,B,D3,E) and other markers 
(CD10, CD44, CD23, c-myc) Results and discussion:
1. While 80% of BL showed rearrangement of CMYC by FISH, only 33% of 
B-like cases were positive.
2. Gains or duplications (3 or 4 copies) of the AURKA gene were observed 
in 24 cases (53%): 48% in BL and 62% in B-like. These gains consistently 
appeared in discrete areas of the tumours, suggesting a secondary role. No 
KLJKOHYHODPSOL¿FDWLRQVRI$85.$ZHUHGHWHFWHG
3. The protein expression analysis revealed a trend (p=0.066) in the asso-
ciation between cyclin D2/D3 overexpression and AURKA gain. In fact, 
F\FOLQ'RYHUH[SUHVVLRQZDVDOVRIRXQGVLJQL¿FDQWO\DVVRFLDWHGZLWKWKH
presence of CMYC rearrangement and an evident cytoplasmic stain for 
the cmyc antibody.
EPIGENETIC SILENCING OF P16 AND P21 IN GAL-01 SPORADIC 
BURKITT LYMPHOMA CELL LINE.
Annalisa Roberti1,2, Giulia De Falco1,2, Eleonora Leucci1, Giovanna Cerino1, 
Alessandro Carugi1, Marcella Macaluso1, Laurence de Leval3,  
Lorenzo Leoncini1, Antonio Giordano1,2
1Sbarro Institute for Cancer Research & Molecular Medicine, Biolife 
Science Building Suite 333, Temple University Philadelphia, PA19122, 
USA; 2Department of Human Pathology and Oncology, University of Siena; 
3Department of Pathology, C.H.U. of Liège, Liege, Belgium.
Burkitt lymphoma (BL) is an aggressive B-cell tumor characterized by high 
growth rate with a large fraction of cycling cells. All Burkitt lymphomas 
(BLs) carry reciprocal chromosomal translocations that activate the c-myc 
oncogene through juxtaposition to one of the immunoglobulin (Ig) loci, pro-
viding a constitutive proliferative signal. 
This genetic anomaly is the critical event in BL development, but subsequent 
tumor progression involves the selection of additional genetic and epigenetic 
changes. It has been reported that both pRb and P53 pathways play a pivotal 
rule in this process.
The alteration of these pathway is well know in endemic Burkitt lymphomas 
BLe but no data as reported for sporadic ones. Here we showed that p16 and 
p21 expression are altered in Gal-01, a new sporadic BL cell line. 
Western blotting and immunocytochemistry assay have revealed the lack of 
S,1.DSURWHLQLQWKH*DOFHOOOLQH0HWK\ODWLRQ6SHFL¿F3&5063
revealed that loss of p16/INK4a is due to improper methylation of the pro-
moter region. 5-Aza-2 deoxycytidine (5-Aza-CdR) treatment reactivates 
S,1.DH[SUHVVLRQDQGVSHFL¿FDOO\LQKLELWHGWXPRUFHOOJURZWKVXJJHVW-
ing that aberrant promoter methylation is a common mechanism in sporadic 
burkitt lymphoma. At the same time, we analyzed the expression changes of 
some cell cycle regulating genes after demethylating tratment. 5-Aza-CdR 
WUHDWPHQWVLJQL¿FDQWO\LQFUHDVHGWKHOHYHORISWAF1/CIP1 without changing 
the amount of its direct activator p53. It suggests that also p21WAF1/CIP1 may 
be silenced by aberrant promoter methylation in Gal1 cell line. These data 
GHPRQVWUDWHGDWWKH¿UVWWLPHWKDWORVVRIH[SUHVVLRQRISDQGSE\SUR-
moter methylation may be a common mechanism in addition with c-myc 
overexpression in sporadic Burkitt lymphoma progression.
MOLECULAR PROFILING OF BURKITT LYMPHOMA
TRANSCRIPTIONAL GENE EXPRESSION PROFILING OF 
SPORADIC AND ENDEMIC BURKITT LYMPHOMAS IN 
RELATION TO OTHER TYPES OF AGGRESSIVE B-CELL 
LYMPHOMAS
Harald Stein1, Stefan Bentink2, Rainer Spang2, Dido Lenze1,  
Giulia De Falco3, Cristiana Bellan3, Mario Cocco3, Robert Iriso4,  
Lorenzo Leoncini3, Michael Hummel1
1Institut für Pathologie, Charité – Berlin, Campus Benjamin Franklin; 
2Institut für funktionelle Genomik, Computational Diagnostics Group, 
Regensburg; 3Department of Human Pathology and Oncology, Division of 
Pathological Anatomy, University of Siena, Siena, Italy; 4Lacor Hospital, 
Gulu, Uganda
The diagnosis of (sporadic) Burkitt lymphoma is not reliabe by means of 
histology, immunohistochemistry, and FISH. Therefore, we attempted to 
GHYHORSDPROHFXODUVLJQDWXUHIRUDPRUHDFFXUDWHGH¿QLWLRQRI%XUNLWWO\P-
phoma. Our approaches led to a detection of a signature which appears to be 
KLJKO\VSHFL¿FIRU%XUNLWWO\PSKRPD7KHDSSOLFDWLRQRIWKLVVLJQDWXUHIRU
WKHLGHQWL¿FDWLRQRI%/VLQDODUJHFROOHFWLRQRIDJJUHVVLYH%FHOOO\PSKRPDV
revealed that the morphological and immunophenotypical spectrum of mo-
OHFXODUO\GH¿QHG%/LVLQGHHGPXFKEURDGHUWKDQSUHYLRXVO\DQWLFLSDWHG8S
to one third of the molecular BLs proved to have the morphology of diffuse 
large B-cell lymphomas and up to 20% of them expressed BCL-2. Even the 
0<&EUHDNZDVPLVVLQJLQRIWKHFDVHV7KHVSHFL¿FLW\RIRXUVLJQDWXUH
ZDVFRQ¿UPHGE\DQRYDOLQGHSHQGHQWELRLQIRUPDWLFDSSURDFKHVWDEOLVKHG
YHU\UHFHQWO\LQRXUJURXS7KHVSHFL¿FLW\RIRXUPROHFXODU%XUNLWWVLJQDWXUH
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gressive B-cell lymphomas described by Dave et al (NEJM June 2006). This 
OHGWRWKHLGHQWL¿FDWLRQRIWKHVDPHFDVHVZKLFK'DYHHWDOKDGLGHQWL¿HGDV
Burkitt lymphomas by using a totally different gene expression signature. 
With information in mind we have now applied our gene expression signa-
ture to endemic Burkitt lymphoma. The results obtained are compared with 
those found for sporadic Burkitt lymphoma. 
Micro RNA EXPRESSION PROFILING OF MATURE AGGRESSIVE 
B-CELL LYMPHOMA WITH SPECIAL REFERENCE TO 
SPORADIC AND ENDEMIC BURKITT LYMPHOMA
Dido Lenze1, Michael Hummel1, Korinna Jöhrens1,Eleonora Leucci2,  
Anna Onnis2, Lorenzo Leoncini2 and Harald Stein1
1Institute of Pathology, Campus Benjamin Franklin, Charité-
Universitätsmedizin Berlin; Germany 
2Dipartimento di Patologia Umana e Oncologia, Università degli Studi di 
Siena, Italy
A delineation of diffuse large B-cell lymphoma (DLBCL) from Burkitt lym-
phoma (BL) or a distinction of clinical relevant subgroups within DLBCL is 
not reliably possible by means of histology, immunhistochemistry and FISH 
DQDO\VLV0<&EUHDN7KHUHIRUHJHQHH[SUHVVLRQSUR¿OLQJKDVEHHQSHU-
formed in order to identify molecular subgroups which are not dependent on 
morphological or immunophenotypic criteria. This led to the discovery of 
a gene signature which is able to identify BL cases among other aggressive 
B-cell lymphomas and divide DLBCL into cases derived from activated B-
cells (ABC) and germinal centre B-cells (GCB), respectively. However, both 
PROHFXODUFODVVL¿FDWLRQVOHDYHDVLJQL¿FDQWSURSRUWLRQRIFDVHVXQFODVVL¿HG
GHPRQVWUDWLQJDQHHGIRUDOWHUQDWLYHPROHFXODUFODVVL¿FDWLRQV6LQFHWKHDQDO-
ysis of microRNA expression is described as an additional approach for the 
LGHQWL¿FDWLRQVRIPROHFXODUDQGFOLQLFDOUHOHYDQWVXEJURXSVZLWKLQGLVHDVH
entities, we extracted RNA from 30 eBL and sBL cases as well as from 288 
DLBCL cases treated with CHOP with or without addition of Rituximab. The 
analysis of the microRNA expression was performed with microarrays car-
rying 303 human mircoRNAs and subsequent bioinformatic interpretations 
(ANOVA, Partitioning clustering) were carried out in order to detect differ-
entially expressed microRNAs. 81 microRNAs were found to differ in their 
H[SUHVVLRQEHWZHHQKLVWRORJLFDOO\GH¿QHG'/%&/DQG%/ZKHUHDVOHVVPL-
croRNAs were able to distinguish between ABC- and GCB-type of DLBCL. 
7KH%/FDVHVDVGH¿QHGE\WKHLUPLFUR51$H[SUHVVLRQSUR¿OHFRPSULVHQRW
only cases with a morphology of BL but also cases with a DLBCL morphol-
ogy. In addition, the microRNAs were able to subdivide the remaining cases 
lacking the microRNA BL signature into groups with clinical relevance. Our 
data show that the expression differences of microRNAs provide a valuable 
tool for the distinguishing of BL from DLBCL and adds to the dissection of 
DLBCL into prognostic molecular subgroups. Furthermore, some microR-
NAs are differentially expressed between sBL and eBL supporting the notion 
that they do not represent completely identical disease entities.
RBL2 NETWORK IN ENDEMIC BURKITT LYMPHOMA 
EXPLORED BY GENE EXPRESSION ANALYSIS.
Pier Paolo Piccaluga1, Giulia De Falco2,3, Andrea Califano4,  
Eleonora Leucci2, Annalisa Roberti2,4, Robert Lukande5,  
Lynette Tumuwine5, Robert Iriso6, Chiara Lucchetti2,4, Antonio Giordano2,3, 
Stefano A Pileri1 and Lorenzo Leoncini2
1Unit of Hematopathology, Institute of Hematology and Medical Oncology 
/DQG$6HUĚJQROL62UVROD0DOSLJKL+RVSLWDO8QLYHUVLW\RI%RORJQD
Italy. 2Dept. of Human Pathology and Oncology, University of Siena, Italy. 
3College of Science & Technology, Sbarro Institute for Cancer Research & 
Molecular Medicine, Temple University, Philadelphia PA 19122, USA.  
4Center for Computational Biology and Biochemistry, Columbia University, 
10032 New York, NY, USA. 5Department of Pathology, Makerere 
University Medical School, P.O. Box 7072, Kampala, Uganda, 6Lacor 
Hospital, Gulu, Uganda
Burkitt lymphoma (BL), the most common lymphoma type in Africa, is a B-
cell tumor typically characterized by translocation t(8;14)(q24;q32), leading 
to MYC over-expression. However, several additional alterations have also 
been described in BL, including RBL2 gene mutations. RBL2 belongs to 
the retinoblastoma family which is composed by three members, pRB/p105, 
p107 and RBL2/p130. Though through different mechanisms, they regulate 
cell cycle progression by inducing cell growth inhibition and arrest in differ-
ent cell lines. It has been previously demonstrated that RBL2 is commonly 
mutated in endemic BL, with consequent nuclear localization and functional 
inactivation of the encoded protein, pRb2/p130. This raises the intriguing 
possibility that RBL2 pathway alteration might play a role in BL pathogen-
esis. Recently, we showed that RBL2/p130 function restoration in BL cell 
lines determined regain of growth control, through the regulation of several 
genes.
:HWKXVSHUIRUPHGDJHQHH[SUHVVLRQSUR¿OH*(3DQDO\VLVRIHQGHPLF%/
cell lines, transfected with either wild type RBL2 or empty vector, and pri-
mary cases and normal B-cell subpopulations in order to 1) assess whether 
RBL2 dependent pathway is actually shut off in endemic BL; 2) assess 
whether introduction of functional RBL2 in BL cells could restore a func-
tional pathway consistent with that of normal B-cells; 3) identify possible 
5%/WDUJHWJHQHVĚĖPYF[RXQGWKDW5%/WUDQVIHFWHGFHOOVKDGDJOREDO
GEP relatively similar to that of wild type cells. However, we could identify 
a RBL2 dependent molecular signature which could clearly distinguish the 
samples according to RBL2 mutational status. Among others, this signature 
included genes relevant for cell cycle regulation. Analysis on primary cases 
DQGQRUPDO%FHOOVLVRQJRLQJDWSUHVHQW,QDGGLWLRQLGHQWL¿FDWLRQDQGFKDU-
acterization of RBL2 target genes is under evaluation by using the ARACNE 
algorithm. Results will be presented and discussed at the meeting.
INDUCTION OF A HODGKIN-LIKE PHENOTYPE OF BURKITT 
LYMPHOMA CELLS BY EPIGENETIC REPROGRAMMING 
Michael Hummel1, Anke Ehlers1, Elisabeth Oker1, Stefan Bentink1,  
Dido Lenze1, Harald Stein1
1Institut für Pathologie, Charité – Berlin, Campus Benjamin Franklin; 
2Institut für funktionelle Genomik, Computational Diagnostics Group, 
Regensburg 
The tumor cells of Burkitt lymphoma (BL) are regarded as derived from 
early germinal centre B-cells. They consistently show an immunophenotype 
of mature B-cells with expression of all B-cell typical antigens and transcrip-
tion factors. In contrast, the tumor cells of classic Hodgkin lymphoma (HRS 
cells), which are also thought to derive from germinal centre B-cells, have 
almost completely lost their B-cell identity. In addition, HRS cells have ac-
quired the expression of several antigens which are regarded as B-cell lineage 
inappropriate. We and others suggested that epigenetic events are involved in 
the silencing of B-cell associated genes as well as in the upregulation of B-
cell inappropriate genes. In order to determine this possibility we treated both 
Hodgkin and BL cell lines with DNA-demethylating (5-aza-dC) and histone-
acetylating (TSA) reagents. Treated and untreated cell lines were analysed 
by Affymetrix GeneChips. Numerous up- and down regulated genes were 
IRXQG7KLVZDVYHUL¿HGE\TXDQWLWDWLYH573&5DQG:HVWHUQEORWDQDO\VLV
Chromatin-immunoprecipitation was carried out to determine the epigenetic 
PRGL¿FDWLRQVLQWKHSURPRWHUUHJLRQRIWKHFRUUHVSRQGLQJJHQHV$JDLQVW
all expectations the treatment of Hodgkin cell lines with demethylating and 
acetylating reagents did not restore the B-cell expression program or parts of 
it. Instead, the treatment of BL cells resulted in a complete loss of their B-cell 
phenotype and – in parallel – to an up-regulation of Hodgkin-characteristic 
genes. Our data clearly demonstrate that DNA-demethylation and histone-
acetylation is able to re-program BL cells into cells with a Hodgkin-like phe-
QRW\SH7KHVH¿QGLQJVLPSO\WKDWGHPHWK\ODWLRQDQGDFHW\ODWLRQXSUHJXODWH
genes in BL cells that down-regulate the genes responsible for the B-cell 
H[SUHVVLRQSURJUDP7KHVH¿QGLQJVVXJJHVWWKDWWKHVDPHJHQHVZKLFKDUH
switched on in BL cells by DNA-demethylation and histone-acetylation are 
constitutively active in Hodgkin cells. It is tempting to speculate that these 
genes are not only involved in the extinction of the B-cell phenotype but also 
in the pathogenesis of Hodgkin lymphoma.
CLINICAL ASPECTS, CHEMOTERAPY AND NOVEL THERAPEUTIC 
TARGETS IN BURKITT LYMPHOMA
NON-ENDEMIC BURKITT’S LYMPHOMA IN MULAGO 
HOSPITAL, KAMPALA.
Dr. Birabwa-Male Doreen, Dr. Sekabira John, Dr. Namuguzi Daniel
Makerere University, Kampala, Uganda
Denis Burkitt, while working in West Nile, Uganda, discovered a jaw tu-
mour in Children which was later called Burkitt’s lymphoma (BL). The same 
tumour was later found to affect other abdominal and thoracic organs. The 
Former is unique to Sub-saharan Africa while the latter can be found else-
62 Journal of Hematopathology (2008) 1:47  74   – where in the world as well. The pattern in Uganda was looked at as it occurs 
in Mulago Hospital (MH).
Methods: In Uganda most of these patients before getting chemotherapy pass 
through the Paediatric Surgical Unit (PSU) of MH for diagnosis. Hospital re-
cords of these patients from 2005 – 2007 were looked at and analysed. The 
author has been looking after these children since.
Results: There were 73 pts with non-endemic BL seen at the PSU. Their 
age ranged from 2yrs – 12yrs. There were 30 males and 43 females. The 
most affected organ was the ovary, 59% and there was only one testicular in-
volvement. The other affected organs included liver, kidney and aortic lymph 
nodes. Most of these patients come late on average > 6/12.
Conclusion: Non- endemic BL is a very common tumour seen in Uganda. 
More efforts should be applied to pick it up early for better results.
SURPRISING PROFILE OF INCIDENT CASES OF BURKITT S 
LYMPHOMA IN THE LAKE ZONE IN TANZANIA.
Schmidt C, Kayange N, Festo E, Kahima, Bayange M 
Department of Paediatrics, Bugando University College of Health Sciences 
(BUCHS), Mwanza, Tanzania
Background: Burkitt`s Lymphoma (BL) is the most important malignant 
GLVHDVHRIFKLOGKRRGLQ(DVW$IULFD:HGHVFULEHWKHSUR¿OHRIUHFHQWLQFLGHQW
cases and the current approaches to diagnosis and therapy in our Department 
at the Bugando Medical Centre (BMC) in the Lake Zone, Tanzania.
Methods: In a period of six months (April-Sept. 2007) we admitted more than 
60 children with a diagnosis of BL. Children with suspected BL underwent 
¿QHQHHGOHDVSLUDWLRQ)1$LIQHFHVVDU\DQGLQDOOFDVHVRIDEGRPLQDOPDVV
under ultrasound (US) control, bone marrow aspiration (BMA) and lumbar 
SXQFWXUHIRUDVVHVVPHQWRIFHUHEURVSLQDOÀXLG&6)ZHUHSHUIRUPHG)XOO
blood picture (FBP), ELISA for HIV, liver and renal function tests (LFT and 
RFT), and abdominal US were done.
Results: 7KHGLDJQRVLVRI%/ZDVFRQ¿UPHGLQSDWLHQWVFKLO-
dren presented with abdominal mass, 22 (42%) head and 4 presented with 
combinations of abdominal mass and jaws. In total in our collective we 
found 30 (58%) children with an intraabdominal mass. The median age was 
6.2 years. 35 (67%) children were male, 17 (33%) female. Only 2 (4%) pa-
tients out of the total number were HIV positive.
Discussion: The African type of BL is characterized by a predominant ce-
SKDOLFORFDWLRQ$OWKRXJKLWLVNQRZQWKDWFOLQLFDOIHDWXUHVYDULHGVLJQL¿-
cantly by different regions in East Africa, the high number of abdominal BL 
in our children is remarkable. On the other hand the very low prevalence 
of HIV in our children with BL is surprising. The prevalence of HIV in our 
children with BL was even lower than the prevalence of all children of the 
Lake Zone in Tanzania.
Conclusions:$UHPDUNDEOHLQFLGHQFHSUR¿OHZDVIRXQGZKLFKGHPDQGVIXU-
WKHUVWXGLHVLQDGGLWLRQWRWKHRXWVWDQGLQJHI¿FDF\LQYHVWLJDWLRQV7KHQHZ
approach to BL at BMC/BUCHS has facilitated more appropriate treatment 
of children with BL.
TRENDS ON CHEMOTHERAPY IN BURKITT LYMPHOMA 
C Patte
Institut Gustave Roussy, Villejuif, France.
Burkitt lymphoma (BL) is the most frequent lymphoma in children, with a 
higher frequency in the so-called “endemic area”. Abdomen and face are the 
most frequent tumor sites. It generally presents as advanced stage disease. 
Bone marrow and CNS is involved in about 20% of the cases. Its outcome 
greatly improved due to several prospective (multi)national studies. 
Treatment must be done by intensive pulse polychemotherapy courses, but 
RIVKRUWGXUDWLRQUHODSVHVRFFXUULQJHDUO\ZLWKLQWKH¿UVW\HDU7KH)UHQFK
LMB studies told us that :a) HDMTX is a very effective drug for prevention 
RI&16GLVHDVHE/$/%DQG&16SRVLWLYHSDWLHQWVEHQH¿WHGIURPWKHLQ-
crease of the dose of HD MTX and the introduction of HD ARA-C (CYVE 
courses), c) treatment intensity can be adapted to stage and resection, but also 
to response to chemotherapy (at D7 and after 3 courses), d) early dose inten-
sity is essential. The German BFM studies told us that a) treatment intensity 
can be adapted to stage and resection, but also to LDH level, b)HDMTX is a 
very effective systemic drug, and exposition to the drug must be all the more 
ORQJDVWKHGLVHDVHLVPRUHDGYDQFHG7KH\DOVRFRQ¿UPHGWKDW+'$UD&LV
important in the advanced diseases. Other studies showed that treatment dura-
WLRQFDQEHRIVKRUWGXUDWLRQDQGFRQ¿UPHGWKDWF\FORSKRVSKDPLGH+'07;
and Ara-c are the major drugs in BL, in addition to vincristine, doxorubicin, 
93FRUWLFRVWHURLGV&16SURSK\OD[LVPXVWEHGRQHE\+'07;+'
$UD&DQG,7LQMHFWLRQVRI07;$UD&EXWQRWE\FUDQLDOLUUDGLDWLRQ
With all these current strategies in Western countries, EFS of BL increase to 
80-90%, but toxicity of the treatment is high and needs adequate supportive 
care. CNS disease remains a bad prognostic factor, with EFS <80%. Next 
questions concern the use of targeted therapy (rituximab), and the modalities 
of improving outcome of poor risk patients: those with CNS disease, with 
poor initial responses, and those who relapsed. In less privileged countries, 
where BL is frequent, EFS might not be so high, mainly due to later diagno-
sis with children arriving in very bad general condition and to lesser access to 
drugs and to supportive care. Cyclophosphamide alone with ITMTX might 
cure 30-50% of the endemic cases with less cost.
In conclusion, story of Burkitt lymphoma was a successful story especially in 
“privileged” countries: where EFS increased from 30-50% to 80-90% in 20 
years, while weight of treatment decreased for the majority of the patients. 
This must encourage the cooperation between countries to aim to cure as 
many patients in “less privileged” countries.
BURKITT’S LYMPHOMA TREATMENT AT THE KENYATTA 
NATIONAL HOSPITAL.
Mwanda O.W
University of Nairobi, Kenya
Background. Treatment of BL is not well endowed settings remain chal-
lenging. The usual approach is to tailor the treatment to prognostic factors, 
feasibility of the drug schedule, drug management and the capacity of the 
setting. Immediate, intermediate and long term management. Methods from 
2001 to 2005 we studied patients age 3 to 10 years who were treated for stage 
B C and D BL. We compared four cycles of Vincristine, cyclphosphamide, 
prednisone and adrimycin (CHOP), methotraxate, cyclophophamide, vin-
cristine, prednisone and reviewed literature for other drug combinations.
Results: The median follow-up was 60 months. The estimated two year 
HYHQWIUHHVXUYLYDOUDWHZDVVLJQL¿FDQWO\KLJKHUDIWHU&+23FRPSDUHGWR
methotraxate based and other drug schedules. The drug management was 
also best in CHOP compared to methotraxate based drugs most of the litera-
ture protocols were not found feasible in our settings.
Conclusion: Cytotoxic drugs improve the lives of many cases of BL, stan-
dard treatment remains CHOP/CHOP-M is the most feasible in our setting.
MULTI-CENTER STUDY OF THE TREATMENT AND 
CHARACTERIZATION OF BURKITT LYMPHOMA (BL) IN 
AFRICA 
Ngoma T1, Kaijage J1, Githang’a J2, Durosinmi MA3, Adeodu OO3,  
Salawu L3, Aken’Ova YA4, Brown BJ4, Rohatiner AZ5, Venzon D6,  
Adde M5, Magrath I5
1Ocean Road Cancer Institute, Dar es Salaam, Tanzania 2Kenyatta National 
Hospital, Nairobi, Kenya 3Obafemi Awolowo University Teaching 
Hospitals Complex, Ile-Ife, Nigeria 4University College Hospital, Ibadan, 
Nigeria 5International Network for Cancer Treatment and Research, 
Brussels, Belgium 6Center for Cancer Research, National Cancer Institute, 
Bethesda, MD, USA
Purpose: The objectives of this study were to characterize the presentation 
features of BL and to assess the response, event-free survival (EFS) and 
overall survival (OS) in patients treated according to a uniform protocol and 
WRDVVHVVHI¿FDF\RIDVDOYDJHUHJLPHQ,WZDVFRQGXFWHGE\LQVWLWXWLRQVLQ
three African countries, Nigeria, Kenya and Tanzania. 
Patients and Methods: All previously untreated patients with BL were eligi-
ble for the study, including those with bone marrow involvement and/or CNS 
disease. Treatment consisted of First-Line (FL) regimen for newly diagnosed 
patients and a Second-Line (SL) regimen for patients who failed to respond 
to or who relapsed after FL. FL consisted of 6 cycles of cyclophosphamide, 
vincristine, methotrexate (MTX) plus IT therapy with both MTX and ara-C. 
SL therapy consisted of 4 cycles of ifosfamide with mesna, etoposide, ara-C 
plus IT MTX and IT ara-C. 
Results: A total of 205 patients (137 males and 68 females) were entered on 
the study. The median age was 7 years (range, 7 months to 28 years). The most 
common presentation features were jaw tumors (61%) followed by abdominal 
disease (57%). To date, 142 patients (73%) have achieved CR, 31 (16%), PR, 
and 5 (2%), NR to FL therapy. Seventeen patients (8%) could not be evaluated 
for response (death during induction or failure to return for evaluation). Ten 
are too early in FL to assess response. Twenty patients relapsed. A total of 33 
63 Journal of Hematopathology (2008) 1:47  74   – patients have received SL therapy; 10 relapses and 23 PR/NR to FL therapy. 
Twelve patients achieved a CR to SL and 18 a PR or NR. Eleven of these 
12 CRs remain alive and free of disease. Survival analyses were performing 
using the Kaplan-Meier method. EFS is 53% at 12 months and 50% at 24 
months. OS is estimated at 69% at 12 months and 63% at 24 months. 
Conclusions: This regimen is feasible in African countries and the results 
to date are encouraging. Patients who relapse or who fail to respond can be 
salvaged with SL treatment. 
THE TREATMENT OF CHILDHOOD’S BURKITT’S LYMPHOMA 
IN AFRICA BY THE FRENCH-AFRICAN PEDIATRIC ONCOLOGY 
GROUP (G.F.A.O.P.)* 
A STUDY OF 714 CASES REGISTERED FROM APRIL 2001 TO 
AUGUST 2007
J.Lemerle, M.Harif, M.Khattab, F.M.Alaoui, P.Doumbe; S.Barsaoui,Y.
Ladjadj, N.Cherif, C.Moreira, B.Togo, F.Traore; J.Andoh, Couitchere, 
JJ.Atteby, L.Kam, Ye,F.Rafaramino, H.Raobijaona, N.Ravelomanana, 
A.Auperin, M.A.Raquin, ,M.Raphael, C.Patte 
*C /O Institut de Cancerologie Gustave Roussy, 94805 Villejuif , France.
*)$23SHUIRUPHGD¿UVWSURVSHFWLYHPXOWLFHQWULFVWXG\LQ
aiming at assessing the feasibility of adapted French protocols in Northern, 
Western, and Central Africa, and Madagascar.
From 04 01 to 04 04, 343 patients were referred to 9 Units in 6 African coun-
tries,306 were suitable for study.
The 2 tested schemes derive from LMB 89 Protocol. One, MAT, is very simi-
lar to the model, and was used in the North. The other, LB 2001, less aggres-
sive, was used in the South. Both contain CPM,VCR, PN, ARA C, MTX 3g 
repeated courses, and I.T. therapy. Neither surgery nore XRT. Slides were 
centrally reviewed.
Patients. Stages were 1- 2: 14%, 3 : 7O% , 4: 16%. Tumor sites: Abdomen in 
242; Face and/or jaw in 131. Most patients had advanced disease and miser-
able general condition, malnutrition in 39%, anemia, fever, infection.
Treatment. 187 PTS received LB 2001 ,and 119 MAT. .
Results. Three yr. O.S. is 61 %,higher in the MAT Group. 76 pts. died during 
treatment, 59 during induction ,. Relapses occurred later. with LB.
7UHDWPHQW±UHODWHGPRUWDOLW\GHFOLQHGIURPWRGXULQJWKH¿UVW\UV
the overall survival raising simultaneously from 54 to 73% .
Conclusion:HI¿FLHQWLQWHQVLYHPXOWLGUXJFKHPRWKHUDS\FDQEHXVHGVXF-
cessfully in the mentioned areas of Africa . Toxicity however is a problem.
2) Second GFAOP studies 2005-2007, ongoing in 11 Units, in 9 countries. 
The MAT protocol is being continued unchanged in 5 Units in Morocco, 
$OJHULD7XQLVLD7KHUHVXOWVDUHVWDEOHRQWKH¿UVWSWV$QHZVWXG\RI
Cyclophosphamide. plus I.T MTX started in 04 05, as an attempt to reproduce 
and to improve the results of P.Hesseling et al. with CPM alone , by adding 
an early“rescue”scheme ,in cases of poor response to CPM. 216 cases reg-
istered and 148 included 04 05 to 10 07.in 6 Units south to Sahara. Limited 
WR[LFLW\2YHUDOOVXUYLYDO8QSURYHQHI¿FLHQF\RIWKH³UHVFXH´VFKHPH
Conclusion: accurate analyses, by Unit, and longer FU needed.
THE INTENSIVE SHORT-TERM CHEMOTHERAPY REGIMEN 
DESIGNED AT INT MILAN IS HIGHLY EFFECTIVE FOR THE 
TREATMENT OF BOTH CHILDREN AND ADULTS WITH 
BURKITT S LYMPHOMA.
E. Schiavello1)6SUHD¿FR2, A. Guidetti1, M. Massimino2, R. Luksch2,  
F. Fossati-Bellani2, A.M. Gianni1, and M. Di Nicola1
C. Gandini Medical Oncology, Bone Marrow Transplantation Unit1 and 
Pediatric Oncology Unit2, Fondazione IRCCS Istituto Nazionale Tumori, 
Milan, Italy
Background. We previously showed the outcome of Burkitt s lymphoma 
(BL) achieved by a short intensive sequential chemotherapy program initial-
ly scheduled for pediatric population and also used for adults in our Institute 
. Purpose. We have analyzed the clinical outcome of 69 newly diagnosed BL 
patients(pts), aged between 2 and 76 years (median 11 years) homogeneous-
ly treated with the chemotherapy regimen originally designed for children to 
evaluate differences based on age and prognostic factors (stage IV Murphy 
and/or CNS involvement).
Methods. Main patient characteristics were: male/female 51/18; age below 
\HDUVLQFDVHV\HDUVVWDJH,,,,,96HYHQRXW
of 18 stage IV pts exhibited CNS involvement. Sequential chemotherapy in-
cluded: after a 5-week induction phase of weekly infusion consisting of vin-
cristine, cyclophosphamide, doxorubicin, HD-methotrexate plus leukovorin 
rescue, and intrathecal methotrexate or AraC, a consolidation phase includ-
ing HD-AraC plus cisplatin was given. 
Results. Overall 9/69 pts suffered from disease failure after median 5 months 
from diagnosis (range, 2-31 months). Two toxic deaths occurred. EFS, DFS, 
OS at 3 years were 83.5% ± 5%, 86% ± 4%, and 87% ± 4% respectively, 
IRUHYDOXDEOHSWV1RVLJQL¿FDQWGLIIHUHQFHVLQ()6')6DQG26ZHUH
REVHUYHGEHWZHHQSWV\HDUVYV\HDUV,QDGGLWLRQDOVRIRUSWVZLWK
VWDJH,9YVVWDJH,,,,,,QRVLJQL¿FDQWGLIIHUHQFHVLQ26DQG')6ZHUH
observed. Pts with CNS involvement showed a lower OS and DFS compared 
ZLWKQR&16LQYROYHPHQWKRZHYHUZLWKRXWUHDFKLQJVWDWLVWLFDOVLJQL¿FDQFH
Conclusion. Our data strongly suggest that the intensive pediatric chemo-
therapy regimen demonstrated to be very effective and feasible in both pedi-
DWULFDQGDGXOWSWV0RUHRYHUZHFRQ¿UPWKHHI¿FDF\DOVRLQSRRUSURJQRVLV
pts stage IV, especially CNS-positive. The addition of Rituximab to chemo-
therapy regimen in a subset of pts is under clinical investigation.
THE SYMPTOM BURDEN AT PRESENTATION AND AFTER 3 
CYCLES OF CHEMOTHERAPY IN CHILDREN WITH BURKITT’S 
LYMPHOMA AT MULAGO HOSPITAL, KAMPALA, UGANDA.
Katie Wakeham1,2, Jonathan Levin1 Caroline Rose2
1Medical Research Council and Uganda Virus Research Institute, 2Hospice 
Africa, Uganda
Background:  There is no published data on the presenting symptoms of 
children in Uganda with BL, or on the side effects associated with treatment. 
Given the lack of research on this important issue, we aim to generate evidence 
regarding the symptom burden of Ugandan children at presentation and after 3 
cycles of chemotherapy, in order to inform clinical practice and policy.
Methods: Hospice Africa, Uganda (HAU) provides symptom management 
and chemotherapy to children presenting with BL at Mulago Hospital. A 
retrospective analysis of HAU records (n=96) was carried out. Presenting 
symptoms and symptoms present between cycles 3 and 4 of chemotherapy 
ZHUHUHFRUGHGIRUELRSV\FRQ¿UPHGFKLOGUHQZLWK%/$OOFKLOGUHQZHUHSUH-
VHQWLQJZLWK%/IRUWKH¿UVWWLPH
Results: 54 children were HIV negative; 4 were HIV positive and 38 had un-
known status. The children’s ages ranged from 2 to 16, with a median age of 6.5 
(IQR 5-9). The major occupation for parents was subsistence farming (n>80, 
83%),and no family was deemed able to pay for their child’s chemotherapy. 
There were slightly more boys than girls (53% vs 47%). All children presented 
at an advanced stage of BL. The most common sites of disease were the jaw and 
abdomen. The most common presenting symptom was a mass (97%), followed 
by pain (82%), low mood (42%), sore mouth (29%), fatigue (28%), halitosis 
(23%), cachexia (23%) and loss of appetite (22%). 10 children presented with 
spinal cord compression (10%) and 5 with blindness (5%). After 3 cycles of 
chemotherapy the most common symptom was a mass (48%), pain (43%), loss 
of appetite (29%), nausea (25%), clinical evidence of infection (23%), cough 
(21%), vomiting (21%) and a fever (13%). 6 children died and 10 children were 
lost to follow up in the period between chemotherapy cycles 1 and 3.
Conclusion: This study shows that children with BL in Uganda present with 
advanced stage disease, most commonly with a mass and pain. The majority 
RISDUHQWVDUHVXEVLVWHQFHIDUPHUVVXJJHVWLQJWKDW¿QDQFHVKHDOWKDZDUHQHVV
and access are likely to be major issues surrounding these advanced presen-
tations. After 3 cycles of chemotherapy the prevalence of a mass and pain 
reduces, but these remain the most common symptoms. At this stage loss of 
appetite, nausea and vomiting become important symptoms to be addressed.
2QWKHEDVLVRIRXU¿QGLQJVZHPDNHWKHIROORZLQJUHFRPPHQGDWLRQV
•  Rigorous research to assess the morbidity associated with chemotherapy 
for BL
•  Public education and health worker training to improve awareness of BL 
and promote early referral and access to treatment.
•  Development and promotion of a co-ordinated African BL programme.
A COMPARISON OF OUTCOME AND TOXICITY OF SHORT 
AND LONG COURSE CHEMOTHERAPY FOR BURKITT‘S 
LYMPHOMA (BL) AT KENYATTA NATIONAL HOSPITAL (KNH) 
William M Macharia
Department of Paediatrics & Child Health, AKU, Nairobi, Kenya
Objective: To compare the effectiveness and toxicity of an intensive, short 
course (SC) and a less intensive long course (LC) chemotherapy regimen in 
treatment of BL. 
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Methods: The study was undertaken at KNH using patients‘ records. 
Children 15 years and below admitted in general wards or in paediatric on-
FRORJ\ZDUGZLWK¿QHQHHGOHDVSLUDWHRUKLVWRORJLFDOGLDJQRVLVRI%/ZHUH
eligible for inclusion. Death before completion of induction and exposure to 
other protocols prompted exclusion. 
Analysis: Median duration of follow-up, event free survival (EFS) and treat-
ment related toxicity. 
Results: Of 101 records, only 25.7% were considered suitable for analysis. 
There were more deaths before completion of induction in the general chil-
dren wards (77.8%) than in the paediatric oncology ward (22.2%). Diagnosis 
ZDVFRQ¿UPHGE\)1$LQDQGKLVWRORJ\LQRIWKHFDVHV
f patients had abnormal CSF cytology at presentation. There was no sig-
QL¿FDQWGLIIHUHQFHLQ()6DQGWR[LFLW\EHWZHHQWKHWZRWUHDWPHQWJURXSV
19.2% received packed cells and 3.8% platelet concentrates while 53.8% 
experienced moderate to severe neutropenia. 53.8% required i.v. antibiotics 
LQ6&DQGLQ/&JURXS7KHUHZDVQRWVLJQL¿FDQWGLIIHUHQFHLQ
toxicity between the two groups. 
Conclusion: Outcome of BL treatment remains poor with many patients dy-
ing prior to commencement of chemotherapy. In the absence of clear dif-
ference in effectiveness and toxicity between SC and LC protocols, choice 
should be based on treatment cost and informed parental choice. Early com-
mencement of therapy and improvement in supportive care may lead to bet-
ter outcomes. Prospective data is recommended for more valid deductions 
from clinical experience. 
A NEW SHORT-TERM HIGH INTENSIVE PROTOCOL BL-
M-04 FOR ADULT PATIENTS WITH BURKITT LYMPHOMA: 
EFFICACY AND TOXICITY.
Baryakh E, Zvonkov E, Kremenetskaja A, Kravchenco S, Magomedova A, 
Obukhova T, Klyasova G, Yatskov K., Valiev T, Vorobjov A
5XVVLDQ+HPDWRORJLFDO6FLHQWL¿F&HQWHU5XVVLDQ$FDGHP\RI0HGLFDO
Science, Moscow, Russian Federation
Aim:WRHYDOXDWHDQHI¿FDF\DQGWR[LFLW\RIWKHUDS\SURWRFRO%/0IRU
adult patients with Burkitt lymphoma (BL). 
Patients and methods:WZHQW\¿YHSUHYLRXVO\XQWUHDWHGSDWLHQWVZLWK%/
WKH\KDGVSHFL¿FIRU%/F\WRJHQHWLFDEHUUDWLRQWTTRUYDULDQW
translocation t(2;8), t(8;22) were eligible for inclusion in our study. All the 
patients (17 males and 8 females, mean age 24 years (from 15 to 56 years)) 
participated in the study performed in Russian Hematological Research 
Center between August 2003 and September 2007. A treatment was based 
on experimental high intensive protocol BL-M-04. The BL staging criteria 
developed by S. B. Murphy was used to stage the patients. The stage I, II, 
III, IV was diagnosed in 1, 2, 14 and 2 patients respectively. B-acute lym-
phoblastic leukemia (L3) – in 6 patients. B-symptoms (night sweets, fever, 
weight loss) showed in 21(84%) patients. Serum lactate dehydrogenase level 
(LDH) was increased in 22 (88%) patients. The main aim of a new treatment 
UHJLPHQEHFDPHDQLQWHQVL¿FDWLRQDQGWUHDWPHQWGXUDWLRQUHGXFWLRQLQSD-
tients with BL. Our new treatment protocol is based on standard NHL-BFM-
90 protocol for group of high risk patients (methotrexate dose 1500mg/m2). 
We know that BL is a chemosensitive tumor and regresses after 1-2 courses 
of chemotherapy. Despite the initial tumor mass we decided to treat BL ac-
cording to 4 courses (2 inductional and 2 consolidational). According to the 
fact that BL is the most sensitive to high dosed methotrexate and cytarabine 
we used these drugs in the induction phase to achieve the most cytoreductive 
effect. Courses A and C were used for remission achievement. Doxorubicine 
was added to course A, methotrexate – to course C. Consolidative courses 
were the same as inductional courses. So, we used A and C courses (without 
%LQWHQVL¿HGZLWKFRXUVH%GUXJVGR[RUXELFLQDQGPHWKRWUH[DWHLQWHUYDO
between courses was 21 day. 
Results: twenty two patients (88%) achieved a common remission (CR) af-
ter 1-2 courses (11 patients – after the 1st course, 11 – after the 2d). Four 
patients died. The course of death was chemotherapy complications in three 
cases, early relapse in one patient. A 3-year disease-free survival – 95%, 
overall survival – 84%. BL-M-04 therapy is associated with higher CR rates 
and longer disease-free survival in adult patients with BL and demonstrated 
DKLJKHI¿FDF\RIVKRUWWHUPLQWHQVLYHWKHUDS\7UHDWPHQWGXUDWLRQZDV±
months. Myelotoxic agranulocytosis completed all courses. Most infectious 
DQGKHPRUUKDJLFFRPSOLFDWLRQVRIWUHDWPHQWZHUHUHJLVWHUHGGXULQJWKH¿UVW
course A, that can be explained by initial severe patient condition in the most 
patients. Unfortunate prognostic factors, which increase the number of che-
motherapy complications, are: B-ALL, acute renal failure, inadequate previ-
ous treatment (surgery and chemotherapy).
Conclusion: BL-M-04 is a highly effective protocol: a 3-year disease-free 
survival – 95%, overall survival during 3 years – 84%. This protocol can 
help us achieve a rapid tumor mass regression and treatment duration reduc-
WLRQEHFDXVHRIFKHPRWKHUDS\LQWHQVL¿FDWLRQDQGDFFHSWDEOHWR[LFLW\:H
conclude, that the majority of relapses occur after 8-12 months of treatment 
and after 24 months we can speak about full recovery. The usage of this pro-
tocol can achieve a rapid BL regression and decrease of treatment duration 
EHFDXVHRIWUHDWPHQWLQWHQVL¿FDWLRQDQGDFFHSWDEOHWR[LFLW\
FISTULAE COMPLICATING BURKITT’S LYMPHOMA 
THERAPY, THE CHALLENGES: 2 CASE REPORTS.
Kitonyi G.W. (MBchB FRCPath.)
Department of Human Pathology/ Haematology and Blood Transfusion 
University of Nairobi, School of Medicine, Kenya
A 5 year old boy with a large right maxillary jaw Burkitt’s, involving the 
nose and protruding into the oral cavity developed a 2 cm diameter oral 
DQWUDO¿VWXODPRQWKVLQWRWUHDWPHQWZLWKWKH&+23UHJLPH7KHGHYHO-
opment was dramatic with a choking cough and voice change. Reluctant 
WRLQWHUUXSWFKHPRWKHUDS\PD[LOORIDFLDOVXUJHRQVIDEULFDWHGDZHOO¿WWLQJ
orbturator prosthesis, which was misplaced by the patient within 48 hours. 
Because of the considered risk of choking, chemotherapy was interrupted to 
allow for corrective surgery. A second patient, 10 year old female, diagnosed 
with Burkitt’s, presented with extensive disease, involving the left jaw, ab-
domen, central nervous system and bone marrow. Two and a half months 
after commencement of the CHOP regime, she developed a vesico-vaginal 
¿VWXOD99)'HVSLWHWKHGLVFRPIRUWWKHSDWLHQWZDVH[SHULHQFLQJVXUJHU\
was postponed in favour of chemotherapy, in view of the still heavy residual 
GLVHDVHEXUGHQ7KHGHYHORSPHQWRI¿VWXODHLQFKLOGUHQZLWK%XUNLWW¶VO\P-
phoma, following tumour lysis by chemotherapy, maybe life threatening and 
incapacitating. It also poses challenges and dilemmas in surgical intervention 
decisions. This report highlights some of these issues.
CLINICAL PRESENTATION AND DIAGNOSTIC FINDINGS 
IN BURKITT LYMPHOMAS AT A SINGLE INSTITUTION IN 
SWEDEN.
Daniel Tesfa1, Monika Jansson1, Birgitta Sander2, Birger Christensson2, 
Mats Merup1
1Hematology Center, 2Department of Laboratory Medicine, Divison of 
Pathology, Karolinska University Hospital at Huddinge, Stockholm, 
Sweden.
Burkitt lymphomas (BL) are rare in Sweden and constitute less than 1% of 
O\PSKRPDVLQWKH6ZHGLVKUHJLVWU\,GHQWL¿FDWLRQRI%/DPRQJKLJKO\SUROLI-
erative non-Hodgkin lymphomas (NHL) is important since BL respond poor-
ly to standard therapy for diffuse large B-cell lymphomas (DLBCL). We have 
analysed 27 adult patients with NHL with a proliferation rate of more than 
90% diagnosed at Karolinska University Hospital at Huddinge between 1996 
and 2005. Twenty patients were diagnosed as BL and 7 as DLBCL. Average 
age was 46 for BL (26-83 ys) and 55 (17-88 ys) for DLBCL. Extranodal 
presentation was seen in 70% of BL compared to 57% for DLBCL and ab-
dominal presentation was seen in 50% of BL patients. Four cases, all BL, 
had CNS involvement. Elevation of lactade dehydrogenase was seen in 80% 
of BL compared to 43% of DLBCL and increase of uric acid was found in 
50% and 29% respectively The typical immunohistochemical phenotype for 
BL was expression of CD20 (100%), CD10 (89%), bcl-6 (83%). Expression 
of bcl-2 was seen in 44% and p53 expression in 25%. All DLBCL expressed 
bcl-2 and bcl-6 was expressed in 71% and CD10 in 43%. No cases expressed 
p53. EBER antigen was evaluable in 24 of 27 cases and expression was seen 
only in three cases, all BL. MYC gene rearrangement was analysed with 
ÀXRUHVFHQFHLQVLWXK\EULGL]DWLRQ),6+RQSDUDI¿QVHFWLRQVXVLQJWZRGLI-
ferent probes, one for detection of break within the myc gene and one for 
detection of the t(8;14) translocation. Evidence for myc gene rearrangement 
was found in 75% of BL and 14% of DLBCL. Twelve of 20 BL patients were 
treated with the Riehm protocol for Burkitt lymphoma. Five cases received 
rituximab. Eleven patients obtained complete remission and 8 patients (67%) 
remained in CR for a median follow up of 24 months. Disease free survival 
at 2 years was 50% for BL and 33% for DLBCL. We conclude that analysis 
RIP\FJHQHUHDUUDQJHPHQWZLWK),6+LVIHDVLEOHRQSDUDI¿QVHFWLRQVDQG
facilitates making a correct diagnosis of BL.
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EG Boerma1, R Siebert2, PhM Kluin1, M Baudis3
1Department of Pathology, University Medical Center Groningen, 
Groningen, The Netherlands, 2Institute of Human Genetics, University 
Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, 3Institute of 
Molecular Biology, University of Zurich, Zurich, Switzerland
Since the discovery of Burkitt lymphoma (BL) in 1958 by Denis Burkitt, 
many investigators have studied its genetic features. Apart from the hallmark 
MYC-translocation, many chromosomal aberrations have been reported. We 
used the online Mitelman s Catalog of Chromosome Aberrations in Cancer 
WRGHWHUPLQHDF\WRJHQHWLFSUR¿OHRI%/
We collected karyotyping data of all 6359 B-NHL. Karyotypes were con-
YHUWHGWRDQEDQGVSHFL¿FVWDWXVPDSZLWKEUHDNSRLQWDQGLPEDODQFH
information using the Progenetix software. We selected all cases with a diag-
nosis of Burkitt lymphoma/leukemia and a MYC-Ig translocation (n=514). 
Original publications were searched for clinical data. Cases were separated 
into different age groups (0-15, 16-30, 31-45, 46-60 and >60). Apart from the 
typical t(8;14) translocation in 417 cases (81%) and variant translocations 
WLQDQGWLQFDVHVZHLGHQWL¿HGGRXEOHKLW
cases with an additional structural aberration (gain or translocation) sugges-
tive for 3q27 (BCL6), 11q13 (CyclinD1) or 18q21 (BCL2). The incidence 
of these double hit cases increased from 6/202 (3%) between 0-15 to 18/45 
(40%) >60 years. After exclusion of these cases, 245 of the 453 cases (54%) 
showed chromosomal imbalances. The most common gains were found 
at 1q2 (20%), 7q3 (6.2%) and 12q2 (5.1%), most common losses at 13q3 
(6.8%), 6q2 and 17p1 (4% each). The average number of chromosomes with 
imbalances steadily increased with age (from 0.85 to 1.8) and was higher in 
females than in males (1.22 vs 0.98). Gain of 1q was more common at young 
age, gain of chr12 at intermediate age and gain of chr7 at high age. Overall, 
87% of the cases had 0-2 chromosomal imbalances (0: 46%, 1: 28%, 2: 12%, 
!7KHFODVVLFF\WRJHQHWLFSUR¿OHRI%/LVD0<&,JWUDQVORFDWLRQ
accompanied with no more than 2 additional aberrations and without a so-
called double hit. Even within this genetic homogenous disease there are 
differences related to age and gender. 
IMPLEMENTATION OF A CHILDREN’S PALLIATIVE CARE 
SERVICE IN A LYMPHOMA TREATMENT CENTRE IN UGANDA
Caroline Rose, Charles Byarugaba, Justin Amery
Hospice Africa Uganda, Kampala, Uganda
This paper will describe the planning and implementation of a children’s 
palliative care service in Uganda at Lymphoma Treatment Centre, Mulago 
Hospital. This programme began in January 2007 with the recruitment of a 
children’s services coordinator and continues to the present time. Children’s 
SDOOLDWLYHFDUHLQ$IULFDLVDPXFKQHHGHGEXWH[WUHPHO\QHZ¿HOG
The paper will describe the six main strands of the project. 
1. Initial situation analysis and planning
2. Recruitment of a Ugandan Children’s Services Coordinator (supported by 
an international volunteer from a children’s palliative care and oncology 
nursing background)
3. Provision of symptom care from diagnosis to end of life for children diag-
nosed with life limiting illness
4. The implementation of a hospital based volunteer led advocacy, play and 
education service
5. Production of IEC materials to improve family and child education about 
their illness and prognosis.
6. Monitoring and Evaluation of the service
The paper will discuss the challenges faced by the team which included re-
VLVWDQFHWRWKHGHYHORSPHQWRIWKHSURMHFW¿UPO\KHOGP\WKVDERXWFKLOGUHQ¶V
pain and pain management and a lack of available resources. It will also 
discuss the steps taken to overcome these challenges. 
Early recommendations coming from this project include the need to ensure 
that both pharmacological and non-pharmacological treatments are used to 
treat pain and intervention pain in children. The need for and interest in spe-
cialist training of palliative care staff in paediatric palliative care should also 
be recognised. Finally it is recommended that facilities providing palliative 
care should develop written and pictorial tools in order that families have the 
information about their child’s illness and prognosis to enable them to make 
informed decisions and choices about their child’s care.
BURKITT‘S LYMPHOMA AND ANGIOCENTRIC NK/T CELL 
LYMPHOMA; PERSONAL EXPERIENCE N THE LAST 45 YEARS 
IN SUDAN
A M EL Hassan DSs, FRCP, FRCPATH
Department of Clinical Pathology, Institute of Endemic Diseases, 
University of Khartoum
It was 45 years ago that Lynch and EL Hassan described a lymphoma in 
Sudanese children under the title‚ Multicentric sarcoma of the jaw‘, a tu-
mor that was later to be known as Burkitt‘s lymphoma. Since then several 
malignant tumours in man that are suspected to be caused by EBV have 
been described in Sudan. These include nasopharyngeal cancer, Hodgkin‘s 
disease, Burkitt‘s lymphoma, and Angiocentric NK/T cell lymphoma. This 
SUHVHQWDWLRQLVDERXWWKHODWWHUWZRWXPRXUVLQ6XGDQVLQFHRXU¿UVWSXEOLFD-
tion on the subject. The majority of the cases of Burkitt‘s lymphoma in the 
sixties and seventies were of the endemic type with the majority involving 
the jaws. The cases were mainly in the holo- and mesoendemic malaria re-
gions. In the last two decades there was a change in the pattern of the tumour. 
For example in a single centre between 2000 and 2005 of 33 Burkitt‘s lym-
phoma cases, only 4 involved the jaws. The epidemiology, clinical manifes-
tations, pathology and possible causes for the change in the epidemiology 
will be described. Recently the virus has been demonstrated in the tumour 
by molecular biological methods. Four patients with Angiocentric NK/T cell 
lymphoma, another EBV related tumour, will be discussed. Three were nasal 
type; the fourth had a tumour involving the perianal region and an associated 
acute myeloid leukaemia.
HIGH GRADE B-CELL LYMPHOMAS OTHER THAN BURKITT 
LYMPHOMA
PATHOLOGY AND BIOLOGY 
HIGH-GRADE B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH 
FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE 
B-CELL LYMPHOMA AND BURKITT LYMPHOMA. WHO 
DEFINITION.
Nancy Lee Harris
Massachusetts General Hospital, USA
B-cell lymphomas with features intermediate between Diffuse Large B-cell 
/\PSKRPD'/%&/DQG%XUNLWW/\PSKRPD%/DUHGH¿QHGLQWKH:+2
&ODVVL¿FDWLRQWKHGDVDJJUHVVLYHO\PSKRPDVZLWKPRUSKRORJLFDODQG
genetic features of both DLBCL and Burkitt lymphoma. This is not a repro-
GXFLEOHFDWHJRU\EXWUDWKHUUHÀHFWVWKHGLI¿FXOW\LQFDWHJRUL]LQJVRPHFDVHV
that are at the borderline between BL and DLBCL. Rather than force such 
cases into one category or the other, it is felt to be preferable to consider 
WKHPXQFODVVL¿DEOHXQWLOIXUWKHULQIRUPDWLRQDERXWWKHVHFDVHVLVDYDLODEOH
The diagnosis should only be made using a combination of morphology with 
immunophenotypic and cytogenetic/molecular studies.
These lymphomas are composed of medium to large sized blastic cells that 
may mimic atypical Burkitt lymphoma, be intermediate in nuclear size be-
tween BL and DLBCL, resembling small centroblasts, or even resemble lym-
phoblastic lymphoma. Starry sky macrophages are often present, and mitotic 
¿JXUHVDQGDSRSWRVLVDUHSURPLQHQW7KH\H[SUHVVSDQ%FHOOPDUNHUVPRVW
are CD10 and bcl6 positive, and MUM1/IRF4 negative, similar to BL. Bcl2 
may be positive. The Ki67 proliferation fraction is high (>90%).
About half of the cases have 8q24/MYC translocations. However, whereas 
in Burkitt lymphoma MYC is juxtaposed to the one of the immunoglobulin 
genes (MYC-Ig), many of these cases have other translocations (MYC-non 
Ig), and may have both BCL2 and MYC translocation (double hit). BCL6 
translocations may be seen, sometimes with MYC and/or BCL2. Cytogenetic 
analysis often shows a complex karyotype, in contrast to classical Burkitt 
O\PSKRPD*HQHH[SUHVVLRQSUR¿OLQJVWXGLHVKDYHIRXQGFDVHVWKDWDUHLQ-
termediate between BL and DLBCL, suggesting that there may be a true grey 
zone between these diseases. These are aggressive lymphomas, and the most 
appropriate therapeutic approach is not established.
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Lynnette K. Tumwine1, Cristina Campidelli2, Simona Righi2, Sophia Neda2, 
Wilson Byarugaba1, Jackson Orem3, Stefano A. Pileri2
1Department of Pathology, Makerere University Medical School, P.O.Box 
7072, Kampala, Uganda. 2Unit of Haematopathology, Institute of 
Hematology and Clinical Oncology “L & A Seragnoli, Bologna University 
School of Medicine, 40138 Bologna, Italy” 3Uganda Cancer Institute, 
Kampala, Uganda.
Background: Diffuse large B cell lymphoma (DLBCL) is the second most 
common lymphoma in Uganda after Burkitt’s lymphoma. It is heterogeneous 
in morphology and immunophenotype and recent studies in the developed 
countries have shown differences in survival. Since the onset of the AIDS 
pandemic it has been noted that more aggressive subtypes predominate here 
with rapid disease progression and very poor outcome. 
Objective: To describe the different subtypes of diffuse large B cell lympho-
mas and correlate them to patient survival in Uganda.
Materials and methods: This study has two designs. A cross sectional de-
scriptive design was used for subtyping and a retrospective cohort to de-
termine duration of surivival. For the cross sectional study, Haematoxylin 
and eosin staining was carried out partly in the Department of Pathology, 
Makerere University and in the Unit of Hematopathology, Institute of 
Hematology and Clinical Oncology “L. & A. Seràgnoli”, Bologna University 
School of Medicine, Bologna, Italy. Nineteen biopsies of patients diagnosed 
between 1991-2000 as non Hodgkin lymphoma were DLBCL after immuno-
histochemistry using CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a, 
CD138, Bcl-6, Bcl-2, IRTA-1, MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, 
and Ki-67/Mib1. These patients were treated at the Uganda Cancer Institute 
ZLWKDQGWKHLU¿OHVZHUHUHWULHYHGWRREWDLQHGGHWDLOVRIWKHLUKRPHDGGUHVVHV
and next of kin. A research assistant did retrospective follow up in their vil-
lages to establish how long they lived.
Results:'/%&/ZHUHVXEW\SHGLQWR$FWLYDWHG%&HOO$%&W\SH&'
&'%FO%FO080,5)&'RU&'*HUPLQDO
&HQWUH%FHOO*&%W\SH&'&'%FO080,5)%FO
DQG8QFODVVL¿HG8&W\SH&'&'%FO%FO7KHSDWLHQWV
survival is summarised in the Kaplan and Meier survival curves.
Conclusion: Most 9 (47.4%) were Activated B Cell (ABC) type that has a 
bad prognosis.
PATTERNS OF LYMPHOMAS IN KENYA
Bessie Byakika, Lucy Muchiri, Wairimu Waweru, Kungu A.
Department of Pathology, The Nairobi Hospital, Nairobi, Kenya.
Objective: The objective was to report and compare the patterns of Lymphoma 
in a developing country with those in the developed world and also to form a 
data baseline for lymphomas in Kenya.
Study Design: A study was conducted to establish the pattern of lymphomas 
in Kenya. 125 lymphoma cases from both urban and rural Kenya were re-
FUXLWHGLQWRWKHVWXG\JURXS$OOFDVHVZHUHFODVVL¿HGXVLQJWKH,QWHUQDWLRQDO
Lymphoma Study Group guidelines. Immunophenotyping was performed 
for each tumour. 
Results: The most frequent diagnosis was that of diffuse large B cell lym-
phoma (29.6%). The relationship with HIV infection was however not estab-
lished. Hodgkin’s lymphoma formed 25.6% with the nodular sclerosis being 
its most common variant. Burkitts lymphoma contributed 16% and was the 
most common Lymphoma seen in the pediatric age group with the average 
patient age of 6 years. Other Lymphomas formed small groups with Marginal 
Zone Lymphoma and Plasmablastic Lymphomas forming the larger group.
Conclusion: From the study the pattern of Lymphoma seen follow closely 
those documented in Western Literature. It would be however interesting to 
determine the genetic phenotypes of our disease. 
IMMUNE ESCAPE AND PROLIFERATION: COMMON 
FEATURES OF BURKITT LYMPHOMA (BL) AND THE MOST 
AGGRESSIVE DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL).
Lisa M. Rimsza MD1, Joseph M. Unger MS2, Randy D. Gascoyne MD3, 
Robin A. Roberts BS1, Daniel O. Persky MD4, Thomas P. Miller MD4, 
Joseph M. Connors MD3, Laurie H. Sehn MD3, Michael L. LeBlanc PhD3
1Department of Pathology, University of Arizona, Tucson, Arizona, USA  
2Fred Hutchinson Cancer Research Center, Seattle, Washington, USA  
3British Columbia Cancer Agency, Vancouver, British Columbia, Canada  
4Arizona Cancer Center, Tucson, Arizona, USA
*HQHH[SUHVVLRQSUR¿OLQJVWXGLHVRI%/DQG'/%&/UHYHDOHGNH\SDWKR-
genic and prognostic signatures. In BL, C-MYC based Proliferation and 
ORVVRI0DMRU+LVWRFRPSDWLELOLW\0+&&ODVV,GH¿QHDGYHUVHIHDWXUHV,Q
DLBCL treated with CHOP chemotherapy, key signatures are Proliferation 
(including C-MYC, adverse), MHC Class II, Germinal center B cell, and 
Lymph Node. We questioned whether these 4 DLBCL signatures and other 
key genes were relevant in the R-CHOP treatment era and if a new gene-risk 
model of DLBCL could be designed.
Using a quantitative nuclease protection assay that measures expression 
OHYHOV LQ IRUPDOLQ ¿[HG SDUDI¿Q HPEHGGHG WLVVXHV $UUD\3ODWH +LJK
7KURXJKSXW *HQRPLFV 7XFVRQ$= ZH TXDQWL¿HG  SURJQRVWLF JHQHV
from 101 DLBCL patients treated with R-CHOP. Cox Proportional Hazard 
0RGHOVGH¿QHGWKHEHVWDQGYDULDEOHJHQHPRGHOVWRSUHGLFWSDWLHQW
outcome.
RIJHQHVZHUHVLJQL¿FDQWO\DVVRFLDWHGSZLWKVXUYLYDOLQFOXG-
ing SERPINA9, HLA-DQA, HLA-DRB, PLAU, C-MYC, BCL6, LMO2, 
PDCD4, and SOD2. These genes were represent the 4 DLBCL signatures: 
Proliferation (C-MYC), MHC Class II (HLA-DQA, HLA-DPB), Germinal 
Center (SERPINA9/GCET2, BCL6), and Lymph Node (PLAU). The best 2-
variable model was the combination of C-MYC and HLA-DRB (chi-square 
:KHQSDWLHQWVZHUHGH¿QHGDVKDYLQJKLJK&0<&RUORZ+/$
DRB, 23 patients (23%) had both adverse factors. These patients had worse 
survival than those with 0-1 factors (2-year OS 42% vs. 84%). Adjusting for 
,3,WKLVGLIIHUHQFHZDVKLJKO\VLJQL¿FDQWS 
In the R-CHOP era, the 4 signatures retain prognostic value. Loss of MHC 
H[SUHVVLRQZLWKLQFUHDVHG&0<&GH¿QHGWKHSDWLHQWVZLWKWKHZRUVWRXW-
FRPH,WLVVWULNLQJWKDWWKHVHDUHDOVRWKHGH¿QLQJDWWULEXWHVRI%/VXJJHVWLQJ
that lack of immunosurveillance and high proliferation are the
NH\IHDWXUHVGH¿QLQJWKHPRVWDJJUHVVLYH%FHOOO\PSKRPDV
B-CELL LYMPHOMA WITH CONCURRENT C-MYC AND BCL2 
TRANSLOCATIONS HAS CLINICOPATHOLOGICAL FEATURES 
DISTINCT FROM ATYPICAL URKITT LYMPHOMA 
Matija Snuderl1, Olga K. Kolman1, Judith A. Ferry1, Ephraim P. Hochberg2, 
Yibin Chen2, Robert P. Hasserjian1 and Aliyah Rahemtullah1
Departments of 1Pathology and 2Medicine, Massachusetts General Hospital 
and Harvard Medical School, Boston, Massachusetts, United States.
Introduction: B-cell lymphoma (BCL) with concurrent CMYC and BCL2 
translocations generally has a poor prognosis. We sought to characterize 
this neoplasm further to help distinguish it from atypical Burkitt lymphoma 
(ABL).
Design: FDVHVRI%&/ZLWKFRQFXUUHQWWTDQGWLGHQWL¿HGE\
conventional karyotype and/or FISH were diagnosed in our practice from 
2004-2007. Clinicopathological data were compared to 9 ABL cases.
Results: The 6 men and 6 women had a median age of 62 yrs (vs 41 yrs in 
$%/JURXSS1RQHZHUH+,9SDWLHQWVKDGDKLVWRU\RIORZJUDGH
follicle center lymphoma (FCL). 7 cases resembled ABL, 4 resembled diffuse 
large B-cell lymphoma (DLBCL), while 1 case with a history of low-grade 
FCL showed diffuse FCL with blastoid features. Secondary involvement of 
ERQHPDUURZDQG&16ZDVSDWKRORJLFDOO\FRQ¿UPHGLQDQGFDVHV
UHVSHFWLYHO\$OOFDVHVH[SUHVVHG%FHOOPDUNHUDQGZHUH&'DQGRU
%FOFDVHVZHUH%FOYV$%/FDVHVSFDVHVZHUH
0XPYV$%/FDVHVS .LSUROLIHUDWLRQLQGH[3,UDQJHG
from 65-100% and was >95% in 3/12 cases (vs 9/9 ABL cases, p<.001). No 
FDVHZDV(%(5)XOONDU\RW\SHDYDLODEOHLQFDVHVZDVFRPSOH[ZLWK
aberrations. 11 patients received combination anthracycline-based chemo-
therapy. Of 4 who achieved a complete response (CR), 3 relapsed within 6 
m. After a median follow-up of 4 m, 9 patients died of disease, 2 were alive 
with disease undergoing chemotherapy and 1 was in CR.
67 Journal of Hematopathology (2008) 1:47  74   – Conclusion: 2XU VWXG\ FRQ¿UPV SRRU RXWFRPHV GHVSLWH LQWHQVLYH FKH-
motherapy in BCL with concurrent CMYC and BCL2 and translocations. 
'LVWLQJXLVKLQJ FOLQLFRSDWKRORJLF IHDWXUHV IURP$%/ RI VWDWLVWLFDO VLJQL¿-
cance include older age at diagnosis, PI < 95% and Bcl2 positivity, with a 
WUHQGWRZDUGVLJQL¿FDQFHVHHQIRU0XPSRVLWLYLW\2WKHUSRWHQWLDOO\KHOS-
ful features in diagnosing this rare neoplasm include absence of HIV and/or 
EBV as cofactors, DLBCL morphology and a complex karyotype.
MISMATCH REPAIR DEFICIENT LYMPHOID PROLIFERATIONS 
OCCUR THROUGH A FIELD CANCERIZATION DEFINED BY 
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE LOSS OF 
EXPRESSION.
Alex Duval, Claire Borie, Martine Raphael 
INSERM-UPMC, France 
O6-methylguanine-DNA methyltransferase (MGMT) repairs DNA ad-
ducts that are mutagenic, favouring transitional events, and toxic by leading 
cells to apoptosis through a mismatch repair (MMR) dependent pathway. 
Cells whose MMR system is inactivated can thus tolerate O6-methylgua-
nine in their DNA. The role of MGMT in human carcinogenesis has been 
poorly investigated. Here we report the frequent loss of expression of this 
enzyme due to methylation of its promoter site in a subset of lymphomas, 
i.e. post-transplant lymphoproliferative disorders (PTLD). Patients whose 
O\PSKRPDVKDG0*07GH¿FLHQF\DOVRH[KLELWHGIUHTXHQWORVVRI0*07
H[SUHVVLRQLQWXPRXULQ¿OWUDWLQJQRUPDOO\PSKRLGFHOOVGH¿QLQJD¿HOGGH-
IHFWE\0*07GH¿FLHQF\LQWKHVHWXPRXUV2ILQWHUHVWDKLJKO\VLJQL¿FDQW
DVVRFLDWLRQEHWZHHQ0*07GH¿FLHQF\DQGLQDFWLYDWLRQRIWKH005V\VWHP
was observed in PTLD as well as in a series of lymphoid cell lines (LCL). 
005GH¿FLHQF\QRWDEO\RFFXUUHGWKURXJKGHOHWHULRXVWUDQVLWLRQPXWDWLRQV
within MMR genes in these tumours. Accordingly, MGMT loss of function 
is highlighted as an early event favouring the transformation of lymphoid 
FHOOVWKURXJK005GH¿FLHQF\7KHVHUHVXOWVKDYHLPSRUWDQWLPSOLFDWLRQV
for the management of grafted patients who are at risk of developing MMR 
GH¿FLHQWO\PSKRPDV
BRD2 GENE AND PROTEIN EXPRESSION IN MALIGNANT 
LYMPHOMA. 
Faisal Fadlelmola, Minglong Zhou, Ronald J. de Leeuw, Pedro Farinha, 
Christian Steidl, Randy Gascoyne, Wan Lam, and Diponkar Banerjee
Centre for Translational and Applied Genomics, Department of Pathology, 
British Columbia Cancer Agency, Vancouver, Canada and BC Cancer 
Research Centre. 
BRD2 (bromodomain-containing protein 2), formerly known as RING3 (re-
ally interesting new gene 3) encodes an 85 kDa mitogen-activated kinase, 
Brd2, a transcription regulator, which localizes to the nucleus and acts as 
a scaffold for various transcription factors. Transgenic mice with lymphoid 
tissue-restricted overexpression of Brd2 develop a splenic B cell lymphoma 
which resembles human diffuse large B cell lymphoma in gene expression 
SUR¿OH7KURXJK JHQH H[SUHVVLRQ SUR¿OLQJ ZH VKRZHG LQFUHDVHG H[SUHV-
sion of BRD2 in Hodgkin Lymphoma (HL) cell lines KMH2, L428 and L-
FHOOVFRQ¿UPHGE\FRQYHQWLRQDO573&5DQGTXDQWLWDWLYH573&5
$PSOL¿FDWLRQRI%5'ZDVGHWHFWHGE\VXEPHJDEDVHUHVROXWLRQWLOLQJDUUD\
CGH (SMRT Array CGH) in L-1236 but not KMH2 or L428 cells. In 3 of 5 
clinical samples of HL, microdissected Reed-Sternberg cells showed gains 
in the BRD2 locus. Immunohistochemistry for Brd2 was carried out on tis-
sue microarray sections of Classical HL in comparison to diffuse large B cell 
lymphoma (DLBCL). In HL (n=50), 90% of cases showed nuclear positiv-
ity in Reed-Sternberg cells, while in DLBCL (n=83), 94% of cases showed 
nuclear positivity in large neoplastic B cells. The intensity of staining varies 
IURPaRISRVLWLYHFDVHVWRaRISRVLWLYHFDVHV,QUHDF-
tive lymph nodes only cytoplasmic Brd2 protein expression was found in 
germinal centre centrocytes and centroblasts, apoptotic germinal centre cells, 
mantle zone cells, and in plasma cells. No nuclear staining was seen. Since 
nuclear Brd2 localisation is indicative of Brd2 activation, these observations 
indicated that germinal centre centrocytes, mantle zone cells and plasma 
cells lack Brd2 activation but neoplastic B cells in HL and DLBCL contain 
activated Brd2. Pathways associated with Brd2 activation will be explored in 
future studies. Funded by the Canadian Institutes of Health Research (CIHR) 
and the Lymphoma Foundation Canada. 
PREVALENCE OF MYC REARRANGEMENTS IN GASTRIC 
DIFFUSE LARGE B-CELL LYMPHOMA: INTERPHASE FISH 
ANALYSIS USING PARAFFIN-EMBEDDED BIOPSY SAMPLES.
Hidekazu Kayano1, Toshinori Nagai1, Mark E Law2, Ellen D Remstein2, 
Takanori Hirose1
1Department of Pathology, Saitama Medical University, Moroyama, 
Saitama, Japan. 2Department of Laboratory Medicine and Pathology,  
Mayo Clinic, Rochester, MN, USA
Background: Diffuse large B-cell lymphoma (DLBCL) has a heterogeneous 
molecular basis; MYC gene abnormality is seen in approximately 15% of 
DLBCL, but BCL2 or BCL6 genes are more frequently rearranged. In con-
trast, Burkitt lymphoma (BL) is characterized by constitutive rearrangement 
of MYC and immunoglobulin (IG) genes with paucity of BCL2 or BCL6 
rearrangements. MYC rearrangements with several non-IG genes in DLBCL 
have recently been reported; in particular, MYC rearrangement without IG 
co-migration is frequently detected in gastric DLBCL. Practically, histologi-
cal distinction of DLBCL from BL occasionally has to be done in gastric 
ELRSVLHVEXWPROHFXODUDQDO\VLVLVOLPLWHGGXHWRGLI¿FXOWLHVLQREWDLQLQJ
VXI¿FLHQWO\ODUJHIUHVKELRSV\VDPSOHV0HWKRGV:HFRQGXFWHGLQWHUSKDVH
),6+DQDO\VLVRQVHFWLRQVRISDUDI¿QHPEHGGHGJDVWULFELRSV\VSHFLPHQV
FRQ¿UPHGDV'/%&/6XEMHFWVFRPSULVHGDGXOWSDWLHQWVDJHWR
years). The following FISH probes were used: 2 break apart rearrangement 
probes for MYC and BCL6 genes, and 4 dual fusion translocation probes for 
MYC/IG fusion (heavy chain (MYC/IGH) and light chains (MYC/IGK and 
MYC/IGL)) and IGH/BCL2 10% of nuclei from 200-250 tumor cells³fusion. 
Abnormal signals in were considered to indicate a positive result. Results: 
Rearrangement of MYC, BCL6 and BCL2 was detected in 4, 3 and 2 cases, 
respectively. MYC rearrangements were associated with IGH/BCL2 fusion 
(two cases) and/or BCL6 rearrangement (two cases). A higher percentage 
of cells had BCL2 and/or BCL6 rearrangements than MYC rearrangement, 
suggesting that MYC aberrations are a secondary event.
MYC/IGL translocation was found in another case. No MYC/IGH or IGK 
fusions were observed in this series. Conclusions: FISH analysis may be use-
ful in distinguishing DLBCL from BL on small gastric biopsy samples. Our 
results suggest that MYC rearrangements in gastric DLBCL may be second-
ary genetic events and usually involve non-IG partner genes.
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH T(14;18) 
AND 8Q24/C-MYC REARRANGEMENT IS A LYMPHOID 
NEOPLASM WITH AGGRESSIVE CLINICAL PRESENTATION 
AND VERY POOR PROGNOSIS.
Steven Le Gouill*1, Pascaline Talmant*2, Cyrille Touzeau1, Anne Moreau3, 
Richard Garand2, Nadine Juge-Morineau4, Fanny Gaillard3,  
Thomas Gastinne1, Noël Milpied5, Philippe Moreau1, Jean Luc Harousseau1 
and Hervé Avet-Loiseau2
1Department of Hematology, Hôtel Dieu, University Hospital of Nantes, 
Place Alexis Ricordeau, 4093 Nantes cedex 01, France; 2Laboratory of 
Hematology, Clinical Hematology Department, University Hospital, 
Place Alexis Ricordeau, 44093 Nantes cedex 01, France; 3Laboratory of 
Anatomopathology, University Hospital, Place Alexis Ricordeau 44093 
Nantes cedex 01, France; 4Centre Catherine de Sienne, 2 rue Eric Tabarly, 
44200 Nantes, France; 5Department of Hematology, University Hospital, 
Hôpital Haut Lévèque, 3604 Pessac, France
:HLGHQWL¿HG'LIIXVH/DUJH%&HOO/\PSKRPDV'/%&/VZLWKFRQ-
current t(14;18) and 8q24/c-MYC rearrangement and describe their clini-
cal, biological, immunophenotyping and cytogenetic features. All patients 
had aggressive features: B symptoms (81%), ECOG PS > 2 (81%), elevated 
LDH (100%), stage IV disease (100 %) with at least one extra nodal lo-
calisation (bone marrow, blood and CNS involvement in 93%, 50% and 
50%, respectively) and age-adjusted IPI = 3 in 81%. Despite intensive che-
motherapy regimens (including allogeneic transplants), all patients died be-
cause of disease progression. PFS and OS were 4 and 5 months, respectively. 
Immunophenotyping analysis (CD20, CD10, Bcl-6, Mum-1, Bcl-2 CD138, 
MIB1, CD19, CD5, CD38 and sIg) was performed and showed DLBCLs 
ZLWKDJHUPLQDOFHQWHU*&SUR¿OH.LVWDLQLQJUDQJHGIURPWR
All cases assessed by cytogenetic analysis (conventional cytogenetic (CC) 
DQGRU),6+DQDO\VLVKDGDFRPSOH[NDU\RW\SH,QRQHFDVHZHLGHQWL¿HG
a 8q24/c-MYC translocation variant never reported in DLBCLs before : 
t(8;9)(q24;p13) and t(14;18)(q32;q21). BCL-6 rearrangement was investi-
gated (FISH) and found rearranged in 4 cases. In conclusion, DLBCLs with 
68 Journal of Hematopathology (2008) 1:47  74   – concurrent t(14;18) and 8q24/c-MYC rearrangement is subgroup of GC-
DLBCLs. Coexistence of dual translocation is worth being searched in Bcl-2 
positive DLBCLs with unusual aggressive presentation.
TRANSFORMATION OF FOLLICULAR LYMPHOMA TO 
BURKITT-LIKE LYMPHOMA WITHIN A SINGLE LYMPH NODE 
Jagmohan S. Sidhu MD1, Sanjay Mukhopadhyay MD2, Joseph Readling 
MD3, Philip Cotter PhD FACMG4, Anthony E Shrimpton PhD5
1Department of Pathology, United Health Services Hospitals, Johnson City, 
NY, 13790. 2Department of Pathology, SUNY Upstate Medical University, 
Syracuse, NY, 13210. 3Department of Oncology, United Health Services 
Hospitals, Johnson City, NY, 13790. 4Cytogenetics and Molecular Genetics, 
US Laboratories, Irvine, CA, 92612. 5Department of Pathology, SUNY 
Upstate Medical University, Syracuse, NY, 13210.
Aberrant expression of bcl-2, caused by a t(14;18) translocation, most com-
monly occurs in follicular lymphoma (FL). In some of these tumors, ad-
ditional acquisition of a translocation involving c-myc leads to transforma-
tion to a high-grade lymphoma, usually to diffuse large B-cell lymphoma. 
Transformation of FL to Burkitt-like lymphoma (BLL) is uncommon. We 
encountered a case of FL containing a t(14;18) translocation transforming 
into a BLL containing the original t(14;18) as well as an additional t(8;14). 
The latter translocation resulted in the phenotype of BLL and transforma-
tion from FL to BLL was demonstrable within a single lymph node in the 
IRUPRIWKUHHGLVWLQFWLYHFRPSRQHQWVLQFRQWLQXLW\ZLWKHDFKRWKHU7KH¿UVW
component consisted of follicles, some showing a predominance of centro-
cytes and others showing an admixture of centrocytes and centroblasts. The 
second component consisted of medium-sized lymphoid cells (Butkitt cells) 
arranged in a follicular pattern, with a “starry-sky” appearance, brisk mitosis, 
and abundant apoptosis. The third component consisted of cells similar to 
the second component but arranged diffusely. Both the FL and the BLL were 
positive for CD20, CD79a, bcl-2, bcl-6DQGVKRZHGțOLJKWFKDLQUHVWULF-
tion. The Ki-67 labeling index was low (25%-50%) in the FL and almost 
100% in the BLL in both the follicular and diffuse areas. Fluorescent in situ 
hybridization (FISH) of the FL region was positive for t(14;18) and nega-
tive for t(8;14). FISH of the Burkitt-like region with follicular pattern was 
positive for both t(14;18) and t(8;14). Similarly, the Burkitt-like region with 
diffuse pattern was positive for both t(14;18) and t(8;14). To the best of our 
NQRZOHGJHWKLVLVWKH¿UVWGHVFULSWLRQRIDFDVHGRFXPHQWLQJGLUHFWWUDQV-
formation of FL into BLL in the same lymph node. This case illustrates the 
dramatic oncogenic stimulus that results from the inhibition of apoptosis by 
bcl-2 combined with the deregulation of cell growth by c-myc.
FREQUENCY AND FEATURES OF THE CMYC 
REARRANGEMENTS (DETECTED BY FISH AND ARRAYCGH) IN 
OTHER B CELL NEOPLASIAS: THE EXAMPLE OF MULTIPLE 
MYELOMA
Bibiana I. Ferreira, Cristina Largo, Juan C. Cigudosa
Molecular Cytogenetics Group, Centro Nacional de Investigaciones 
Oncologicas (CNIO). Madrid. Spain.
Text: Chromosome translocations involving CMYC oncogene and the loci of 
Immunoglobulin gene constitute the genetic hallmark of Burkitt lymphomas. 
However, such translocation and other rearrangements of CMYC have also 
EHHQGHVFULEHGLQ%FHOOWXPRXUVWKDWGRQRWEHORQJWRWKLVVSHFL¿FFDWHJRU\
We and others have described that CMYC translocation and genomic gains 
are frequent in multiple myeloma (MM) (1,2). It is assumed that CMYC 
SOD\VDVLJQL¿FDQWUROHDVDVHFRQGDU\JHQHWLFDEHUUDWLRQLQ00
Objective: To study of the frequency and the nature of CMYC rearrange-
ment in MM. 
Material and Methods: (1) A home made TMA containing 31 primary sam-
ples of MM was subjected to FISH analysis. We used the CMYC breakapart 
probe (BA) that has been developed by DAKO (Cat # Y5410). FISH assay 
was carried with standard protocols as provided by the supplier. (2) An ad-
GLWLRQDOSDQHORI00FDVHVZHUHDQDO\]HGIRUJHQRPLFSUR¿OLQJE\DU-
rayCGH). ArrayCGH was performed in a Human Genome CGH Microarray 
44B platform from Agilent Technologies (Palo Alto, CA). This platform con-
tains 44000 60-mer oligonucleotides covering the genome with an average 
resolution of 45 Kb. CGHAnalytics and InSilicoArray were used for array
analysis. 
Results: 23 out of 31 cases were successfully analyzed by FISH. Six cases 
(19%) showed CMYC rearrangements. Four cases could be diagnosed as 
positives for the translocation (separated signals with the BA CMYC probe) 
and two more cases showed three copies of the gene. In the arrayCGH study, 
three cases (11%) showed gain of the CMYC genomic region. The discrep-
ancy of the percentage is due to the limitation of the arrayCGH technique 
detecting translocations.
Refs:
/DUJRHWDO,GHQWL¿FDWLRQRIDPSOL¿HGRYHUH[SUHVVHGJHQHVLQPXOWLSOH
myeloma. Haematologica. 2006, 91:184
2. Keatts et al. Promiscuous mutations activate the noncanonical NF-kappaB 
pathway in multiple myeloma. Cancer Cell. 2007,12:131
CHLAMYDIA INFECTION AND THE DEVELOPMENT OF THE 
OCULAR ADNEXAL LYMPHOMAS
A. Carugi1, A. Onnis1, M. Cocco1, A. Luzzi1, J. Nyagol4, G. Cerino1,  
S. Shaheen4, GM. Tosi2, C. Bellan1, G. De Falco1,3, A. Giordano1,3,  
L. Leoncini1
1Dpt. Human Pathology and Oncology, University of Siena, Italy; 2Dpt. 
of Ophtalmology, University of Siena, Italy; 3Sbarro institute for Cancer 
Research & Molecular Medicine, Temple University, Philadelphia PA 
19122, USA; 4Dpt of Pathology, Aga Khan University Hospital, Nairobi-
Kenya
Non-Hodgkins lymphomas develop from nodal and extra-nodal tissue. A 
particular extra-nodal lymphoma type arises from B cells of the marginal 
zone (MZ) of mucosa-associated lymphoid tissue (MALT). The geographic 
heterogeneity in the incidence of B-cell non Hodgkin’s lymphomas and the 
growing evidence suggest that MZ lymphomas are associated with chronic 
antigenic stimulation by microbial pathogens, among which H. pylori-as-
sociated gastric MALT lymphoma is the best studied.
Recently, MALT lymphomas have been described in the context of chronic 
conjunctivitis, which can be associated with Chlamydia infection. Studies 
from Italy showed Chlamydia psittaci in 87% of ocular adnexal MALT lym-
phomas and complete or partial regression of the lymphoma after C. psittaci 
eradication in four of nine cases. However C. psittaci was not founded in 
ocular adnexal lymphoma from other studies. As association with C. psittaci 
does not seem to be a constant parameter, this variability may depend on 
geographic heterogeneity.
This project was designed to further investigate the role of Chlamydia psit-
taci in the development of ocular adnexal MALT lymphomas, by comparison 
of cases retrieved from different geographic areas, as Kenia and Italy.
The presence of C. psittaci DNA in biopsies of ocular adnexal lymphomas 
ZDVGHPRQVWUDWHGE\7(753&5DPRGL¿HG3&5UHDFWLRQXVHGWRDPSOLI\
different DNA sequences in the variable regions of the 16S and 23S spacer 
U51$JHQHVVSHFL¿FIRUChlamydia psittaci.
DNA was extracted from 31 ocular adnexal lymphomas, retrieved from two 
different geographical regions. The prevalence of C. psittaci infection in 
MALT lymphoma showed a marked variation between the two geographical 
regions. 20% (5/25) of the samples from Italy were positive for C. psittaci, 
but no association with this pathogen was observed in any of the samples 
from Kenya.
Furthermore, we investigated a possible relationship between C. psittaci in-
fection and the promoter hypermethylation of p16/INK4a. This epigenetic 
alteration has been described in H. pylori-associated gastric MALT lympho-
ma. Our results show a partial methylation of p16/INK4a promoter in 46% 
(12/26) of C. psittaci-negative cases, whereas no hypermethylation of this 
gene was found in C. psittaci-positive cases. As genetic alterations, as the 
t(11;18) and t(1;14), have been described in MALT lymphomas, we are cur-
rently performing FISH studies to evaluate whether such genetic alterations 
may also occur in adnexal lymphomas, besides Chlamydia association.
)URPWKHVH¿QGLQJVZHPD\FRQFOXGHWKDWPDQ\DQGGLIIHUHQWLQIHFWLRXV
agents may play a critical role in MALT lymphoma development.
SERO-PREVALENCE OF HEPATITIS VIRUSES IN  
NON-HODGKIN‘S LYMPHOMA IN OMAN
Ikram A Burney, and Mansour S Al Moundhri.
Medical Oncology unit, Department of Medicine, Sultan Qaboos University 
Hospital, Muscat 123, Oman.
There is a growing body of evidence suggesting the possible role of hepati-
tis C virus (HCV) in the etiology of Non-Hodgkin‘s Lymphoma (NHL). A 
high rate of association between HCV and NHL has been reported especially 
from areas of high endemicity. The data on Hepatitis B virus (HBV) is less 
69 Journal of Hematopathology (2008) 1:47  74   – GH¿QLWLYH2PDQLVRQHRIWKHDQGWKHUHDUHQRGDWDRQWKHDVVRFLDWLRQRIYL-
ruses in NHL. This study addresses the issue of sero-prevalence from Oman. 
The data were collected retrospectively from consecutive adult patients (>14 
years) diagnosed to have NHL between June 1999 and Dec 2006, and the 
sero-prevalence of HBV and HCV was compared with the healthy blood 
GRQRUV7KHGLDJQRVLVZDVHVWDEOLVKHGDFFRUGLQJWRWKH:+2FODVVL¿FDWLRQ
Patients with ALL and CLL were excluded. Data were available from a to-
tal of 94 patients. Median age was 49 (14-86) years. There were 61 males 
and 33 females. 59% patients had DLBCL, 8.5% had ALCL, and 8.5% had 
FL. 6/94 (6.5%) showed positivity for Anti-HCV, 9/94 (9.4%) were positive 
for HepBsAg, whereas, 26/54 (48%) were positive for total core antibody. 
Four patients had concomitant HIV infection. The sero-prevalence rate for 
HCV and HBV in the control group were 1.2% and 4.9% respectively. There 
ZHUHQRVLJQL¿FDQWGLIIHUHQFHVLQHLWKHUWKHFOLQLFRSDWKRORJLFDOIHDWXUHVRU
the overall survival among patients who were either HBV/HCV positive or 
negative. Sero-prevalence rates for HBV from different reported studies are 
shown as under:
&RXQWU\ 5HSRUWHG&DVHVSRVLWLYH &RQWUROVSRVLWLYH 6LJQL¿FDQFH
Romania  1999  68 (30.8%)  943 (6.3%)  p<0.001
Japan  2001  348 (6.9%)  1,513,358 (?)  p=0.05
Japan 2005  218  (7.3%)  (1.2%)  p<0.05
Italy  2006  400 (8.5%)  392 (2.8%)  p<0.05
Turkey 2006  203  (14.5%)  NR(8.2%)
Singapore  2006  556 (10.3%)  4698 (4.1%)  p<0.001
Current Study  2008  94 (9.4%)  4.9%  p<0.05
In conclusion, the sero-prevalence rate for both HBV and HCV is higher in 
patients with NHL compared to the controls in Oman.
THE CURRENT STATE OF LYMPHOMA HISTOPATHOLOGY IN 
UGANDA
S. Kalungi1,2, A. Molven2, H.R. Wabinga1, L. Bostad2
1Department of Pathology, Faculty of Medicine, Makerere University, 
Uganda 2The Gade Institute, Section for Pathology, University of Bergen, 
Haukeland University Hospital, Bergen, Norway
Introduction: The epidemiology of haematopoietic and lymphoid tumours 
continues to pose a challenge in the developing countries. The lack of ad-
equate clinical and demographic information is part of the problem. During 
WKHODVWWZHQW\\HDUVWKHUHKDYHEHHQDQXPEHURIGLIIHUHQWFODVVL¿FDWLRQV\V-
WHPVDOVRFDXVLQJSUREOHPVLQWKLVVHWWLQJ0RGHUQO\PSKRPDFODVVL¿FDWLRQ
requires ancillary techniques that may be unavailable.
Objective: To look at the standard of hematopathology reporting and exam-
LQHWKHIUHTXHQF\DQGGLDJQRVWLFSUR¿OHRIO\PSKRPDVGLDJQRVHGLQ8JDQGD
in the period 1980-1989
Setting: Department of Pathology, Faculty of Medicine, Makerere University, 
Kampala, Uganda.
Methods: Review of the patients` pathology records for the years 1980-1989 
IURPWKH¿OHVRIWKH'HSDUWPHQWRI3DWKRORJ\0DNHUHUH8QLYHUVLW\
Results: A total of 1013 patients were diagnosed with lymphoma in the pe-
riod 1980-1989. The most common type of non-Hodgkin lymphoma was 
Burkitt lymphoma (36%). The frequencies of lymphocytic, histiocytic and 
other histological types were 34%, 8% and 22%, respectively. Light micros-
copy of Haematoxylin and Eosin stained slides is the only method used for 
lymphoma diagnostics in Uganda.
Conclusion: Burkitt lymphoma continues to be the most common subtype of 
lymphoma diagnosed in Uganda. Some lymphoma subtypes are not reported 
LQWKHFRXQWU\LQWKLVSHULRG0RGHUQO\PSKRPDFODVVL¿FDWLRQLVEDVHGRQD
multimethodological approach and includes the clinical picture, morphol-
ogy, immunophenotype and molecular genetic features. Accordingly,quality 
LPSURYHPHQWLQWKLV¿HOGRIVXUJLFDOSDWKRORJ\UHTXLUHVLPSOHPHQWDWLRQRI
ancillary laboratory techniques
TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMA OF 
GERMINAL CENTER ORIGIN APPEARING „BURKITT-LIKE“ 
ON MORPHOLOGIC AND TYPE 3 (NON-GC/NON-ABC TYPE)ON 
IMMUNOHISTOCHEMICAL EXAMINATION
Jagmohan S. Sidhu MD1, Madhuri Yalamanchili MD2 and  
Peter R. Papenhausen PhD3
1 and 2UHS Hospitals, Department of Pathology and Laboratory Medicine, 
-RKQVRQ&LW\1<86$DI¿OLDWHGZLWK681<8SVWDWH0HGLFDO8QLYHUVLW\
Syracuse, NY). 3Laboratory Corporation of America,Center for Molecular 
Biology and Pathology, Research Triangle Park, NC,USA.
We performed immunohistochemical and interphase cytogenetic analysis us-
LQJÀXRUHVFHQFHLQVLWXK\EULGL]DWLRQ),6+RQDFDVHRIWUDQVIRUPHGGLIIXVH
ODUJH%FHOOO\PSKRPD'/%&/ZLWKÄ%XUNLWWOLNHµPRUSKRORJ\LQRUGHU
WRFRQ¿UPWUDQVIRUPDWLRQDQGWRUXOHRXWUXOHLQ%XUNLWWO\PSKRPD%/
These studies were performed on a cervical lymph node excision specimen 
of a 64-year-old male who had developed cervical lymphadenopathy a few 
years after a diagnosis of low-grade follicular lymphoma was made on an 
inguinal lymph node biopsy. He was not treated for his low-grade lymphoma. 
7KHFHUYLFDOO\PSKQRGHELRSV\VKRZHGGLIIXVHLQ¿OWUDWHRIPHGLXP
to large sized lymphoid cells with 1-2 prominent nucleoli, numerous mitoses, 
PDUNHGDSRSWRVLVDQGÄVWDUU\VN\³DSSHDUDQFHFUHDWHGE\ÄWLQJLEOHERG\³
macrophages. About 90% of the lymphoid cells were positive for CD20, 
CD10, BCL2, BCL6, and Ki67. MUM1 was negative. This immunopheno-
type is neither of germinal center (GC) type nor of activated B-cell (ABC) 
type and is, therefore, of type 3 DLBCL. Flow cytometric analysis of the 
lymph node showed monotypic B-cell population with surface expression of 
CD19, CD20, CD23 (dim), CD38, and lambda light chain. FISH for c-MYC 
gene rearrangement and BCL2 gene rearrangement was performed on the 
IRUPDOLQ¿[HGSDUDI¿QHPEHGGHGWLVVXHZKLFKVKRZHGF0<&JHQHUHDU-
rangement in about 44% of nuclei in an apparent tetraploid clone, BCL2 
gene rearrangement in about 86% of nuclei, and an extra BCL2 gene signal 
additional chromosome 18) in most of the nuclei with BCL2 gene rearrange-
ment. Additional chromosome 18 supports transformed DLBCL and the pres-
ence of c-MYC gene rearrangement only in about 44% nuclei rules-out the 
possibility of BL. Our case emphasizes the value of looking at the percent-
age of c-MYC gene arrangement positive nuclei as a way of differentiating 
Ä%XUNLWWOLNH³'/%&/IURP%/DQGDOVRVKRZVWKDWVRPHFDVHVRIDSSDUHQW
type 3 DLBCL can actually be transformed GC type DLBCL.
CLINICAL ASPECTS, CHEMOTHERAPY AND NOVEL 
THERAPEUTIC TARGETS 
IS INTENSIVE CHEMOTHERPAY FOR AGGRESSIVE AND 
HIGHLY AGGRESSIVE NON-HODGKIN’S LYMPHOMA 
NECESSARY IN AFRICA, AND IS IT FEASIBLE?
NA Othieno Abinya – MB, ChB M’Med
Department of Clinical Medicine and Therapeutics, School of Medicine, 
College of Health Sciences, University of Nairobi.
Aggressive and highly aggressive phenotype non-Hodgkin’s lymphomas 
(NHLs) were categorised as intermediate and high grade variants in the 
International Working Formulation. Whereas this categorization is not easily 
applicable wholesome in the current widely used World Health Organization 
(WHO) update of the Revised European/American Lymphoma (REAL) clas-
VL¿FDWLRQIRUO\PSKRLGQHRSODVPVO\PSKRPDW\SHVFRQVLGHUHGDUHGLIIXVH
large B-cell lymphoma, variants of mantle cell lymphoma, variants of lym-
phoplasmacytic lymphoma, angioimmunoblastic T-cell lymphoma, enterop-
DWK\W\SH7FHOOO\PSKRPDSHULSKHUDO7FHOOO\PSKRPDXQVSHFL¿HGDGXOW
T-cell leukaemia/lymphoma (ATL). Others in the highly aggressive category 
include sub variants of diffuse large-B cell lymphoma, precursor B- and T- 
cell lymphoblastic leukaema/lymphoma, Burkitt’s lymphoma, sub variants 
RISHULSKHUDO7FHOOO\PSKRPDXQVSHFL¿HGDQJLRLPPXQREODVWLF7FHOOO\P-
phoma, enteropathy-type T-cell lymphoma, sub variants of anaplastic large-
cell lymphoma, primary-systemic type, sub variants of ATL.
Treatment of these lymphomas has evolved over the years from the predomi-
nant use of single agent chemotherapy with 5 year survivals being virtu-
ally zero. When the combination of C-MOPP protocol was introduced in the 
1960s by workers from the US National Cancer Institute, complete remis-
sion (CR) rates of 45% were realised, with most patients who achieved CR 
remaining disease-free 24 years later. The cure rates were estimated at 37%, 
a far cry from the CR rates of 73-80% with cure rates of over 60% achiev-
70 Journal of Hematopathology (2008) 1:47  74   – able with the current intensive chemotherapies that incorporate high dose 
salvage protocols, with or without monoclonal antibody therapy in patients 
with advanced disease.
Africa today is still at the stage where industrialised countries were in the 
1960s and 1970s. The problem is not lack of technology, drugs or support 
requirements. These can be imported. The problem is the weak economies 
WKDWPDNHLWGLI¿FXOWWRSXUFKDVHWKHUHTXLUHGPHGLFLQHVDQGHTXLSPHQW7KH
gross national income per-capita for Kenya is 1396 US Dollars not different 
from most of Africa. Here 46% of the population survive on less than one US 
Dollar per day. The cost of medication required for the cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP) protocol plus effective anti-
emetics for example is 450 US Dollars and is not affordable for the majority 
of the population in countries like Kenya with total expenditure on health per 
capita of 8.3 US Dollars. From this perspective it is prudent to limit Africa 
to tailored protocols that are affordable. After all something is always better 
than nothing. The problem is, the protocols such as those used in the 1960s 
and 70s were basically palliative and left large chunks of the population with 
heavy disease burdens. 
Africa has enough resources but proper resource utilization is wanting. 
Rather than give up and subject everyone including some of the most de-
serving cases to treatments that are basically palliative, it is better to apply 
the rule ‘what is good for Europeans and Americans is also what is good for 
Africans’, and encourage policy makers to practise good governance and 
proper utilization of resources. An intensive protocol dubbed BEMACOPPA 
is undergoing phase II trials in Nairobi, though accrual rate is slow.
OPTIMIZING CHEMOIMMUNOTHERAPY IN AGGRESSIVE 
LYMPHOMAS.
Lorenz Trümper
Georg August University of Göttingen, Germany
Aggressive lymphoma comprises a group of clinically and biologically 
heterogeneous diseases characterized by rapid growth of lymphoma cells 
and good response to chemotherapy with CHOP-based regimens, immuno-
therapy with CD20 antibodies and radiotherapy. Recently, gene expression 
DQG,+&EDVHGFODVVL¿HUVKDYHEHHQGHYLVHGEDVHGRQUHWURVSHFWLYHSDWLHQW
groups. In the clinic, the easily applicable international prognostic index is 
prognostically valid. Data modifying this index have been presented by Sehn 
et al (Vancouver group); data of our group based on the Ricover-60 collective 
still uphold the validity of this index (Ziepert et al).
Standard treatment has been improved by dose density approaches utilized 
by our group (Pfreundschuh, Trümper et al., 2004) and by the addition of 
5LWX[LPDE&RLI¿HUHWDO3IUHXQGVFKXKDO7KH5LFRYHUWULDO
compared in a bifactorial fashion 6 vs 8 cycles of CHOP and R-CHOP vs 
CHOP alone in a dose dense fashion (Pfreundschuh et al., submitted).
R-CHOP-14 for 6 cycles is the standard regiment for elderly patients for the 
DSHNHL. Further trials by GELA and HOVON will be presented in the 
near future. Based on initial Rituximab-denser treatments by the SWOG, the 
DSHNHL has started phase II trials with denser applications of Rituximab at 
the initiation of treatment, thereby improving responses. This regiment will 
now be tested in a phase III trial. Further escalation of chemotherapy by dose-
dense high dose chemotherapy has not been shown to be superior to standard 
CHOP-based therapy so far. The results and reasons will be discussed in 
GHWDLO$OORJHQHLFWUDQVSODQWDWLRQPRGL¿HGE\DQWLERGLHVKDVJDLQHGDSURPL-
nent role in the relapse treatment of aggressive lymphomas. Results of the 
DSHNHL R3 trial will be updated. In summary, clinical approaches have 
JUHDWO\GLYHUVL¿HGRYHUWKHODVW\HDUVDOORZLQJWUHDWPHQWVWUDWHJLHVEDVHGRQ
LQGLYLGXDOULVNIDFWRUV,PSURYHGFODVVL¿HUVEDVHGRQELRORJLFDOGLIIHUHQFHV
are needed.
NOVEL TARGETED THERAPEUTIC APPROACHES FOR THE 
TREATMENT OF VIRAL LYMPHOMAS. 
Ethel Cesarman
Department of Pathology and Laboratory Medicine, Weill Medical College 
of Cornell University, New York, NY, USA
Epstein-Barr virus (EBV), Kaposi‘s sarcoma herpesvirus (KSHV), also 
called Human Herpesvirus 8 (HHV-8), and human T-cell lymphotrophic vi-
rus (HTLV-1) are viruses that are well documented to be causally associated 
with lymphoid neoplasia in humans. Other viruses have also been proposed 
to be involved in lymphomagenesis, but their role may be indirect, or the 
association is not well established. Current knowledge suggests that EBV, 
KSHV and HTLV-1 contribute to lymphomagenesis by subverting the host-
cell molecular signaling machinery to deregulate cell growth and survival. 
For example, deregulation of the NF-kB pathway is a common strategy used 
by all three three lymphomagenic viruses to promote cell survival, thereby 
playing a critical role in tumorigenesis. Therefore, new drugs that inhibit 
1)N%PD\EHEHQH¿FLDOIRUWKHWUHDWPHQWRIYLUDOO\PSKRPDVDORQHRULQ
combination with chemotherapy. Other cellular pathways that may represent 
good therapeutic targets as they are deregulated in viral malignancies include 
cMYC, p53 and mTOR. Inhibitors for these molecules are in development or 
are currently in clinical trials for other malignancies. Recent data indicates 
that at least in some viral lymphomas, the elimination of a single viral protein 
inhibits the proliferation of tumor cells or leads to their apoptosis in vitro. 
This has been shown for EBV EBNA1, LMP1 and LMP2, and for KSHV 
vFLIP and vIRF-3 genes using RNA interference. This gives us the unique 
and exciting opportunity to target these viral proteins for the treatment of the 
PDOLJQDQFLHVDVVRFLDWHGZLWKVSHFL¿FLQIHFWLRQV7DUJHWLQJRIYLUDOSURWHLQV
involved in oncogenesis would be advantageous over inhibiting cellular pro-
WHLQVDVWKHUDS\FRXOGEHFRPSOHWHO\VSHFL¿FDQGQRQWR[LF
CANNABINOID RECEPTORS AS MEDIATORS OF CELL DEATH 
IN NON-HODGKIN´S LYMPHOMA
Kristin Gustafsson1, Xiao Wang1, Maeve Eriksson1, Denise Severa1,  
Eva Kimby2, Mats Merup2, Birger Christensson1, Jenny Flygare1,  
Birgitta Sander1
1Department of Laboratory Medicine, Division of Pathology, F46 
Karolinska Institutet and Karolinska University Hospital Huddinge, SE 141 
86 Stockholm, Sweden.
,QSUHYLRXVVWXGLHVZHLGHQWL¿HGWKHFDQQDELQRLGUHFHSWRUW\SH&%DQG
type 2 (CB2) as over expressed in mantle cell lymphoma (MCL). Endogenous 
and synthetic cannabinoids inhibited proliferation and induced apoptotic cell 
death in MCL while normal B cells were spared; suggesting that targeting of 
cannabinoid receptors could provide a new treatment option in MCL. In the 
present study, expression of CB1 and CB2 was evaluated in a broad panel 
of indolent and aggressive B lymphocyte malignancies (n=62). A major-
ity of the B cell lymphomas expressed higher levels of CB1 and CB2 than 
reactive lymphoid tissue. In contrast to MCL, that uniformly express CB1 
and CB2, the expression in other malignant B cell lymphomas was highly 
YDULDEOH7KHUHZDVDVLJQL¿FDQWFRUUHODWLRQEHWZHHQWKHH[SUHVVLRQRI&%
and CB2 in malignant lymphomas. Low levels of the splice variant CB1a, 
SUHYLRXVO\VKRZQWRKDYHDGLIIHUHQWDI¿QLW\IRUFDQQDELQRLGVWKDQ&%ZDV
detected in 30% of CB1 expressing lymphomas. In functional studies, using 
cell lines derived from MCL, Burkitt lymphoma, CLL and plasma cell ma-
lignancies, cannabinoids induced cell death in cells expressing both CB1 and 
CB2. Finally, in mice xenotransplanted with human MCL tumors, there was 
DVLJQL¿FDQWUHGXFWLRQLQPLWRWLFLQGH[DQGWXPRUVL]HLQFDQQDELQRLGWUHDWHG
mice compared to control mice. Our studies demonstrate that cannabinoid 
receptors are widely expressed in malignant lymphoma. Thus, targeting of 
the endocannabinoid system might provide a new mode of treatment in ma-
lignant lymphoma.
RESULTS OF BURKITT‘S LYMPHOMA AND OTHER 
AGGRESSIVE B-CELL MALIGNANCY BY REVISED PROTOCOL 
NHL-BFM-90: SINGLE CENTRE EXPERIENCE.
Semochkin S.V., Loriya S.S., Rumiantsev A.G.
)HGHUDO6FLHQWL¿F&OLQLFDO&HQWHUIRU3HGLDWULF+HPDWRORJ\2QFRORJ\DQG
Immunology, Moscow, Russia 
Patients and methods: 57 (m-40, f-17) de novo patients (pts) have been en-
rolled in this study during 1990-2005. Treatment under the revised proto-
col NHL-BFM-90 has been conducted to 34 (60%) pts (median age 12.7, 
range 10-61 years) with Burkitt‘s lymphoma (BL) and Burkitt-like acute 
lymphoblastic leukemia (B-ALL) and 23 (40%) pts (median age 16.1, 10-
50 years) with diffuse large B-cell lymphoma (DLBCL). Treatment corre-
sponded to the original protocol except for use of intermediate doses of the 
Methotrexate (1 g/sqm i.v. over 36 h) instead of high doses (5 g/sqm i.v. over 
24 h). Toxicity estimated for patients of 15 years and upward according to a 
CTC-NCIC 2.0 scale. Results: CR reached at 85% pts with BL/B-ALL and 
79% with DLBCL. 6-years overall survival was 0.71 (SE 0.09) for BL/B-
ALL and 0.61 (SE 0.12) for DLBCL. 6-years event free survival (6y-EFS) 
was 0.69 (SE 0.09) and 0.55 (SE 0.13) relatively. The age of 30 years and up-
ward (6y-EFS 0.17 vs. 0.69; p = 0.027) and Lactate dehydrogenase increase 
71 Journal of Hematopathology (2008) 1:47  74   – (6y-EFS 0.49 vs. 1.0; p = 0.023) were adverse prognosis factors by results 
of the multifactorial analysis (Cox regression). Hematological toxicity of 3-4 
degrees developed in most cases: anemia - 26%, granulocytopenia - 40% and 
thrombocytopenia - 30%. Infectious episodes of 2-3 degrees of toxicity reg-
istered in 16 % cases. Mucositis of 3 degrees connected with Methotrexate 
administrathion have been registered in 12 % blocks of AA and BB. Increase 
of ALT/AST of 3-4 degrees diagnosed in 16 % cases. The interval between 
1 and 2 block of therapy practically has not carried out at patients of 30 
years and upward (median 19, range 17-25 days) because of toxicity un-
like patients of 15-29 years (median 16, range 14-22 days). Conclusions: our 
UHVXOWVKDYHSURYHGKLJKHI¿FLHQF\RIWKHUHYLVHGSURWRFRO1+/%)0
for treatment of adolescents and young adults with BL/B-ALL and DLBCL. 
)DLOXUHVLQWUHDWPHQWRISDWLHQWVRI\HDUVDQGXSZDUGKDYHFRQ¿UPHGZDQW
in other therapy. 
RITUXIMAB-CHOP VERSUS CHOP ALONE IN PATIENTS WITH 
DIFFUSE LARGE B CELL LYMPHOMA
Mustafa Cetiner, Burhan Ferhanoglu, Fergun Aydin, Nil Molinas, Nukhet 
Tuzuner, Murat Ozbalak, Isik Kaygusuz
Istanbul Lymphoma Goup-ILeG
Recently, the cyclophosphamide, doxorubicin, vincristine and prednisone 
(CHOP) regimen plus rituximab (R-CHOP) have been used widely to treat 
patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) and 
it has also been reported to improve the outcome of DLBCL. We represent 
a retrospective analysis of newly diagnosed DLBCL patients to evaluate 
the impact of R-CHOP therapy on response rates. Fifty nine patients with 
DLBCL between 20-60 years of age (median: 48.0 and mean 51.5 ± 15.3) 
received 6-8 cycles of R-CHOP. For comparison, DLBCL patients between 
21-60 years of age (median: 44.0 and mean 42.9 ± 12.4) who received 6-8 
courses of CHOP therapy (n=45) were used as the control group. All patients 
received classical CHOP (cyclophosphamide 750 mg/m m2, doxorubicin 50 
mg/m2, vincristine 1.4 mg/m m2 on day 1 and prednisone 40 mg/m m2 for 
5 days) every 4 weeks. In R-CHOP group, rituximab 375 mg/m m2 was ad-
ministered prior to CHOP chemotherapy. The median follow-up for R-CHOP 
and CHOP groups were 23.3 ± 11.5 (2-60) and 42.2 ± 32.0 (2-132) months, 
respectively. The International Prognostic Index (IPI) scores were not sig-
QL¿FDQWO\GLIIHUHQWEHWZHHQWKHVHJURXSVPHGLDQ,3,RI5&+23DQG
mean IPI 1.9 ± 1.2 versus median IPI of CHOP: 2.0 and mean IPI 1.7 ± 1.2). 
&RPSOHWHUHVSRQVH&5DQGFRPSOHWHXQFRQ¿UPHGUHVSRQVH&X5UDWHIRU
5&+23ZDVRISDWLHQWVZKLFKZDVVWDWLVWLFDOO\VLJQL¿FDQWO\
higher than CHOP (32 of 45 patients, 71.1%) (p > 0.001). Partial response 
(PR) rates for R-CHOP and CHOP groups were 5.0% (3 of 59 patients) and 
8.8% (4 of 45 patients), respectively. Primary refractory patients was %5 (3 
of 59 patients) in the R-CHOP group and 10% (8 of 49 patients) in the CHOP 
group. Three patients in R-CHOP (%5.0) and 1 patients in CHOP group 
(%2.2) were died because of treatment related complications. Relapse rates 
during the follow up period were 24.4 % (11 of 45 patients) for CHOP and 
11.8% (7 of 59 patients) for R-CHOP group (p > 0.001). No long-term tox-
icity appeared to be associated with the addition of rituximab to the CHOP 
FRPELQDWLRQ7KHVHUHVXOWVDOVRFRQ¿UPHGWKHEHQH¿WRIWKHDGGLWLRQRIULWX[-
imab to standard CHOP chemotherapy in DLBCL even in young patients 
under the age of 60.
HIGH LIGHT LECTURE
BURKITT LYMPHOMA: A PARADIGMATIC TUMOUR
Ian Magrath, DSc (Med), FRCP, FRCPath
International Network for Cancer Treatment and Research
7KHGLVFRYHU\RI%XUNLWWO\PSKRPD%/RFFXUUHGDWDWLPHZKHQVFLHQWL¿F
progress was rapidly accelerating. Heralded by advances in a broad range 
of disciplines, the last half century has witnessed a revolution in our un-
derstanding of the treatment, epidemiology and pathogenesis of cancer. In 
each of these areas BL has provided an important paradigm that has led to 
many new discoveries. Burkitt and colleagues provided encouragement to 
cancer chemotherapy pioneers by demonstrating that several recently devel-
oped chemotherapy agents were capable of inducing long term survival in 
BL. In part based on early combination regimens used in Africa, modern, 
highly effective therapies have been developed for sporadic BL and large 
cell lymphomas in children and adolescents, although, unfortunately, most 
African BL patients still die. The primitive but effective epidemiological 
studies of Burkitt and colleagues demonstrated a link with malaria and led 
to the discovery of Epstein-Barr virus (EBV). EBV infects almost the entire 
human race, but is also associated with a wide range of diseases, both benign 
and malignant. The study of EBV’s survival mechanisms at biological and 
molecular levels has led to considerable but still incomplete understanding 
of the pathways that lead to EBV-related diseases in normal and immuno-
GH¿FLHQWVXEMHFWV7KHGLVFRYHU\RIWKHDQGYDULDQWWUDQVORFDWLRQVOHG
WRWKHUHFRJQLWLRQRIWKHFHQWUDOUROHRIF0\FLQ%/DQGWRWKHLGHQWL¿FD-
tion of similar translocations in other lymphoid neoplasms, resulting in the 
discovery of many genes involved in lymphomagenesis. Recently published 
JHQHH[SUHVVLRQSUR¿OHVRIVSRUDGLF%/KDYHVKHGQHZOLJKWRQWKHFHOOXODU
RULJLQDQGGH¿QLWLRQRI%/DQGUHODWHGGLVHDVHV*HQHWLFVLJQDWXUHVPD\DOVR
prove useful in predicting treatment response and improving risk-adaptation 
of therapy, while EBV genes and genetic abnormalities are likely to provide 
WDUJHWVIRUIXWXUHPRUHVSHFL¿FWUHDWPHQWDSSURDFKHV
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